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Alzheimer’s disease (AD) is characterized by the presence of amyloid plaques 
and neurofibrillary tangles (NFT) in the brains of patients. Being a core 
component of plaques, much research has focused on the amyloid β peptide 
(Aβ) as a therapeutic target. Besides Aβ, the amyloid precursor protein (APP) 
intracellular domain (AICD) is one of many fragments released from 
proteolytic processing of APP. Binding of AICD to interacting proteins 
facilitates its nuclear translocation, allowing it to regulate target gene 
expression. However, the identity of AICD targets remains controversial due 
to conflicting data or a lack of independent replication. 
In a previous study, chromatin immunoprecipitation coupled to DNA 
sequencing (ChIP-Seq) and microarray techniques were used to identify AICD 
target genes. In these experiments, AICD levels were manipulated indirectly 
via the overexpression or knockdown of APP in neuroblastoma cells prior to 
ChIP-Seq and microarray analysis.  
Hypothesis 
In the current study, we test the hypothesis that changes in AICD levels alone 
are sufficient to alter the expression of target genes independently of its 
precursor. Since increased β-secretase levels and activity in AD result in more 
Aβ generation and a concomitant increase in AICD nuclear signalling, 
changes in expression of protein products derived from translation of the 
AICD targets are expected to be associated with AD. 
 x 
Aims/Methods 
Given that the large datasets generated by ChIP-Seq and microarray are 
subject to false positives, it was imperative to evaluate the reliability of the 
results at the mRNA level using quantitative real-time polymerase chain 
reaction (qPCR). In order to have any functional consequence, changes in 
mRNA expression have to be sustained at the protein level and this was 
assessed using Western blot analysis. Relevance of the AICD targets to AD 
was determined by examining their expression in human cortical samples 
compared with control samples. Finally, a combinatorial approach involving 
drug treatment or transfection of cells with various APP fragments was used to 
identify the specific APP metabolite responsible for regulating target 
expression.  
Results 
CACNA2D1, MCM4, PDE7A and SPOPL were verified as APP/AICD targets. 
Unexpectedly, transient transfection of the 6 kDa AICD was insufficient to 
modify target expression. This was also the case when the APP copper-
binding domain (CuBD) was investigated as a potential target regulator. 
Western blot comparison of cell lysates used in the original study and brain 
homogenates from AD patients revealed that a 50 kDa APP fragment was 
upregulated compared with controls, which could be crucial for the regulation 
of CACNA2D1, MCM4, PDE7A and SPOPL expression. The fragment 
identified in this study accumulates as a result of long-term changes associated 
with AD; can be induced by stable APP transfection in vitro; and is distinct 
 xi 
from previously reported 50 kDa fragments that were either induced by 
leupeptin treatment or generated by frameshifted APP mutation (APP+1).  
Conclusion 
By demonstrating that APP differentially regulates gene expression in 
physiology and AD, changes in cellular signaling and function that potentially 
contribute to disease can be elucidated and new biomarkers or therapeutic 
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1.1 Alzheimer’s disease  
1.1.1 Epidemiology, symptoms and diagnosis  
Alzheimer’s disease (AD) is a medical term coined for a progressive and 
ultimately fatal neurodegenerative disorder that was first reported by Alois 
Alzheimer in 1907 (English translation by Stelzmann et al., 1995). Currently, 
there are at least 36 million people worldwide who are living with AD. 
Approximately 5% of individuals over the age of 65, 20% over the age of 80 
and more than a third of those over the age of 90 will develop late-onset AD 
(LOAD) and they make up the majority of patients diagnosed with AD. By 
contrast, early-onset familial AD (FAD), which affects individuals younger 
than the age of 65, accounts for about 1-5% of total cases (Wimo and Prince, 
2010).  
Regardless of onset, AD is associated with debilitating memory loss and 
extensive deterioration of cognition, behavior and personality. In living 
individuals, diagnosis is determined clinically because no laboratory tests are 
available to confirm AD. The Clinical Dementia Rating (CDR) is one of the 
most widely used scales to classify individuals along a continuum from 
normal aging through AD. After interviewing both the patient and an 
informant, scores are assigned according to the degree of decline from 
previous level due to cognitive loss, and not impairment due to other factors. 
Normal individuals achieve a CDR of 0. Those with questionable and mild 
dementias have a CDR of 0.5 and 1 respectively; moderate dementia scores as 
2; and severe dementia is given a CDR of 3 (Morris, 1993). However, the 
CDR cut-off for mild cognitive impairment (MCI) remains controversial. MCI 
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is defined as the transitory condition between normal aging and AD, in which 
a greater than expected memory loss is observed in an individual of a 
particular age but without fulfilling the criteria for clinically probable AD. 
Although problems with memory, language or other cognitive functions are 
noticed by others and are reflected on cognitive tests, they are not severe 
enough to interfere with daily life (Daviglus et al., 2010). Longitudinal studies 
reveal that individuals with MCI progress to clinically probable AD at an 
accelerated rate compared with healthy age-matched individuals (Petersen et 
al., 2001). While some investigators believe that CDR 0.5 is equivalent to 
MCI, others are of the opinion that CDR 0.5 includes subjects with MCI and 
mild AD (Petersen, 2000). Besides CDR, the cognitive mental status of AD 
patients is also frequently scored using the Mini-Mental State Examination 
(MMSE), which consists of questions that test orientation, registration, 
attention, calculation, recall and language (Folstein et al., 1975). The 
maximum total score that can be achieved is 30. Normal individuals score 
around 27-30 and patients can be stratified into three groups based on their 
MMSE scores. “Mild” AD cases achieve scores of 24 or greater; “moderate” 
AD patients score between 19 and 23; while individuals with “severe” AD 
score between 10 and 18 (Welsh et al., 1992). In addition to CDR and MMSE, 
Mini-Cog; Montreal Cognitive Assessment; and Blessed Dementia Scale are 
also relevant examples of neuropsychological tests that are used to diagnose 
probable AD. Prior to end-stage illness, patients with AD experience variable 
clinical symptoms such as depression, insomnia, incontinence, delusions, 
illusions, hallucinations, verbal, emotional or physical outbursts, sexual 
disorders, weight loss, visual field deficits, incoordination, seizures and gait 
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disturbances (McKhann et al., 1984). Due to declining social and occupational 
functions, individuals suffering from AD become increasingly dependent on 
their caretakers in order to engage in daily activities as the disease progresses. 
The typical clinical duration of AD ranges from one to 25 years, with a 
median of 10 years, and death usually results from general inanition, 
malnutrition, and pneumonia (Bird, 1993; Ghezzi et al., 2013).  
While AD accounts for 70% of all dementias (Ott et al., 1995), other causes of 
dementia include: vascular dementia, Lewy body dementia and frontotemporal 
dementia. Since no clinical feature is unique to AD, distinguishing AD from 
similar disorders is difficult. Neuroimaging is indicated in the evaluation of 
patients with a typical clinical presentation of AD. Structural magnetic 
resonance imaging (MRI) and functional brain imaging using amyloid 
positron emission tomography (PET) tracers are used to diagnose AD in life. 
Reduced hippocampal volume is a characteristic MRI finding in AD patients 
(Barkhof et al., 2007; van de Pol et al., 2006; Whitwell et al., 2012) while PET 
reveals low metabolism and hypoperfusion in several brain regions such as the 
hippocampus, lateral parietal cortex and posterior temporal cortex (Duara et al., 
1986; Minoshima et al., 1997; Powers et al., 1992; Silverman et al., 2001). 
Detection of amyloid plaques and neurofibrillary tangles (NFT) following 
postmortem neuropathological examination of the brain (Khachaturian, 1985; 
McKhann et al., 1984) provides further evidence for definitive diagnosis of 
AD. Plaques and NFT are not distributed evenly across the brain in AD but are 
concentrated in vulnerable neural systems. Extracellular plaques consist 
primarily of amyloid β peptides (Aβ) and may be described as diffuse, if made 
up of poorly marginated collections of aggregated Aβ that are not fibrillar; or 
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neuritic, if the central core consists of fibrillar Aβ and are surrounded by 
neighboring dystrophic neurites (Mott and Hulette, 2005). There is 
hierarchical involvement of brain regions with respect to Aβ deposition. 
Amyloid imaging technology using the PET agent Pittsburgh compound-B 
reveals that the earliest amyloid plaques are detected in the striatum (Handen 
et al., 2012; Klunk et al., 2007; Villemagne et al., 2009). Extensive diffuse and 
neuritic amyloid plaques also form throughout the neocortex in AD. This is 
followed by involvement of allocortical brain regions. Several brainstem 
nuclei become additionally involved before cerebellar Aβ deposition takes 
place in the last phase (Thal et al., 2002). In some cases, plaques occur with 
amyloid infiltration of blood vessel walls and adjacent perivascular neuropil 
(Khachaturian, 1985). Because diffuse plaques also occur in normal ageing 
(Knopman et al., 2003; Morris et al., 1996), it is imperative that only neuritic 
plaques are included in the diagnosis of AD (Hyman et al., 2012). On the other 
hand, intracellular NFT are made up of paired helical filaments of the 
hyperphosphorylated microtubule-associated protein, tau; and are commonly 
found in the neuronal perikarya and in pyramidal neurons of the hippocampus, 
entorhinal cortex (EC) and neocortex, nucleus basalis of Meynert and 
periaqueductal gray matter (Khachaturian, 1985). As with amyloid plaque 
deposition, NFT display a characteristic distribution pattern permitting the 
differentiation of six stages. The first two stages are characterized by mild to 
severe alterations of the transentorhinal layer Pre-α with little involvement of 
the CA1 region of the hippocampus. In stages III and IV, NFT development is 
observed in layer Pre-α of both the transentorhinal region and proper EC. In 
addition, there is some involvement of the first Ammon's horn sector. In the 
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final two stages, almost all isocortical association areas are destroyed in 
addition to the cumulative NFT deposition described in Stages I to IV (Braak 
and Braak, 1991).  
 In 2012, updates were made to the consensus criteria for neuropathological 
diagnosis of AD, known as the National Institute on Aging/Reagan Institute of 
the Alzheimer Association Consensus Recommendations for the Postmortem 
Diagnosis of AD, that was originally published in 1997 (Hyman and 
Trojanowski, 1997). Recommended brain regions to be sampled are: medulla, 
pons, midbrain, cerebellar cortex and dentate nuclei, thalamic and subthalamic 
nuclei, basal ganglia at level of anterior commissure with basal nucleus of 
Meynert, hippocampus and EC, anterior cingulate nuclei, amygdala, medial 
frontal gyrus, superior and medial temporal gyri, inferior parietal lobe, 
occipital cortex and white matter at the anterior, middle and posterior cerebral 
artery watershed. Following appropriate immunohistochemical staining, 
neuropathological changes will be ranked according to Aβ plaque score, NFT 
stage and neuritic plaque score based on modifications to the methods of Thal 
(Thal et al., 2002), Braak (Braak and Braak, 1991) and the Consortium to 
establish a registry for AD (Mirra et al., 1991) respectively. The combination 
of ranks is then transformed into one of four AD levels: “not”, “low”, 
“intermediate” or “high”. Non-AD brain lesions associated with co-morbid 
conditions in cognitively impaired elderly should also be assessed and 
integrated with clinical findings in the neuropathologic assessment for each 
individual (Hyman et al., 2012).  
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1.1.2 Morphological, neurochemical and electrophysiological features of 
AD  
Besides the occurrence of plaques and NFT, other morphological changes take 
place in the AD brain. Computerized tomography revealed that the volume of 
the ventricular system and the width of the third ventricle are increased, gyri 
are narrowed, and sulci are widened in AD (McKhann et al., 1984). Neurons 
in the EC, CA1 region of the hippocampus and frontal cortical regions are 
among the first to be affected (Gómez-Isla et al., 1996; Price et al., 2001; West 
et al., 1994) but an overall decrease in brain weight and volume is 
subsequently observed following shrinkage and loss of neurons in other brain 
regions. Neuronal cell death in AD is thought to be preceded by re-entry into 
the cell cycle and DNA replication. Fluorescent in situ hybridization of 
hippocampal pyramidal and basal forebrain neurons in AD revealed that a 
significant fraction of these neurons have fully or partially replicated genetic 
loci on different chromosomes. The cells remain hyperploid because mitosis is 
not initiated following S phase (Yang et al., 2001). Although hyperploid 
neurons are present at a frequency of about 10% in control brains, AD brains 
contain a significantly higher number of these anomalies. Hyperploid neurons 
are already elevated at preclinical stages of AD and remain high as disease 
progresses towards mild AD. However, the number of hyperploid neurons 
decreases significantly at more severe stages of AD and are only marginally 
different from controls. The loss of hyperploid neurons in severe AD, 
correlates significantly with the total loss of neurons. The genetic imbalance 
may persist for many months before the cells die and hyperploidy serves as a 
signature for cells prone to degeneration in AD (Arendt et al., 2010). Rather 
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than loss of the entire neuron, the physical basis of cognitive decline in AD is 
specifically attributed to the loss of synapses and dendritic spines (Jacobsen et 
al., 2006; Ji et al., 2003; Scheff et al., 2007; Terry et al., 1991). Although AD 
is generally considered to affect gray matter, a significant reduction in the 
integrity of association white matter fiber tracts such as the splenium of the 
corpus callosum, superior longitudinal fasciculus, and cingulum is observed 
using magnetic resonance imaging (MRI) of AD brains (Rose et al., 2000). In 
particular, partial loss of myelin, axons, and oligodendroglial cells are 
associated with the white matter lesion in AD (Brun and Englund, 1986). 
Other brain imaging studies report that decreased cerebral blood flow (Alsop 
et al., 2000; Bartenstein et al., 1997; Pearlson et al., 1992) and glucose 
hypometabolism (Anchisi et al., 2005; Ibáñez et al., 1998; Mosconi et al., 
2009) correlate well with AD severity. Another MRI study investigating the 
network of cortical regions that characterizes the resting state or default 
network mode of the brain revealed decreased activity due to loss of functional 
connectivity between both hippocampi in the medial temporal lobes and the 
posterior cingulate cortex in the default network of AD patients (Greicius et al., 
2004; Sorg et al., 2007). 
Changes in neurotransmission also arise in AD and one way by which this 
occurs is due to excessive and selective loss of cholinergic neurons in the 
basal forebrain (Coyle et al., 1983; Whitehouse et al., 1982). A variety of 
studies in humans demonstrate that the basal forebrain and rostral forebrain 
cholinergic pathways serve important roles in conscious awareness, attention, 
working memory as well as mnemonic processes (reviewed in Perry et al., 
1999). The decrease in cholinergic transmission in AD is associated with the 
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degree of cognitive impairment and density of amyloid plaques and NFT 
(Davis et al., 1999; Perry et al., 1978). Agonists of the M1 muscarinic 
cholinergic receptor are known to decrease Aβ levels through the activation of 
protein kinase C and mitogen-activated protein kinase (Haring et al., 1998); 
and reduce tau phosphorylation (Genis et al., 1999). There is also direct 
physical interaction between the cholinergic system and Aβ as the α7 nicotinic 
receptors serve as high-affinity binding sites for Aβ (Wang et al., 2000). 
Binding of Aβ blocks the interaction of nicotinic agonists with receptors on 
hippocampal neurons (Liu et al., 2001). In addition, the number of astrocytes 
expressing the α7 nicotinic acetylcholine receptor subunit increases 
significantly and is positively correlated with the number of neuritic plaques in 
the AD brain. By contrast, expression of the α7 and α4 nicotinic acetylcholine 
receptor subunits are concomitantly decreased in neurons of the hippocampus 
and temporal cortex of AD patients (Yu et al., 2005). Overall, cholinergic 
abnormalities in AD take the form of alterations in choline transport, 
acetylcholine release, nicotinic and muscarinic receptor expression and nerve 
growth factor support to cholinergic neurons (Terry Jr and Buccafusco, 2003). 
Changes to the cholinergic system in AD may also contribute to behavioral 
and psychological symptoms. Thus, treatment with acetylcholinesterase 
(AChE) inhibitors (AChEI) is associated with improvement in a number of 
symptoms including depression, psychosis and agitation (reviewed in 
Cummings, 2003). Administration of AChEI restores some of the cholinergic 
neurotransmission that is lost due to reductions in choline acetyltransferase 
and AChE levels or activity in severe AD cases (Davis et al., 1999; Perry et al., 
1992). Nevertheless, several groups have independently found that the 
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expression and/or activity of these key cholinergic players are actually 
preserved in the neocortex and nucleus basalis of individuals with MCI or 
mild AD (Davis et al., 1999; Gilmor et al., 1999). Conversely, other groups 
report increased choline acetyltransferase activity in the frontal cortex and 
hippocampus of MCI subjects (Dekosky et al., 2002). Thus, it appears that 
cholinergic markers may not be useful as early indicators of AD since 
cholinergic deficits are not reliably and consistently detected in pre-
symptomatic AD (Davis et al., 1999). 
Besides the loss of cholinergic neurons, substantial serotonergic denervation is 
reported in AD. Reduction in serotonin levels are prominent in the cortex, 
hippocampus, caudate nucleus and putamen; while the concentration of its 
metabolite, 5-hydroxyindoleacetic acid, is reduced in the thalamus, putamen 
and several cortical areas of AD patients (Reinikainen et al., 1988). A 
significant negative correlation is found between 5-hydroxyindoleacetic acid 
concentration and the number of NFT. Furthermore, serotonin uptake and 
potassium ion-stimulated release of endogenous serotonin are reduced in the 
frontal lobe but appear to be more severely affected in the temporal lobe 
(Palmer et al., 1987). In general, changes in serotonergic pathology are more 
pronounced in AD patients who display signs of aggression as compared with 
AD patients who are not as likely to cause actual physical harm to another 
person (Procter et al., 1992). 
Glutamatergic transmission is also affected in AD as a result of increased or 
decreased expression of different glutamate transporter subtypes and receptors 
in various regions of the AD brain (Jacob et al., 2007); and loss of 
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glutamatergic neurons in several regions of the cerebral cortex (Procter et al., 
1988). Altered expression of excitatory amino acid transporters is observed in 
the vicinity of amyloid plaques (Jacob et al., 2007) and impaired functioning 
of glutamate transporters is involved in synaptic pathology and 
neurodegeneration by preventing clearance of excess glutamate at the synaptic 
cleft (Masliah et al., 1996). Consequently, excess glutamate neurotransmitter 
release and binding to receptors causes increased entry of calcium ions into the 
cell, associated production of damaging free radicals and activation of 
proteolytic processes that contribute to cell injury or death. The three classes 
of glutamate-gated ion channels are the α-Amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors, kainate receptors and N-methyl-d-
aspartate (NMDA) receptors. Among these, ion channels coupled to NMDA 
receptors are the most permeable to calcium ions (Lipton, 2006). Assembly of 
the neuron-specific isoform of the APP holoprotein with NMDA receptors 
leads to increased delivery of NMDA receptors to the cell surface (Cousins et 
al., 2009; Cousins et al., 2013). Destabilization of calcium homeostasis in AD 
renders neurons vulnerable to cell death as a result of excitotoxicity (Mattson 
et al., 1992). Calcium ion responses to NMDA or glutamate exposure are 
exacerbated by Aβ production (Mattson, 1997). Thus, Aβ toxicity has been 
partially attributed to effects on voltage-gated calcium channels (Bobich et al., 
2004; Ramsden et al., 2002; Ueda et al., 1997), which trigger increased 
calcium release from intracellular stores through the inositol 1,4,5-trisphospate 
receptor or ryanodine receptors (Ferreiro et al., 2004).  
Death of neurons and changes in neurotransmission are among the factors that 
alter the electroencephalogram (EEG) dynamics of AD. In general, the 
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hallmark of EEG abnormalities in AD is a shift to lower frequencies and a 
decrease in coherence of fast rhythms (reviewed in Jeong, 2004). The power 
spectrum is usually calculated using a fast Fourier transform and divided into 
five subbands corresponding to delta (1–4 Hz), theta (4–8 Hz), alpha (8–13 
Hz), beta (13–30 Hz), and gamma (30–50 Hz) rhythms (Mantini et al., 2007). 
AD has consistently been associated with increases in theta and delta activities 
and decreases in alpha and beta activities accompanied by reduced coherence 
of alpha and beta bands (Besthorn et al., 1994; Coben et al., 1985; Huang et al., 
2000; Koenig et al., 2005). These abnormalities correlate with the severity of 
mental impairment in AD (Jelic et al., 2000; Kowalski et al., 2001). On the 
whole, changes in neural connectivity and brain activity are thought to be 
responsible for interfering with learning, memory and cognitive function in 
AD.  
1.1.3 Drug treatment  
The therapies proposed or attempted in AD thus far derive from observations 
of cell loss and neurotransmitter level reductions. Far from curing AD, 
currently approved interventions at best provide temporary restoration of 
cognitive capability and delay the inevitable neuronal death as well as aberrant 
metabolic changes in affected neurons. The four pharmacotherapies that 
provide symptomatic benefits include AChEI (donepezil, rivastigmine and 
galantamine) as well as the uncompetitive voltage-dependent NMDA receptor 
antagonist, memantine.  
The mechanistic action of AChEI is to restore balance to the cholinergic input 
that is lost in AD. Results from randomized, double blind, placebo-controlled 
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trials reveal that enhancement of cognitive function is achieved after 6 months 
of treatment with donepezil, galantamine or rivastigmine. These drugs 
increase the action of acetylcholine through inhibition of its primary 
metabolizing enzyme, AChE (Birks, 2006). AChEI may also have additional 
effects with respect to decreasing Aβ production and Aβ-induced toxicity; and 
increasing the expression of nicotinic receptors (reviewed in Nordberg, 2006). 
Treatment with rivastigmine selectively increases the expression of the AChE-
R isoform by about 10%. This isoform attenuates neurodegeneration, as 
opposed to the AChE-S isoform that exacerbates neurodegeneration (Darreh-
Shori et al., 2004).  
In the case of memantine, its action on NMDA receptors is dependent on prior 
receptor activation by agonists like glutamate. Being an uncompetitive 
antagonist, memantine blocks higher concentrations of glutamate that are 
associated with AD to a greater degree than lower concentrations of glutamate 
that are needed for physiological function. In other words, memantine displays 
binding kinetics that allow blocking of NMDA receptors when they are 
excessively open, while allowing normal neurotransmission to take place to a 
certain degree (Lipton, 2006). Other possible effects of memantine include 
decreasing Aβ toxicity, preventing hyperphosphorylation of tau, decreasing 
microglia-associated inflammation and increasing the release of neurotrophic 
factors from astroglia (reviewed in Mangialasche et al., 2010).  
The 2013 clinical practice guidelines on dementia that provides doctors and 
patients in Singapore with evidence-based treatment for dementia are as 
follows: AChEI should be considered for the management of patients with 
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mild to severe AD; and memantine may be considered for the management of 
moderately severe to severe AD, either alone or in combination with AChEI. 
The choice of AChEI should be based upon the experience of the clinician, 
clinical profile of the patient and tolerance to side effects such as nausea, 
vomiting, diarrhea, anorexia, and bradycardia. Where tolerated, donepezil 
should be titrated to the recommended dose of 5–10 mg/day; galantamine to a 
concentration of 16–24 mg/day; and transdermal rivastigmine should be 
administered at 4.6–9.5 mg/24 hours. In the event that AChEI therapy is not 
tolerated or if disease progression persists, memantine may be considered for 
the treatment of mild to moderate AD (Nagaendran et al., 2013).  
At the time of writing, there were a total of 129 ongoing or completed Phase 3 
clinical trials that involved administration of drugs other than those already 
approved for use in AD and were not related to the study of imaging 
techniques for the diagnosis of AD (https://clinicaltrials.gov/). Some of the 
drugs that are/were being tested include neurotrophic and neuroprotective 
agents that restore balance of growth factors; cholesterol-lowering drugs; anti-
inflammatory drugs; drugs that alter glutamatergic, cholinergic or serotonergic 
neurotransmission; drugs that prevent accumulation of misfolded proteins 
and/or promote their clearance; drugs that rescue mitochondrial function; 
insulin and glucagon-like peptide-1 receptor agonists; and nutritional 
interventions such as the consumption of docosahexaenoic acid or the extracts 
of Ginkgo biloba, Angelica gigas or oleanolic-glycoside saponins from 
Pulsatilla koreana (reviewed in Berk and Sabbagh, 2013; Mangialasche et al., 
2010; Schneider et al., 2014). For the majority of studies, results have not been 
reported. Otherwise, no therapeutic recommendations were made due to a lack 
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of significant results following assessment of primary outcome measures. 
Strikingly, even strategies targeting Aβ production (β- or γ-secretase inhibitors 
or modulators), aggregation (inhibitor of glycosaminoglycans), degradation or 
clearance (anti-amyloid plaque or anti-Aβ antibodies); as well as those 
focused on tau pathology (tau inhibitors) fail to show significant clinical 
benefits (Allgaier and Allgaier, 2014).  
The current consensus on designing drugs for AD focuses on the development 
and incorporation of better biomarkers as detection tools for gauging drug-
target interactions and biochemical changes that are relevant to AD pathology. 
Since disease-modifying therapies may be more effective at the pre-
symptomatic stage, when pathological events have yet to produce irreversible 
cognitive deficits, biomarkers can potentially be used as a measure of drug 
efficacy. Furthermore, the duration of disease-modifying therapies will likely 
have to be prolonged as many years of administration might be required before 
differences can be observed on primary outcome measures such as tests of 
cognition and daily function. It is now widely accepted that the discovery of a 
single cure for AD is highly improbable. Hence, future strategies should 
include a combination of pharmacological and non-pharmacological 
interventions to counter the multi-factorial nature of AD and ideally be 
personalized to the treatment of each individual (Herrmann et al., 2011).  
1.1.4 Etiology and risk factors 
Owing to a lack of treatment options and in view of the increasing life 
expectancy, it is estimated that more than 100 million individuals will be 
affected with AD by 2050 (Wimo and Prince, 2010). A better understanding of 
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AD etiology is needed in order to identify molecular players that contribute to 
disease and design disease-modifying drugs that target the underlying 
mechanisms leading to AD. 
FAD is inherited in an autosomal dominant manner and is attributed to 
mutations in the amyloid precursor protein (APP), presenilin-1 or presenilin-2 
(PS1/2); and has been associated with APP locus duplication (Bertram et al., 
2010; Kasuga et al., 2009; Rovelet-Lecrux et al., 2006; Sleegers et al., 2006; 
Thonberg et al., 2011). Down's syndrome individuals, who inherit an extra 
copy of chromosome 21, where the APP gene is located, overexpress APP and 
brain Aβ deposition is observed in their late 20s. NFT develop later and 
correlate with the onset of cognitive decline that is commonly seen in Down's 
syndrome individuals (Hof et al., 1995). Overall, the prevalence of dementia 
in Down’s syndrome individuals doubles with each 5-year interval up to the 
age of 60 and peaks at 32.1% in individuals between the age of 55 to 59 
(Coppus et al., 2006).  
The number of PS1, PS2 and APP mutations that have been identified are 197, 
25 and 40 respectively, and only a minority of these do not result in disease 
(Alzheimer Disease & Frontotemporal Dementia Mutation Database, 2014). In 
one of the rare cases, an APP coding mutation that involves substitution of 
alanine with threonine in residue 673 of APP has been shown to be protective 
against AD and the cognitive decline in elderly who are not diagnosed with 
AD (Jonsson et al., 2012). In most pathogenic cases, mutations in APP are 
single or double missense mutations; while mutations in the PS gene may be 
missense mutations, small deletions, insertions or splice mutations. Together 
 17 
with nicastrin, anterior pharynx defective 1 (APH1) and PS enhancer 2; PS1/2 
makes up the multi-component γ-secretase complex (De Strooper, 2003). This 
complex works together with either α- or β-secretase in the proteolytic 
processing of APP; and APP mutations that contribute to FAD are located 
close to the cleavage sites recognized by the secretases (Kowalska, 2003). On 
the contrary, mutations affecting tau are not sufficient to cause AD. Instead, 
the 32 different missense, deletion, or silent tau mutations result in inherited 
frontotemporal dementia and parkinsonism linked to chromosome 17. Tau 
mutations may also give rise to diseases that resemble progressive 
supranuclear palsy, corticobasal degeneration or Pick’s disease (Pickering-
Brown et al., 2000). In particular, the H1 haplotype of tau is a significant risk 
factor for progressive supranuclear palsy and corticobasal degeneration 
(Goedert, 2005).  
Although the clinical course and neuropathology of FAD and LOAD are 
highly similar, the causes of LOAD are still not completely understood. The 
wide range of symptoms and pathologic lesions in AD suggests that it is a 
complex disease that encompasses a combination of genetic, environmental 
and lifestyle factors. Age is the most important risk factor for AD as the 
majority of individuals are diagnosed after the age of 60 and the incidence of 
AD increases thereafter. The strongest genetic risk factor associated with AD 
is Apolipoprotein E (APOE) gene variation (Daviglus et al., 2010). Astrocytes 
are the primary cells that synthesize APOE in the brain and the common 
isoforms in humans are APOE ε2, ε3 and ε4. Genome-wide association studies 
conducted on AD patients from different parts of the world link the APOE ε4 
allele to both FAD and LOAD (Farrer et al., 1997; Genin et al., 2011). 
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Inheritance of the ε4 allele has a gene-dose effect on increasing the risk of 
developing AD (Corder et al., 1993). Since each inherited APOE ɛ4 allele 
lowers the age of onset by 6–7 years, 60% of individuals with two copies of 
APOE ε4 and 30% of those who inherit one copy of APOE ε4 develop AD by 
the age of 85 (Genin et al., 2011). However, the APOE ε4 allele seems to have 
a weaker or no clear effect on AD in certain ethnic groups, such as African 
Americans or Hispanics; suggesting that other genes or risk factors are 
involved in increasing the risk of AD in these individuals (Tang et al., 1998). 
APOE ε4 overexpression in transgenic mice results in age-dependent loss of 
GABAergic interneurons, impaired hippocampal neurogenesis and associated 
learning and memory deficits (Andrews-Zwilling et al., 2010). This could be 
attributed to the tendency of APOE ε4 proteins to form intermediates with 
pathological activities. In response to stress or injury, neurons can synthesize 
APOE ε4. Following neuron-specific proteolysis, APOE ε4 cleavage results in 
the generation of C-terminally truncated toxic fragments that enter the cytosol, 
alter the cytoskeleton, disrupt mitochondrial function and cause cell death. C-
terminally truncated APOE ε4 fragments are also capable of increasing tau 
phosphorylation and the formation of NFT-like inclusions in vitro and in vivo 
(Mahley et al., 2006). Combined with its pro-inflammatory nature, APOE ε4’s 
ability to inhibit Aβ clearance, stimulate Aβ deposition and aggregation, affect 
synaptic function and promote neurotoxicity also contributes to the disease 
process (reviewed in Kim et al., 2009). One example of an environmental 
factor that has been shown to moderate the APOE genotype effect is lifetime 
cognitive activity. Aβ appears to be diminished in APOE ε4 carriers that are 
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engaged in higher cognitive activities over the course of life (Wirth et al., 
2014).  
Besides APOE, other AD genetic factors have been identified by genome-wide 
association studies and validated in at least one replication stage. They 
include: BIN1, CR1, CLU, PICALM, EPHA1, MS4A6, ABCA7, CD2AP, 
SORL1, HLA-DRB5/DRB1, PTK2B, HSTS31, SQSTM1, TREML2, NDUFAF6, 
ECHDC3, AP2A2, ADAMTS20, IGH, SPPL2A ACE, SCIMP, SLC24A4/RIN3, 
INPP5D, MEF2C, NME8, ZCWPW1, CELF1, FERMT2, CASS4, and TRIP4 
(reviewed in Reitz and Mayeux, 2014). However, only sortilin-related 
receptor 1 (SORL1) is found to be consistently associated with AD by several 
independent studies. Reduced SORL1 expression is detected in the neurons of 
some individuals with LOAD but not FAD (Scherzer et al., 2004). Unlike 
APOE, in which only one allelic variant is associated with increased risk for 
AD; multiple SORL1 variants in distinct linkage disequilibrium blocks have a 
modest effect on the risk for AD (Reitz et al., 2011; Rogaeva et al., 2007). It is 
postulated that intronic SORL1 variants might modulate the cell type-specific 
transcription or translation of SORL1 in carriers of AD-associated haplotypes. 
SORL1 affects Aβ production by preferentially sorting APP into a subcellular 
compartment that prevents Aβ generation from its precursor (Rogaeva et al., 
2007). 
In addition, epigenetic changes may modulate the risk of developing AD. 
Decrements in DNA methylation have been described in layer II of the EC, 
where AD-vulnerable neurons are located (Mastroeni et al., 2010). On the 
other hand, levels of histone deacetylase 2 (HDAC2) are increased in CA1 
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hippocampal neurons of AD patients. HDAC2 reduces the histone acetylation 
of several genes that are important for learning and memory, thereby 
suppressing the expression of these genes (Graff et al., 2012). Changes in 
histone acetylation levels are also observed in an AD transgenic mouse model 
during associative memory formation. After fear conditioning training, levels 
of hippocampal acetylated histone 4 in APP/PS1 mice are about 50% lower 
than wild type littermates and this is associated with impaired contextual 
freezing performance (Francis et al., 2009). 
On the other hand, modifiable risk factors that are repeatedly associated with 
AD include diabetes, hypertension, obesity, current smoking status, depression, 
cognitive inactivity and physical inactivity. According to Barnes and Yaffe, up 
to half of AD cases worldwide might be attributable to these seven factors 
(Barnes and Yaffe, 2011). However, a report by the National Institutes of 
Health State-of-the-Science Conference asserts that firm conclusions cannot 
be drawn regarding the contribution of modifiable risk factors to AD because 
the overall scientific quality of the evidence is low (Daviglus et al., 2010). 
Conflicting results have been presented for most of the modifiable risk factors. 
Furthermore, studies were compromised in terms of assessing both exposures 
and outcomes. In some cases, AD was not even examined as the primary 
outcome of interest. As with the problem faced in clinical diagnosis of AD, 
cardiovascular diseases or other co-morbidities may be presented with AD and 
act as confounding factors that hinder the identification of true associations 
with AD (Daviglus et al., 2011). 
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1.2 Amyloid hypothesis  
As a result of the lack of consensus regarding the main contributing cause of 
AD, multiple hypotheses have been put forward to assign responsibility to 
different molecular players or processes that are known to be implicated in AD. 
These include the cell cycle/DNA replication stress (Woods et al., 2007; 
Yurov et al., 2011), cholinergic (Francis et al., 1999; Terry and Buccafusco, 
2003), cognitive reserve (Kemppainen et al., 2008; Scarmeas et al., 2003), 
metal/oxidative stress/inflammation (Bush and Tanzi, 2008; Markesbery, 
1997; Padurariu et al., 2013; Pratico and Trojanowski, 2000), calcium 
(Berridge, 2010; Khachaturian, 1994), insulin (Hoyer, 1998; Qiu and Folstein, 
2006), and tau (Bhatia and Hall, 2013; Maccioni et al., 2010) hypotheses.  
However, the amyloid hypothesis of AD that was first formulated by Hardy 
and Higgins in 1992 (Hardy and Higgins, 1992) is probably the most widely 
cited because for a long time, it served as the principle basis for understanding 
AD pathogenesis and for the design of potential therapeutics. According to 
this hypothesis, excessive accumulation, oligomerization and deposition of Aβ 
is neurotoxic and plays a central role in AD by initiating cellular cascades that 
lead to synapse loss, inflammation, NFT formation and death of susceptible 
neurons. Although Aβ species comprising of between 39-42 amino acids may 
be generated by proteolytic processing of APP, Aβ42 (refers to the number of 
amino acids that make up a particular Aβ fragment) is responsible for 
triggering the disease process due to its greater tendency to form β-pleated 
sheet structures. The majority of FAD mutations either increase total Aβ levels 
or the ratio of Aβ42/Aβ40 production, thereby resulting in earlier disease 
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onset and accelerated disease progression while LOAD may develop when 
other risk factors accelerate the normal age-dependent process of Aβ 
accumulation. Nonetheless, developments within the field in the last two 
decades have led to a wealth of new information that warrants reappraisal of 
the amyloid hypothesis. Aβ deposits are detected in elderly individuals 
without dementia and it is now widely accepted that the spatial and temporal 
patterns of amyloid deposition do not correlate well with the cognitive 
dysfunction in AD (Arai et al., 1999; Dickson and Yen, 1989; Villemagne et 
al., 2008). Instead, increasing evidence suggests that soluble Aβ oligomers 
may be responsible for synaptic dysfunction and impairing long-term 
potentiation (LTP) in both AD patients and transgenic animal models (Hu et 
al., 2008; Lambert et al., 1998; Snyder et al., 2005). Furthermore, Aβ 
oligomers inhibit neuronal viability 10-fold more than fibrils and 40-fold more 
than monomers under the same experimental conditions (Dahlgren et al., 
2002). Thus, it is obvious why much of AD-related pharmaceutical and 
academic research has focused on Aβ as a therapeutic target for AD. Clinical 
trials involving the use of inhibitors that target the secretases involved in Aβ 
generation show that this intervention tampers with the cleavage of substrates 
other than APP, resulting in adverse side effects (Notch toxicity) and/or 
worsening of cognitive impairments (Schor, 2011). In another phase III 
clinical trial, a γ-secretase modulator that decreases the production of Aβ42 in 
favor of Aβ40 was found to be ineffective in alleviating AD (Green et al., 
2009). Even so, numerous trials are ongoing to determine the safety and 
efficacy of more selective pharmacological agents that modulate Aβ 
generation and release, oligomerization and deposition and/or enhance Aβ 
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degradation and clearance. In any case, it is becoming apparent that APP 
metabolites other than Aβ do not only play important roles in normal brain 
functioning but can also contribute to, or protect against AD and may provide 
new opportunities for therapeutic intervention.  
1.3 APP expression, trafficking and processing 
APP belongs to a small gene family that includes two other members in 
humans: the APP-like proteins 1 and 2 (APLP1 and APLP2). Deletion of all 
three family members results in mice that survive through embryonic 
development but die shortly after birth. These mutants display cranial 
abnormalities that resemble human type II lissencephaly (Herms et al., 2004). 
Although APLP2-/-/APLP1-/- and APLP2-/-/APP-/- double knockout mice are 
perinatal lethal, APLP1-/-/APP-/- knockout mice and single mutants are viable 
and fertile. Overall, these phenotypes are indicative of the partially 
overlapping physiological functions among APP family members and suggest 
that APLP2 is crucial when either APP or APLP1 is absent (Heber et al., 2000). 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
1 2 3 4 5 6 7 9 10 11 12 13 14 15 16 17 18
1 2 3 4 5 6 9 10 11 12 13 14 15 16 17 18





Figure 1. Three major APP isoforms in humans generated by alternative splicing. Compared with the longest isoform APP770, APP751 lacks exon 8; while APP695 lacks exons 7 and 8, as indicated in red. 
The human APP gene is located on chromosome 21 and consists of 18 exons. 
APP is a 100-140 kDa type I transmembrane protein. Alternative splicing of 
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APP mRNA gives rise to eight isoforms, of which APP695, APP751, and 
APP770 (refers to the number of amino acids that make up each isoform) are 
the three major species in humans (Figure 1). APP770 and APP751 differ 
from APP695 by the inclusion of a 56 amino acid Kunitz protease inhibitor 
(KPI) domain. In addition to the KPI domain, APP770 contains a 19 amino 
acid sequence that is homologous to the MRC OX-2 antigen. Structural 
features that are common to all three isoforms include the N-terminal signal 
peptide; the cysteine-rich globular E1 domain that has a heparin-binding 
domain (HBD) and a copper-binding domain (CuBD); an acidic domain; a 
helix-rich E2 domain, which has several putative metal-binding sites and 
contains the second HBD; the Aβ sequence, which partially extends into the 
transmembrane domain; and the short cytoplasmic domain at the C-terminus 
(Dawkins and Small, 2014). While APP695 is the predominant isoform 
expressed in neurons, APP751 and APP770 are expressed mostly in non-
neuronal cells of the brain and are found at varying levels in many tissues 
throughout the body (reviewed in Selkoe, 2001). After translation of APP at 
the endoplasmic reticulum, APP passes to the Golgi compartment and is 
transported in secretory vesicles to the cell surface. During passage through 
the secretory pathway, APP undergoes posttranslational modifications such as 
sulfation, phosphorylation and glycosylation (reviewed in Walter and Haass, 
2000). The N-glycosylated form of APP is localized to the Golgi and trans-
Golgi network and is designated as immature APP. Immature APP represent 
the majority of APP at steady state and do not undergo proteolytic processing. 
70-80% of immature APP are degraded and only 20–30% reach the Golgi 
(Kuentzel et al., 1993). As N-glycosylated APP is further trafficked within the 
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Golgi, it is subjected to O-glycosylation, after which it is designated as mature 
APP (reviewed in Suzuki and Nakaya, 2008; Thinakaran and Koo, 2008). 
Only mature APP reaches the cell surface where APP is either released or 
undergoes endocytosis because of the “YENPTY” internalization motif within 
its cytoplasmic domain. The majority of APP that has been re-internalized into 
the cell undergoes degradation in the lysosome (Haass et al., 1992), while the 
rest are trafficked through the endocytic and recycling compartments back to 
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Figure 2. Amyloidogenic and non-amyloidogenic APP processing. APP is metabolized via the non-amyloidogenic or the amyloidogenic pathway when it is initially cleaved by α- or β-secretases respectively. In both pathways, the remaining C-terminal fragment undergoes a second cleavage by γ-secretase to release the intracellular C-terminal domain (AICD). AICD binds to co-factors, such as Fe65, that facilitate translocation into the nucleus where additional players may be recruited to regulate target expression. The positions where two different APP antibodies (that will be mentioned later in the thesis) bind to the full-length protein are depicted in red (MAB348) and turquoise (A8717). 
APP is a substrate for secretases and may be constitutively metabolized via 
one of two pathways, depending on its subcellular localization (Figure 2). The 
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non-amyloidogenic pathway represents the major route of APP processing in 
most peripheral cells (Evin et al., 2003). APP that is expressed at the plasma 
membrane is first cleaved by α-secretase to release the soluble N-terminal 
ectodomain (sAPPα). The major candidates for α-secretase belong to the 
ADAM (a disintegrin and metalloprotease domain) family of proteins and 
include ADAM9, ADAM10 and ADAM17/TACE (Tanzi and Bertram, 2005). 
Since α-secretase cleaves APP within the Aβ peptide region, it prevents Aβ 
formation. The remaining C-terminal fragment (C83) is then acted on by the γ-
secretase complex via a mechanism referred to as regulated intramembrane 
proteolysis (RIP, because cleavage occurs in the middle of the transmembrane 
domain) to produce a p3 fragment and the APP intracellular domain (AICD). 
Although the amyloidogenic pathway represents the minor route by which 
APP is processed in peripheral cells, it is predominant in neuronal cells (Evin 
et al., 2003). In order for APP to be processed via the amyloidogenic pathway, 
it must first undergo endocytosis. This process is enhanced when APP is found 
in association with lipid rafts, which are membrane microdomains rich in 
cholesterol (Ehehalt et al., 2003). The major neuronal β-secretase is a 
transmembrane aspartyl protease identified as β-site APP cleaving enzyme 1 
(BACE1) (Vassar, 2004). However, BACE2 and Cathepsin D are also known 
to demonstrate β-secretase activity (Ahmed et al., 2010). Optimum β-
secretase activity requires reducing and acidic conditions. β-cleavage mostly 
occurs in the early endosomes where APP is cleaved to generate a soluble N-
terminal ectodomain (sAPPβ) and a C-terminal fragment (C99) (Rajendran et 
al., 2006). Subsequently, γ-secretase activity on C99 results in the production 
of Aβ and AICD. Less than 1% of the Aβ that are generated are sorted from 
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the early endosomes to the intraluminal vesicles of multivesicular bodies. The 
multivesicular bodies then fuse with the plasma membrane to release the Aβ 
that are bound to exosomes (Rajendran et al., 2006). The majority of Aβ 
transport and secretion to the extracellular space is greatly influenced by 
autophagy. Autophagy deficiency significantly reduces extracellular Aβ 
plaque deposition but leads to aberrant intraneuronal Aβ accumulation in the 
perinuclear region (Nilsson et al., 2013).   
Two different PS subunits (PS1 and PS2) and two different APH1 subunits 
(APH1A and APH1B) are encoded by separate genes in humans. Like APP, the 
PS and APH1 mRNAs can be alternatively spliced, giving rise to different 
permutations of the γ-secretase population and each γ-secretase complex 
produces a characteristic Aβ signature (Acx et al., 2013). RIP by γ-secretase is 
thought to occur as a series of cleavages, starting from the C-terminal region 
of the substrate and moving towards the N-terminal region of the 
transmembrane domain (Qi-Takahara et al., 2005). The three sites, where γ-
secretase cleavage possibly takes place have been termed the γ-, ε- and ζ- sites. 
Aβ40 and Aβ42 are the two most commonly generated Aβ fragments and they 
are formed following γ-secretase activity at amino acid 40 or 42 of the γ-site. 
Under normal physiological conditions, 90% of the secreted Aβ are the fairly 
benign Aβ40 while the remaining 10% are the longer Aβ42 species that are 
more fibrillogenic as they are prone to aggregation (Klafki et al., 1996). 
Accordingly, AICD that comprises of 59 or 57 amino acids are generated. 
These AICD species consist of the 47 amino acids that make up the APP 
cytoplasmic region and either 12 or 10 amino acids of the transmembrane 
domain (Cupers et al., 2001). A further cleavage event occurs late in the 
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secretory pathway and is relevant to AICD produced from amyloidogenic APP 
processing. Endoproteolytic (ε)-site cleavage occurs either between residues 
50 and 51 or between residues 49 and 50 of C99 to generate even shorter 
AICD fragments that are only 50 or 51 amino acids in length (Weidemann et 
al., 2002) and the corresponding Aβ49 or Aβ48. Aβ49 and Aβ48 are 
subsequently shortened by consecutive carboxypeptidase-like γ-cleavages. 
Thus, endopeptidase cleavage by the γ-secretase defines AICD and total Aβ 
levels but the length of Aβ generated depends on carboxypeptidase-like 
activity, which is mainly affected by the APH1 subunit (Acx et al., 2013). 
1.4 Functions of APP and its metabolites  
1.4.1 APP holoprotein 
APP expression is increased during neural maturation and differentiation 
(Hung et al., 1992) and following brain injury (Ciallella et al., 2002). In 
neurons, APP is required for synaptogenesis, synapse remodeling and neurite 
outgrowth (Zheng and Koo, 2006). In some cases, these effects have been 
shown to be mediated by specific APP metabolites (refer to following 
sections) but the holoprotein as a whole has important functions. For instance, 
APP can influence neural stem and progenitor cell proliferation either via the 
production of sAPPα or through an sAPPα-independent mechanism that 
involves cystatin C release (Dawkins and Small, 2014).  
The structure of APP and the presence of several conserved motifs are 
indicative of a membrane-associated receptor. A hydrophobic pocket is 
located adjacent to the HBD near the N-terminus and the size of the putative 
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binding domain suggests that besides acting as a receptor for ligands, APP 
might also be a growth factor or bind to an extracellular matrix 
component such as heparan sulfate proteoglycans (reviewed in Dawkins and 
Small, 2014). Unlike other receptors, the primary signal initiating APP 
proteolysis remains unknown. Regardless, APP is a receptor coupled to Go, 
which is a major GTP-binding protein in the brain. The cytoplasmic APP 
sequences between residues 657-676 (amino acid residues mentioned in this 
thesis correspond to APP695, unless otherwise stated) are necessary for 
complex formation and Go activation (Nishimoto et al., 1993). Although 
various APP antibodies were tested, only binding of the 22C11 monoclonal 
antibody to the extracellular domain of APP results in signal transduction by 
increasing GTPγS binding and turnover of the Go GTPase, indicating that APP 
function can be regulated in a ligand-dependent and ligand-specific manner 
(Okamoto et al., 1995). Proteins like F-spondin, TGFβ2 and TAG1 are 
suggested to be functional ligands for APP. Binding of F-spondin to the 
conserved central extracellular domain of APP inhibits β-secretase cleavage of 
APP (Ho and Südhof, 2004); TGFβ2 activates an APP-mediated death 
pathway via Go, c-Jun N-terminal kinase (JNK), NADPH oxidase, and caspase 
(Hashimoto et al., 2005); and TAG1 interaction with APP results in increased 
AICD release and negative modulation of neurogenesis through Fe65 (Ma et 
al., 2008). Interestingly, APP homodimerization is induced upon binding to 
heparan sulfate and the resulting APP dimers can act as receptors for sAPPα. 
sAPPα binding disrupts the APP dimers and this appears to be necessary for 
the protection of cells against starvation-induced cell death (Gralle et al., 
2009).  
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In addition to heparan sulfate binding, APP dimerization is induced due to the 
presence of a GxxxG motif within the APP transmembrane domain as well as 
other domains close to the N-terminus (reviewed in Dawkins and Small, 2014). 
The GxxxG motif is also important for cholesterol binding (Munter et al., 
2007). Homodimerization of APP and heterodimerization with APLP 
homologs promotes transcellular adhesion in vivo (Soba et al., 2005). Since 
APP also contains several copper/metal binding domains, which possess high 
binding affinity for their respective metals; APP can function as neuronal 
metallotransporter and/or metallochaperone to regulate metal homeostasis 
(Chasseigneaux and Allinquant, 2012). The metal-binding site in the E2 
domain possesses a ferroxidase activity that is involved in cellular iron export 
through interaction with ferroportin and this function can be inhibited by zinc-
binding (Duce et al., 2010). Overexpression of APP results in significantly 
reduced brain copper levels. Binding of copper to the ectodomain of APP 
mediates copper efflux when sAPPα is secreted. Conversely, copper levels are 
increased in APP knock-out mice (Treiber et al., 2004) and this is associated 
with decreased Aβ cleavage (Bayer et al., 2003). Binding of copper to the 
ectodomain of APP results in reduction of copper II to copper I. This generates 
free radicals which regulate degradation of the glypican-1 heparan sulfate in 
vivo (Cappai et al., 2005; Multhaup et al., 1996).  
Although the regulation of gene transcription has been attributed to at least 
three APP metabolites, the holoprotein itself participates in transcriptional 
regulation. APP recruits the Tip60 histone acetyltransferase to the membrane 
where it is phosphorylated by cyclin-dependent kinase. Once activated, Tip60 
and Fe65 drive the transcription of a Gal4-Tip60 reporter in PS1/2-deficient 
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cells and in HEK 293 or SH-SY5Y cells that have been treated with γ-
secretase inhibitors (GSIs) (Hass and Yankner, 2005). In primary cultures of 
cortical neurons, APP overexpression significantly downregulates early 
growth response 1 (EGR1) expression at the mRNA and protein levels 
(Hendrickx et al., 2013) Furthermore, the CuBD at the APP E1 domain is 
specifically responsible for mediating APP repression of AChE expression 
(refer to Section 3.3.3) 
1.4.2 Soluble N-terminal ectodomains 
Both sAPPα and sAPPβ can stimulate neurite outgrowth by increasing 
MAPK/ERK pathway activation and EGR1 expression (Chasseigneaux et al., 
2011). In particular, continuous generation of sAPPα is required for 
depolarization-induced ERK phosphorylation in order to promote neurite 
outgrowth in neural stem cell-derived neurons (Gakhar-Koppole et al., 2008). 
sAPPα and sAPPβ are known to interact with the p75 neurotrophin receptor, 
and this interaction appears to be necessary for sAPPα to mediate its 
neurotrophic effects on mouse cortical neurons (Hasebe et al., 2013). sAPPs 
also act as growth factors to enhance embryonic neurogenesis (Hayashi et al., 
1994); regulate proliferation of progenitors in the subventricular zone of the 
adult brain (Caillé et al., 2004); and stimulate proliferation of non-neuronal 
cells (Pietrzik et al., 1998; Saitoh et al., 1989) as well as cancer cells (Hansel 
et al., 2003; Meng et al., 2001). sAPPα is also well-known for its 
neuroprotective effects, which have been demonstrated against glutamate 
neurotoxicity and glucose deprivation (Mattson et al., 1993); Aβ-induced 
deregulation of intracellular calcium homeostasis, mitochondrial dysfunction, 
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oxidative stress and apoptosis (Guo et al., 1998); traumatic brain injury 
(Thornton et al., 2006); and proteasomal and genotoxic stress (Copanaki et al., 
2010). The C-terminal portion of sAPPα is important for mediating 
its neuroprotective effects by allowing sAPPα to act through insulin-like 
growth factor 1 (IGF1) and/or insulin receptors, resulting in the activation of 
the PI3K/Akt pathway that is required for the phosphorylation of GSK3B 
(Jimenez et al., 2011). While the neuroprotective effects of sAPPβ are thought 
to be less potent by about 50- to 100-fold (Chasseigneaux and Allinquant, 
2012), sAPPβ can induce neuronal differentiation of human embryonic stem 
cells more efficiently than sAPPα (Freude et al., 2011). Other functions for 
sAPPβ include binding to the death receptor DR6 to result in axonal pruning 
and neuronal death via the action of caspase 6 (Nikolaev et al., 2009) and 
regulating the expression of transthyretin and Klotho genes (refer to Section 
3.3.3). Like sAPPβ, sAPPα is involved in regulating the expression of 
downstream target genes and also increases the expression of transthyretin. 
Upregulation of transthyretin and IGF2 by sAPPα is necessary for protection 
against Aβ-induced neuronal death (Stein et al., 2004). Microarray analysis of 
gene networks and pathways induced by sAPPα in rat hippocampal 
organotypic slice cultures revealed that sAPPα regulation of gene expression 
is temporally specific. Short-term exposure to sAPPα increases the expression 
of immediate early gene transcription factors while medium and long exposure 
results in overall downregulation of gene expression. The gene networks that 
are modulated following medium and long exposure to sAPPα are associated 
with the inflammatory response, apoptosis, neurogenesis and cell survival 
(Ryan et al., 2013). 
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In addition to its neurotrophic and neuroprotective functions, sAPPα plays 
beneficial roles in cognition. Infusion of sAPPα into rats for two weeks results 
in increased synaptic density and improved memory retention (Roch et al., 
1994). sAPPα blocks learning deficits induced by scopolamine in normal and 
amnesic mice (Meziane et al., 1998). Knock-in of sAPPα is sufficient to 
correct the impairments in spatial learning and LTP that are displayed by APP 
knock-out mice (Ring et al., 2007). Besides enhancing LTP, sAPPα also shifts 
the frequency dependence for induction of long-term depression of synaptic 
transmission in hippocampal slices from adult rats (Ishida et al., 1997). 
Peripherally, both sAPPs are known to inhibit platelet activation and secretion 
through a pathway which inhibits the formation of arachidonic acid 
metabolites (Henry et al., 1998). Involvement of sAPPα in blood coagulation 
is demonstrated by its ability to inhibit coagulation factors IXa (Schmaier et 
al., 1993) and XIa (Smith et al., 1990). Lastly, secretion of sAPPα by 
immunocompetent T cells is indicative of a role in modulating immune 
responses (Monning et al., 1992). Transgenic sAPPα-overexpressing mice 
exhibit immune dysfunction in the form of increased cytokine production after 
challenge with mitogens, increased proportions of CD8+ T cells but decreased 
numbers of memory T cells in the thymus. This is accompanied by decreased 
apoptotic signal transduction in the thymus where active caspase 3/total 
caspase 3 and Bax/Bcl2 ratios are decreased (Bailey et al., 2012).  
1.4.3 Aβ 
The functions of Aβ that are related to AD have been touched on in the 
different sections of Chapter 1.1 and will not be discussed in this section. 
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Although soluble Aβ dimers (Shankar et al., 2008) and oligomers (Walsh et al., 
2002) are known to inhibit hippocampal LTP, enhance long-term depression 
and reduce dendritic spine density in vivo; Aβ are not always associated with 
neurotoxicity, particularly when expressed at low concentrations which do not 
allow the formation of oligomers (Chasseigneaux and Allinquant, 2012). By 
activating the PI3K pathway and stimulating IGF1 receptors and/or other 
receptors of the insulin superfamily, Aβ monomers can exert neuroprotective 
effects that enhance the survival of developing neurons under trophic factor 
deprivation and protect mature neurons against excitotoxic cell death 
(Giuffrida et al., 2009). Aβ40 promotes the self-renewal and proliferation of 
neural progenitor cells and induces these cells to differentiate into neurons 
while Aβ42 promotes differentiation into astrocytes (Chen and Dong, 2009). 
By depressing excitatory synaptic transmission, Aβ are involved in regulating 
synaptic function and may be important for keeping neuronal hyperactivity in 
check (Kamenetz et al., 2003).   
Aβ is involved in the regulation of gene or protein expression. Aβ40 and Aβ42 
treatment significantly reduce zyxin protein levels in HEK 293 cells (Lanni et 
al., 2013). Aβ40 alone induces an increase in the GABA(A) receptor α6 
subunit expression at the translational level via the ERK and mTOR signaling 
pathways and this leads to increased outward current of the GABA(A) 
receptor in rat cerebellar granule neurons (Zhan et al., 2014). Exposure of 
cultured human brain endothelial cells to Aβ40 increases the expression of 
inflammatory genes such as MCP-1, GRO, IL-1β and IL-6. These genes are 
also upregulated in human AD brains. In vitro, the Aβ40-induced effects are 
mediated through the JNK-AP1 signaling pathway (Vukic et al., 2009). 
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Besides indirect regulation of target gene expression that involves the 
activation of signaling pathways, intracellular Aβ42 can directly activate the 
p53 promoter, resulting in p53-dependent apoptosis (Ohyagi et al., 2005).   
1.4.4 p3 
The p3 fragment, which is generated in the non-amyloidogenic pathway, is 
in fact a truncated version of Aβ that consists of residues 17-42. Based on 
the crystal structure of p3, it is predicted that this fragment may potentially 
form oligomeric species (Streltsov et al., 2011). Sedimentation analysis 
reveals that as a result of N-terminal truncation, p3 apparently enhances 
aggregation of Aβ into beta-sheet fibrils, suggesting a role for p3 in 
initiating and/or nucleating Aβ deposition (Pike et al., 1995). Like Aβ, p3 
deposition has been reported in the brains of AD patients (Gowing et al., 
1994) and Down’s syndrome patients (Lalowski et al., 1996), indicating 
that p3 fragments may contribute to some aspects of AD-associated 
amyloid pathology (Zheng and Koo, 2011). 
Not much is known about p3’s functions in physiology except that 
intracerebroventricular infusion of p3 induces the expression of cytokines 
and chemokines in the hippocampus, revealing its pro-inflammatory 
nature in vivo (Szczepanik et al., 2001). 
1.4.5 AICD  
Double transgenic mice that overexpress AICD and one of its binding partners, 
Fe65, exhibit AD-like phenotypes (Ghosal et al., 2009). Hyperphosphorylation 
and aggregation of tau is observable from Western blots of hippocampal and 
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cortical lysates. Quantification of NeuN-positive cells from the dentate gyrus, 
CA1, and CA3 regions of the hippocampus revealed a significant reduction in 
the number of neurons in mice that are at least 18 months old, which is 
indicative of age-dependent neurodegeneration. These mice exhibit deficits in 
working memory when assessed using a paradigm involving spontaneous 
alternation in the Y-maze. Furthermore, EEG recordings exhibit abnormal 
spiking events, as defined by amplitudes that are at least three times greater 
than the baseline and last for at least three seconds (Vogt et al., 2011). This 
hyperexcitability is associated with increased vulnerability to kainic acid-
induced seizures and becomes more pronounced as the animals age (Ghosal et 
al., 2009). On the other hand, crossing AICD transgenic mice with tau-bearing 
mice has  no effect on tau phosphorylation, formation of NFT or GSK3B 
activity in 21-month-old double transgenic mice (Giliberto et al., 2010). 
Evidently, AICD is another APP metabolite with important biological 
functions that may contribute to AD pathology under certain circumstances. 
Just as the HBD and CuBD domains mediate some functions of the APP 
holoprotein, AICD contains the basolateral sorting signal between residues 
649-659; a VEVD caspase cleavage motif at residues 661-664 that has a 
putative function in AICD-mediated apoptosis; the YTSI endocytosis-
mediating motif at residues 653-656; the VTPEER motif at residues 667-672; 
as well as the YENPTY motif at residues 682-687 (reviewed in Muller et al., 
2008). The latter three are known to influence AICD interaction with binding 
partners. Interactions with adaptor proteins may increase AICD’s cellular 
lifetime, modify its structure, influence AICD transport, and alter signal 
transduction and/or regulation of target gene expression. For instance, JIP 
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mediates anterograde axonal transport and PAT influences intracellular APP 
sorting; isomerization of AICD depends on binding to PIN and FKBP12; and 
AICD is stabilized upon binding to Fe65 and MINT. Fe65 and SET are 
involved in AICD transactivation of target genes while MINT may also be 
involved in mediating crosstalk with Notch signaling. Binding of AICD to the 
cytosolic adaptor proteins Numb and Numb-like represses Notch activity 
(Roncarati et al., 2002). By forming a trimeric complex with the Notch 
intracellular domain (NICD) and Fbw7, AICD suppresses NICD 
transcriptional activity by dissociating existing NICD-RBP-Jκ complexes and 
enhancing NICD degradation via the proteasomal pathway while 
downregulating RBP-Jκ levels through the lysosomal pathway (Kim et al., 
2011). To date, more than 20 proteins have been reported to interact with 
AICD (reviewed in Muller et al., 2008). While the majority of proteins such as 
mDab1, cAbl, clathrin, p53, Numb, Grb2, X11, JIP, KLC, Shc, and Fe65 
contain phosphotyrosine binding domains that recognize and bind to the 
YENPTY sorting motif of AICD; the PAT1 microtubule-interacting protein 
binds to the YTSI motif and 14-3-3γ displays interaction with the VTPEER 
motif (reviewed in Slomnicki and Lesniak, 2008).  
AICD function can also be regulated by the phosphorylation of key residues 
that alter its structure. AICD contains eight potential phosphorylation sites, 
seven of which have been found to be phosphorylated in the brains of AD 
patients (Slomnicki and Lesniak, 2008). Other than Thr-668 and Tyr-682, the 
functional impact of phosphorylation at most of these sites is unknown. 
Constitutive phosphorylation of Tyr-682 in the YENPTY motif may be 
mediated by kinases like cAbl (Perkinton et al., 2004) or TrkA (Tarr et al., 
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2002) and this interferes with Fe65 and X11 binding (Zambrano et al., 2001). 
Phoshorylation of Thr-668 in the VTPEER motif has been attributed to 
various kinases such as JNK3, GSK3B, SAPK1b and CDK5 (Inomata et al., 
2003; Standen et al., 2001), to name a few, and this inhibits AICD interaction 
with 14-3-3γ and blocks subsequent gene transactivation (Sumioka et al., 
2005). Thr-668 phosphorylation causes a conformational change in AICD, and 
this functions as a “molecular switch” to regulate AICD interaction with some 
proteins, including those that normally bind to the YENPTY motif. However, 
some APP-binding partners such as X11s and JIP appear to be unaffected by 
Thr-668 phosphorylation (reviewed in Suzuki and Nakaya, 2008). Another 
consequence of Thr-668 phosphorylation is to facilitate APP cleavage by 
BACE1, indicating a role for AICD in regulating the processing of its 
precursor (Lee et al., 2003). The Thr-668 phosphorylated form of AICD is 
also found to dominantly translocate to the nucleus and result in 
neurodegeneration (Chang et al., 2006). Neuronal cell death is also triggered 
by AICD dimerization and is mediated via the JNK signaling pathway, 
following AICD complex formation with JIP1 and apoptosis signal-regulating 
kinase 1 (Hashimoto et al., 2003). Apoptosis is induced upon binding of AICD 
to p53, which enhances the latter’s transcriptional and apoptotic functions 
(Ozaki et al., 2006). Gel shift assays show that AICD also physically interacts 
with the p53 promoter and increases p53 mRNA levels (Alves da Costa et al., 
2006).  
On the whole, AICD’s role in development, synaptic plasticity, cytoskeletal 
dynamics and apoptosis (Müller et al., 2008) are probably achieved as an 
extension of its transcriptional regulatory function. AICD was first postulated 
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to participate in nuclear signaling based on similarities between APP and 
Notch processing (Annaert and De Strooper, 1999). Binding of Notch to its 
ligands triggers cleavage by ADAM-17 followed by RIP by γ-secretase to 
release NICD. However, PS1/2 that make up the catalytic core of the γ-
secretase complex are known to act on at least 89 other proteins besides APP 
and Notch. Most γ-secretase substrate proteins are also type I transmembrane 
proteins and they usually harbour a cytoplasmic C-terminal fragment that is 
capable of initiating or mediating intracellular signaling. Besides NICD, the 
intracellular domains of alcadeins, CD44, DCC, E- and N-cadherins, RPTP 
and LAR are known to affect gene transcription (reviewed in Haapasalo and 
Kovacs, 2011). Confocal imaging studies provided direct evidence for the 
existence of two AICD transcriptional regulatory complexes that are localized 
to the nucleus. AICD-Fe65-Tip60 (AFT) complexes are concentrated in 
spherical nuclear spots that are postulated to represent active loci of gene 
transcription. Although AICD-JIP1-Tip60 (AJT) complexes are also found in 
the nucleus, they display a distinct speckle-like morphology, as compared with 
the smaller spherical spots generated by AFT complexes. Furthermore, lower 
levels of AICD are associated with the AJT speckles compared with the AFT 
nuclear spots (von Rotz et al., 2004). Differences in morphology of AFT and 
AJT prove to be indicative of the different mechanisms by which Fe65 and 
JIP1 regulate the expression of target genes. While Fe65 may enter the nucleus 
in the absence of the APP holoprotein (and hence, AICD), JIP1 does not. 
Furthermore, JIP1-mediated transactivation of a Gal4-dependent reporter gene 
is independent of Tip60, whereas formation of the AFT complex is necessary 
for Fe65-induced activation (Scheinfeld et al., 2003). Immunoprecipitation 
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(IP) experiments revealed that AICD forms a complex with Fe65 and 
CP2/LSF/LBP1, which is present in the nuclear fraction of rat cortical primary 
neurons and overexpression of AICD increases the expression of GSK3B 
(Kim et al., 2003). Conversely, interaction of AICD with other proteins like 
NICD (Kim et al., 2007), Nedd8 (Lee et al., 2008) and RanBP9 (Domingues et 
al., 2014) prevents AICD nuclear signaling by trapping AICD in the 
cytoplasm and/or inhibiting AFT formation. Besides protein-binding, 
activation of the NF-κB pathway either by overexpression of NF-κB-inducing 
kinase or by treatment with the proinflammatory cytokine IL-1β 
downregulates AICD transcriptional activity (Zhao and Lee, 2003). The 
nuclear signaling capability of AICD is not only dependent on the rates of 
AICD production and degradation but it appears that APLP1 may play a 
regulatory role by sequestering Fe65 (Gersbacher et al., 2013), thus making 
less Fe65 available for stabilizing AICD and facilitating its nuclear 
translocation. 
Although AICD’s role in the regulation of target gene expression is now 
indisputable, the identity of some of these targets (Table 1) remains a 
controversy due to conflicting data or the lack of independent replication. 
Over the years, diverse experimental methods have been used to identify genes 
that may potentially be regulated by AICD. While some involved large-scale 
gene transcriptome analysis, others focused on monitoring changes associated 
with a specific group of genes. In one study, embryonic carcinoma cells were 
treated with retinoic acid to induce differentiation into neurons. Expression of 
AICD results in neuron-specific apoptosis. Subsequent microarray analysis 
revealed that 277 genes are upregulated by more than 10-fold while 341 genes 
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are downregulated to less than one-tenth of the original level in the presence 
of AICD. Validation of seven upregulated genes (Ptprt, Cpb1, Nr2e1, Myh1, 
Dnahc7c, Alkbh3 and Ctgf) and seven downregulated genes (Hes5, Sk10ab, 
Nid1, LOC213332, Dtx1, Rbp4 and Col3a1) by reverse transcription-
polymerase chain reaction showed that the results are in agreement with the 
microarray data (Ohkawara et al., 2011). In a more targeted study, real-time 
PCR was used to determine whether inducible expression of AICD alters the 
transcription of genes coding for proteins that are involved in APP processing 
or signaling. While the expression of BACE1 and Tip60 increase after 48 
hours of AICD induction, the levels of ADAM10, PS1 and Fe65 are not 
significantly changed. What stood out however, was the finding that AICD is 
capable of regulating the transcription of its own precursor, APP (von Rotz et 
al., 2004). In one of the first demonstrations of physical association between 
AICD and the promoters of target genes, chromatin immunoprecipitation 
(ChIP) using an antibody directed to the C-terminus of APP showed that the 
AFT complex is recruited to the KAI1 promoter upon co-transfection of APP, 
Fe65 and Tip60 (Baek et al., 2002). In addition, the neprilysin (also known as 
CD10) gene promoter appears to be transactivated not only by AICD by also 
by the intracellular domains of APLP1 and APLP2 (Pardossi-Piquard et al., 
2005). In 2007, Müller and colleagues established AICD- and AICD/Fe65-
inducible cell lines and conducted a genome-wide analysis to identify target 
genes. Analysis of gene expression after AICD induction revealed increased 
expression of genes associated with organization and dynamics of the actin 
cytoskeleton, such as α2-actin and transgelin. However, AICD or AICD/Fe65 
expression is not associated with changes in expression of previously proposed 
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AICD targets like KAI1 and GSK3B (Müller et al., 2007). This is not 
surprising given that one year earlier, Herbert and colleagues had already 
reported that KAI1, GSK3B, CD10 and APP expression are unaltered in APP-
deficient models; γ-secretase-deficient models; and in murine embryonic 
fibroblasts, HeLa, COS and Neuro2A cells that were treated with two different 
GSIs (Hebert et al., 2006). Similarly no significant differences in the 
expression of BACE1, KAI1, GSK3B, p53, Tip60 or VGLUT2 are found 
following DNA microarray transcriptome profiling of prefrontal cortical 
samples from adult wild type, APP knockout (APP-/-), APLP2 knockout 
(APLP2-/-) and sAPPα knock-in mice (Aydin et al., 2011). While the CD10 
promoter was subsequently shown to be bound by AICD in NB7 cells and in 
rat primary neurons but not in HUVEC cells (Belyaev et al., 2009; Xu et al.), 
the promoters of GSK3B and Aquaporin do not appear to be associated with 
AICD in SH-SY5Y cells (Kerridge et al., 2014). 
Table 1. AICD target genes. (Adapted from Grimm et al., 2013; and Pardossi-Piquard and Checler, 2012) AICD Target Genes  Physiological function Up- or down-regulation 
Promoter binding References 
RA-responsive genes  Cell–cell communication and development 
Down  Unknown  Gao and Pimplikar (2001) KAI1/CD82  Metastasis suppressor, apoptosis  
Up Yes Baek et al. 2002; von Rotz et al. (2004) GSK3B  Kinase, glycogen metabolism, cell development, cell cycle regulation, proliferation and apoptosis 
Up No  Kim et al. (2003); von Rotz et al. (2004); Ryan and Pimplikar (2005); Kerridge et al. (2014) APP  Cell adhesion and migration, neurite outgrowth, synaptogenesis 
Up Unknown von Rotz et al. (2004) 
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BACE Aspartyl protease, APP cleaving enzyme 
Up Unknown von Rotz et al. (2004) 
Tip60  Histone acetyltransferase Up Unknown von Rotz et al. (2004) NEP/CD10 Metallopeptidase, Aβ degrading enzyme 
Up Yes Pardossi-Piquard et al. (2005); Belyaev et al. (2009); Xu et al. (2011) p53 Tumor suppressor, apoptosis Up Yes Alves da Costa et al. 2006; Ozaki et al. (2006) α2-Actin, FN1, TAGLN, SM22, TPM1, MICAL2, RAB3B 
Organization and dynamics of the actin cytoskeleton 
Up Unknown  Muller et al. (2007) 
Transgelin Organization and dynamics of the actin cytoskeleton 
Up Unknown  Muller et al. (2007) 
IGFBP3   Transport of insulin growth factor Up Unknown  Muller et al. (2007) EGFR  Cell cycle, proliferation, differentiation, survival function 
Down  Yes Zhang et al. (2007) 
LRP1 Endocytic and signaling receptor, APOE/cholesterol metabolism 
Down  Yes Liu et al. (2007) 
Cyclins B1 and D1 Cell cycle activation Up Unknown Ahn et al. (2008) VGLUT2  Transport of glutamate, neurotransmission 
Up Unknown Schrenk-Siemens et al. (2008) CHOP  ER stress, unfold protein response, apoptosis 
Up Yes Takahashi et al. (2009) 
Aquaporin 1   Water channel  Up No  Huysseune et al. (2009); Kerridge et al. (2014) S100a9  Inflammation-associated calcium-binding protein 
Up Unknown  Ha et al. (2010) 
ApoJ/clusterin Lipoprotein, transport of lipid, survival function 
Down  Unknown  Kogel et al. (2011) 
Ptch1 Shh pathway, cell division, proliferation, brain 
Up Yes Trazzi et al. (2011); Mukhopadhyay 
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development and Raychaudhuri (2011) AGPS Plasmalogen synthesis Up Unknown Grimm et al. (2011) SPTLC2 Sphingolipid synthesis Down Unknown Grimm et al. (2011) TRPC5 Component of receptor-activated nonselective calcium permeant cation channel 
Down Unknown Mukhopadhyay and Raychaudhuri (2011) 
GD3S Ganglioside synthesis Down Unknown Grimm et al. (2011) Stathmin1 Regulatory protein of microtubule dynamics 
Down Unknown Müller et al. (2013) 
PGC-1α Mitochondrial master transcriptional coactivator 
Up Unknown Robinson et al. (2014) 
Transthyretin Aβ-binding protein,  Aβ clearance Up Yes Kerridge et al. (2014) 
1.5 Addressing the discrepancies in AICD target modulation 
In view of the conflicting data, it is suggested that AICD regulation of target 
gene expression may be specific to a particular set of experimental conditions. 
For instance, genes that are altered in one cell type, tissue or animal model 
may not show a significant change when tested in a different sample. 
Furthermore, different methods of AICD induction have been employed in 
previous studies. Overexpression of AICD fragments that vary from 31-51 
amino acids in length have been reported in the literature. AICD plasmids may 
be introduced by transfection, viral transduction or electroporation; AICD 
expression may be controlled through the use of inducible systems or AICD 
may be constitutively expressed in cells that have been stably transfected with 
full-length APP. In some cases, the effects of AICD alone were investigated; 
others studied AICD in combination with Fe65 and there were also cases 
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where AICD, Fe65 and Tip60 were overexpressed together. In cases where 
physical binding of AICD to the putative target promoter has not been 
demonstrated, AICD-induced changes in target expression might have resulted 
from alterations of other signaling pathways such as crosstalk with Notch 
(Kim et al., 2011; Kim et al., 2007) or Wnt (Zhou et al., 2012; Zhou et al., 
2011) signaling; epigenetic mechanisms such as altering histone acetylation 
(Hong et al., 2012; Kim et al., 2004); or by indirectly affecting other 
protein/transcription factors (Muller et al., 2011; Ozaki et al., 2006). These 
factors serve as additional variables that affect the reproducibility of finding 
the same AICD targets across samples. According to Slomnicki and Lesniak, 
changes in target expression that are observed in vitro are evoked by high 
AICD levels that are unlikely to exist in vivo. Considering the instability of 
AICD in vivo, any effect on the transcription of target genes can be 
counteracted by other mechanisms or compensated to avoid pathological 
outcomes. However, it is possible that the transcriptional potential of AICD 
and its partners may become apparent if studied over a longer duration, in 
cases where APP processing is enhanced (for instance in FAD) and/or under 
as yet unknown conditions whereby the compensatory mechanisms become 
inactive (Slomnicki and Lesniak, 2008).  
1.6 Alterations to APP processing in AD may affect release of functional 
AICD 
APP processing can be regulated by various factors such as neurotransmitters, 
intracellular signaling pathways, sterols, estrogen and even stress (reviewed in 
Mills and Reiner, 1999). More importantly, deregulation of APP metabolism 
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has been implicated in AD. The roles of SORL1 and APOE ε4 in influencing 
the amyloidogenic pathway have been discussed in Section 1.1.4 and the 
effects of mutations that lead to FAD were highlighted in Section 1.2. Both 
BACE (Holsinger et al., 2002) and C99 (Evin et al., 2003) levels are 
significantly upregulated by at least 2-fold in AD, indicative of preferential 
processing of APP via the amyloidogenic pathway in AD. The majority of 
APP expressed in the brain is neuronal, so Aβ is secreted largely from neurons 
(Suzuki and Nakaya, 2008). The resulting overproduction of Aβ and/or 
increased Aβ42 to Aβ40 ratio in AD has led to extensive studies elucidating 
the roles of Aβ in AD (reviewed in Glabe, 2005; LaFerla et al., 2007; Walsh 
and Selkoe, 2007). Accordingly, the amount of AICD that is released from the 
amyloidogenic pathway is also expected to increase. Although AICD can be 
produced from both APP processing pathways, only AICD generated from 
amyloidogenic processing of APP695 is capable of nuclear signaling and 
regulation of gene expression (Belyaev et al., 2010; Goodger et al., 2009). 
AICD generated at the plasma membrane (from non-amyloidogenic APP 
processing) and AICD generated in the endosomal system (from  
amyloidogenic APP processing) have different propensities for translocation 
to the nucleus as a consequence of their spatial location. AICD generated at 
the plasma membrane is released into the cytoplasm and is tightly regulated by 
proteolysis. Degradation of AICD as it travels through the cytoplasm en route 
to the nucleus renders it non-functional and involves the proteasome (Nunan et 
al., 2001) or insulin-degrading enzyme (Edbauer et al., 2002). Alternatively, 
AICD can be cleaved at amino acid residue 664 by caspases 3, 6, and 8 to 
generate a shorter C31 fragment that is capable of inducing apoptosis 
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(Bertrand et al., 2001). As a result, AICD has a reportedly short half-life of 5 
minutes (Cupers et al., 2001) and this is consistent with the short-lived nature 
of many transcriptional regulators which are rapidly degrading and not 
abundant (Belle et al., 2006). By contrast, active retrograde transport of 
endosomal vesicles to perinuclear regions increases the likelihood of AICD 
being delivered to the nucleus (Goodger et al., 2009).  
1.7 Research objectives 
In a previous study, ChIP-Seq was conducted to identify AICD binding sites 
on chromatin. The AICD binding profile represents the physical sites of action 
where AICD transcriptional complexes may exert their regulatory function on 
target genes. In addition, microarray analysis was carried out to reveal genes 
that are differentially regulated by AICD and to complement the chromatin 
binding data in order to allow identification of direct AICD targets. In both 
cases, manipulation of AICD levels was achieved indirectly, via stable 
transfection of APP and/or siRNA-knockdown of APP (Wong, 2012). In the 
current study, we test the hypothesis that changes in AICD levels alone are 
sufficient to alter the expression of target genes independently of its precursor. 
Since increased β-secretase levels and activity in AD result in more Aβ 
generation and a concomitant increase in AICD nuclear signaling, changes in 
expression of protein products derived from translation of the AICD targets 
are expected to be associated with AD. 
As the large data sets generated by ChIP-Seq and microarray studies are prone 
to false positive errors, the present study aims to: 
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(1) extract data from the two datasets in a way that allows validation of a 
reasonable number of putative AICD target genes by quantitative 
polymerase chain reaction (qPCR) 
(2) determine whether AICD-induced changes at the mRNA level are 
sustained at the protein level using Western blot and by extension, 
potentially result in alteration of function 
(3) demonstrate relevance of the AICD targets to AD by examining their 
expression levels in human cortical samples and simultaneously 
checking for reproducibility of AICD targets in a different sample 
(4) examine whether direct manipulation of AICD levels can induce 
changes in target expression independently from APP 
At the very least, our findings would contribute to the understanding of 
APP/AICD downstream signaling, with regard to the regulation of gene 
transcription. The best-case scenario would be the identification of proteins 
that are altered in AD as this will improve our understanding of cellular 
functions that are associated with disease and reveal potential biomarkers or 























2.1 Cell culture 
SH-SY5Y human neuroblastoma cells and SH-SY5Y cells that were stably 
transfected with the pcDNA-APP695 plasmid (SH-SY5YAPP695) were handed 
down from Dr. Chen Zhong-Can (National Neuroscience Institute, Singapore) 
and maintained in Dulbecco's modified Eagle's media (DMEM) containing 
4500mg/L glucose, 110mg/L sodium pyruvate, 4mM L-glutamine (Gibco) and 
supplemented with 10% heat inactivated fetal bovine serum (Gibco) and 
100U/mL penicillin-streptomycin (Gibco). Adherent cells were cultured as a 
monolayer in a humidified atmosphere at 37°C and 5% CO2. Once confluent, 
cells were rinsed twice with phosphate-buffered saline (PBS, pH 7.4) (1st 
BASE) before treatment with TrypLE Express (Gibco) and incubation at 37°C 
for three minutes to detach cells from the tissue culture dish. Culture media 
was added to inactivate TrypLE Express and cell pellets were collected after 
centrifugation at 300 x g for three minutes. Cell pellets were resuspended in 
fresh culture media before passaging at a ratio of 1:5.  
2.2 Drug treatment 
2.2.1 Leupeptin 
106 SH-SY5Y cells were seeded in each well of a 6-well plate. 20μg/ml of 
leupeptin (Roche) was added to the culture media. Equal volume of deionized 
water was added in place of leupeptin for control cells. Cells were cultured in 
the presence or absence of leupeptin at 37°C and 5% CO2 for 24 hours. 
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2.2.2 γ-secretase inhibitors 
3.5 x 105 SH-SY5Y or 7 x 105 SH-SY5YAPP695 cells were seeded in each well 
of a 6-well plate. Since SH-SY5YAPP695 cells grow slower than SH-SY5Y cells, 
the initial plating density was increased to achieve similar levels of confluency 
after the same duration of drug treatment. 1μM, 5μM or 10μM of L-685,458 
(Sigma-Aldrich) or BMS 299897 (Tocris) was added to the culture media. 
Dimethyl sulfoxide (DMSO, Sigma-Aldrich) was added to the culture media 
as control for L-685,458 while absolute ethanol (EtOH, Millipore) was used 
instead of BMS 299897. Cells were cultured in the presence or absence of 
drug at 37°C and 5% CO2 for 48 hours. 
2.3 Constructs 
pcDNA4 vector expressing the human APP695 isoform and the pCDF vector 
expressing Fe65, AICD, or a mutant AICD fragment incapable of binding to 
Fe65 (AICD*: P685A, Y687A) were provided by Dr. Chen Zhong-Can 
(National Neuroscience Institute, Singapore). pIREShyg vector expressing 
triple mutations in the APP copper-binding domain (APP ΔCuBD: H147A, 
H149A, H151A) was a kind gift from Dr. Edward Parkin (Lancaster 
University, UK). For ease of comparison with available positive and negative 
control plasmids, the APP ΔCuBD insert was sub-cloned into the pcDNA4 
vector (see Sections 2.3.1-2.3.4). 
2.3.1 Transformation of plasmids into dam-/dcm- competent E. coli  
To generate plasmids that were free of Dam and Dcm methylation for 
subsequent restriction endonuclease activity, dam-/dcm- competent E. coli 
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(New England Biolabs) underwent transformation with pIREShyg-APP 
ΔCuBD or pcDNA-APP695. 100ng of plasmid was added to 50μl of 
competent cells and incubated on ice for 30 minutes, followed by heat shock 
in a 42°C water bath for 45 seconds. After incubation on ice for another two 
minutes, 500μl of SOC media was added and cells were grown in a 37°C 
shaking incubator for one hour. 50μl of the transformation was plated onto a 
10cm LB agar plate containing 100μg/ml ampicilin (Sigma-Aldrich) and 
allowed to grow for 18 hours at 37°C.  The ampicilin resistance protein 
encoded on the plasmid backbone allows selection of bacterial clones that 
have taken up the plasmid of interest. Successfully transformed E. coli were 
grown in 5ml of LB media containing 100μg/ml ampicilin in a 37°C shaking 
incubator for 18 hours and plasmid DNA was isolated using the PureLink 
Quick Plasmid Miniprep Kit (Invitrogen). Purified plasmid DNA was 
quantified using the Thermo Scientific NanoDrop 2000 spectrophotometer. 
2.3.2 Restriction enzyme digestion and gel electrophoresis 
BSABI makes blunt-ended cuts at nucleic acid residues 361 and 2124 of 
APP695 (NCBI accession number NM_201414.2). 4μg of pIREShyg-APP 
ΔCuBD or pcDNA-APP695 were digested with 40 units of BSABI (New 
England Biolabs) at 60°C for one hour and the resulting fragments were 
resolved on a 0.8% agarose gel at 100V for 80 minutes. Ethidium bromide 
(Sigma-Aldrich) was incorporated into the gel and running buffer at 0.5 μg/ml 
and bands were visualised immediately after electrophoresis using the Gel Doc 
EZ Imager (Bio-Rad). The 5.7kb pcDNA vector that includes partial APP 
sequence and the 1.8kb partial APP ΔCuBD insert (Figure 3) were excised 
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from the gel and DNA was purified using the PureLink Quick Gel Extraction 









Partial APP ΔCuBD insert
Partial wild-type APP insert
 Figure 3. Subcloning of APP ΔCuBD insert into pcDNA vector. Generation of the 5.7kb pcDNA vector that includes partial APP sequence and the 1.8kb partial APP ΔCuBD insert from respective plasmids following BSABI digestion at APP nucleotide residues 361 and 2124, followed by ligation of the two to produce pcDNA-APP ΔCuBD. 
2.3.3 Calf intestinal alkaline phosphatase (CIAP) treatment 
In order to prevent re-circularization of the plasmid backbone due to blunt 
ends generated by BSABI digestion, 0.05 units of CIAP (Promega) was added 
to 550ng of pcDNA vector. This mixture was incubated at 37°C for 15 
minutes and at 56°C for another 15 minutes. An additional 0.05 units of CIAP 
was added before the 30 minute incubation was repeated.  
2.3.4 DNA ligation 
After removal of CIAP using the PureLink PCR Purification Kit (Invitrogen), 
the 5.7kb pcDNA vector that includes partial APP sequence was added to the 
BSABI-digested APP ΔCuBD insert in a molar ratio of 1:3. 3 units of T4 
DNA ligase (Promega) was used for the ligation reaction. The mixture was 
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incubated for one hour at room temperature before overnight incubation at 4°C. 
Inactivation of ligase was achieved by incubation at 70°C for 10 minutes in an 
Eppendorf Mastercycler Gradient. This was followed by transformation of the 
ligation mix into DH5α competent cells, selection and expansion of cells that 
have taken up the pcDNA-APP ΔCuBD plasmid, and purification of DNA as 
described in Section 2.3.1. 
2.4 Transient gene overexpression or knockdown 
2.4.1 Plasmid transfection 
SH-SY5Y cells were plated at an initial density of 3.5 × 105 cells per well of a 
6-well plate. 24 hours later, cells were transfected using the Effectene 
Transfection Kit (Qiagen). 0.4μg of plasmid was diluted in Buffer EC and 
mixed with 3.2μl of Enhancer to aid DNA condensation. After incubation at 
room temperature for five minutes, 20μl of Effectene transfection reagent was 
added and complex formation was allowed to take place for 10 minutes at 
room temperature. Old culture media from the cells was replaced with fresh 
culture media. Effectene-DNA complexes were mixed with 600μl of fresh 
culture media before drop-wise addition to the cells. Plates were immediately 
swirled to ensure proper mixing of the transfection complexes with the cells 
before incubation in a humidified atmosphere at 37°C and 5% CO2 for another 
48 hours. In the case of AICD or AICD* transfection, cells were incubated for 
24 hours post-transfection followed by addition of 20mM ammonium chloride 
into the culture media for another 24 hours. For controls, an equivalent volume 
of water was added instead of ammonium chloride. 
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2.4.2 Small interfering RNA (siRNA) knockdown 
21-mer double-stranded siRNA targeting APP were designed and synthesized 
by Sigma-Aldrich. The sense and anti-sense sequences are 
CCAACCAACCAGUGACCAUdTdT and 
AUGGUCACUGGUUGGUUGGdTdT respectively and MISSION siRNA 
Universal Negative Control #1 (Sigma-Aldrich) was used as the non-target 
siRNA. 6μl of Lipofectamine RNAiMAX was added to 150pmol of siRNA 
duplex that was pre-diluted in Opti-MEM reduced serum media (Gibco). After 
incubation for 20 minutes at room temperature, 106 SH-SY5Y cells in culture 
media without antibiotics were added to the RNAi-Lipofectamine complexes 
in each well of a 6-well plate. Cells were incubated in a humidified 
atmosphere at 37°C and 5% CO2 and harvested for RNA or protein after 48 
hours. 
2.5 Gene expression analysis 
2.5.1 RNA extraction 
PureLink RNA Mini Kit (Life Technologies) was used to extract total RNA 
from SH-SY5Y or SH-SY5YAPP695 cells. Cells were detached from 10cm 
tissue culture dishes as described in Section 2.1, diluted in a ratio of 1:1 with 
Trypan blue (Sigma-Aldrich) and quantified using the Countess Automated 
Cell Counter (Invitrogen). 1 x 107 cells were pelleted by centrifugation and the 
recommended volume of lysis buffer containing beta-mercaptoethanol (β-ME) 
was added. After vortexing to ensure dispersal of the cell pellet, an equal 
volume of 70% ethanol in diethyl pyrocarbonate (DEPC) water was added to 
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the cell homogenate. Homogenates were transferred to spin cartridges and 
processed according to the manufacturer’s instructions. To remove genomic 
DNA from the RNA preparation, 20 units of DNase (Roche) was diluted in 
10x buffer and DEPC water and added to each spin cartridge. DNase 
incubation lasted for 15 minutes at room temperature. After several washes 
using the buffers provided in the kit, RNase-free water was added to the centre 
of the spin cartridge before centrifuging at 21 000 x g for two minutes at room 
temperature to elute the RNA. Purified RNA was quantified using the Thermo 
Scientific NanoDrop 2000 spectrophotometer. 
2.5.2 Reverse transcription 
1ug of RNA was diluted in RNase-free water to a volume of 9μl before 
addition of 0.5μg of Oligo dT primer (Promega). This mixture was incubated 
at 70°C for five minutes followed by 4oC for another five minutes in an 
Eppendorf Mastercycler Gradient. At the end of 10 minutes, the following 
reagents were added in the order listed: 2.4μl of 25mM MgCl2, 2μl of 10mM 
dNTP mix, 0.5μl of RNAsin and 1μl of ImPromp-II (Promega). The mixture 
was returned to the thermocycler and incubated at 25°C for five minutes, 42°C 
for 90 minutes, and inactivated at 70°C for 15 minutes. 
2.5.3 Quantitative real-time polymerase chain reaction (qPCR) 
qPCR was performed on the Applied Biosystems ViiA 7 Real-Time PCR 
System with SYBR green fluorescent label. Each reaction consisted of 1× 
SYBR green master mix, 100nM of each primer and 1μl of cDNA or nuclease-
free water (non-template control), for a final volume of 20μl. Samples were 
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run in triplicate in 96-well plates (Applied Biosystems). Cycling parameters 
were as follows: 50°C for two minutes, 95°C for 10 minutes and 40 cycles of 
95°C for 15 seconds and 60°C for one minute. At the end of the amplification 
phase, a dissociation step was performed at 95°C for 15 seconds, 60°C for 15 
seconds, 95°C for 15 seconds and 60°C for 15 seconds to identify a single 
melting temperature for each primer set. Sequences of primers used are listed 
in Table 2. Where applicable (as in the case of detecting the APP695 splice 
variant), intron-spanning primers were designed using NCBI Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). qPCR amplifications were 
examined by agarose gel electrophoresis. 2% agarose gels were run at 100V 
for 100 minutes and bands were visualised as described in Section 2.3.2 to 
verify the expected molecular weights for target mRNA and reference gene 
(RPLP0) products. 
Table 2. qPCR target gene and internal control primers Gene Sequence (5’ to 3’) 
ADAMTS3 Forward: CCTGAGTCGGTCAGAGCCTGTCA Reverse: AGGGTGCTACTGCGCTTGCTG 
AFTPH Forward: CAGGAGTCTCTACCACCCGTCCA Reverse: CACCTGGGATTGTGGTGCTGCTG 
ANG Forward: GTTCTGAGGCCGAGGAGCCTGTG Reverse: GTCAGACCCAGACCCAGCACGA 
APP Forward: ACGATCTCCAGCCGTGGCATTC Reverse: GTCAACCCAGAACCTGGTCGAGTGG 
ARL5B Forward: GGGTGTATGACAGCAGCTGAA Reverse: GGCATAACCCTTCTCCTGTGA 
CACANA2D1 Forward: AGTGGACCTGGTGCCTATGA Reverse: ACCAGCACACGGATCTCTGA 
CDKN1A Forward: GTTCCTTGTGGAGCCGGAGCTGG Reverse: GCCTTGCTGCCGCATGGGTTC 
CLCN7 Forward: GAACTTTTGGACCCGGATATGG Reverse: GGACAGGAGCTTCTCGTTGT 
CLSTN3 Forward: CCTGCAGCATGTGGCTTACA Reverse: ATGGAGACGCAGGACTCTTC 
CNN2 Forward: AAGGCTGGCCAGTGCGTCATC Reverse: GGCTGGCGCATTTGTTGGTGC 
EZH2 Forward: ACCCCCAACATAGATGGACCAAATGC Reverse: TCTTCCGCTTATAAGTGTTGGGTGTTGC 
FILIP1L Forward: ACTGCAGGCTCGAGATGAGG Reverse: CCTCCTGCCAAGGGGTAGAT 
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GAS1 Forward: TGCGCGCAGGACGAGAACTG Reverse: GGGCAGGCACGGCTCAATGG 
GTSE1 Forward: AGAAGCACACGTGGCTGTAG Reverse: AGGGGAGCTCAGGTCTATGA 
IL17RB Forward: CAGGCGTCCCTTTCCCTCTGG Reverse: ACCCATGTGGCCACCAGCAGA 
ITGB3BP Forward: GGACTTCCTCACAAAGCATCACGTC Reverse: GGCAGATGCAGAAGTTGGTGCTCA 
LAYN Forward: ATAGCACAGCCTGCCAGGACC Reverse: CCGCAGGATGGCTCATCCACA 
LHPP Forward: GTCTGCCCTGCAAGCGATAG Reverse: CACCTGCAGCGCTCTCATTC 
LMO4 Forward: GGCTTCGCTCGCATTTCACCG Reverse: AGCTGCTGCCCGGATTCACCA 
MAGI3 Forward: GACCATGGTTTGGCTCCTTC Reverse: TTGCTCGGGTTTCACGTAGG 
MCM4 Forward: TCCAGAAGACATTGACCAGCTC Reverse: CCTCCTGCATCTCGGGAATC 
MCM7 Forward: AGCCCCAAGGGTCTAGGATACAGTC Reverse: TCCAAGGGGGACCCGCTCATCTA 
MLF1IP Forward: GCGCAAGACGTTCAAAGAACAC Reverse: CTGCCAATGCTTGAGACATCAG 
PACRGL Forward: CCGTTTGGTGAACAGTCACG Reverse: GTCTCTCTCAGACCCTCAGCTA 
PAG1 Forward: TTTCCTCCAAGGACACAGCTC Reverse: GCCGAGGGAATCAGTCAGTC 
PDE7A Forward: ATGCAGCGGGCTTTTGATTG Reverse: GGAAATAGCTCCACGCCTCTTA 
PDE8B Forward: GCGTGAAGCAGGTGTCTTCTG Reverse: TAGGGTCCTGCGTCAGTCTC 
PHLDA3 Forward: CGGGCGCACCATCTTTCCTTCA Reverse: TCCCAGGGCTCGTCCATTCCT 
RBL1 Forward: CCAAGAAGCGCTCTGCTGTA Reverse: GCAGGGGATTCTGCATCACTA 
RPLP0 Forward: CACGGGCACCATTGAAATCC Reverse: ATGCTGCCATTGTCGAACAC 
RRM2B Forward: CAGCGGACCAGCGGACCACC Reverse: TCGCCCATCGCGCAGACTCC 
SLC161A0 Forward: GTCGTGGGTGCTGCTGTTGGA Reverse: AAAGGAGCAGCCGCAGGCAA 
SP3 Forward: GGTGGTGGAAGAGGTACCAATC Reverse: GAATGCCAACGCAGATGAGC 
SPOPL Forward: AGGTGCAGTGTACTTCGACA Reverse: TATGTCGGTTGCTTGGTTGC 
TMEFF2 Forward: GGAGCCATCTTGCAGGTGTG Reverse: ACAGGACCGGGAACAACGTA 
TRPC1 Forward: GACTACGGTTGTCAGTCTGC Reverse: TTCAGAGTCGATTGCCACCA 
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ZMAT3 Forward: CTCATTCTCGGAATCCTCAGAGCTGG Reverse: AGCGGGGATTGAAGTAAGGACCTG 
2.6 Protein expression analysis 
2.6.1 Human AD brain lysates 
Human AD brain lysates and controls were provided by Assistant Professor Dr. 
Mitchell Lai. The Brodmann area 9 (BA9) region of the brain from 16 human 
AD patients (mean age: 88 + 8 years), who were diagnosed based on clinical 
neuropathology, and 20 controls (mean age: 80 + 8 years) were dissected free 
of white matter and meninges. Tissue samples were homogenized in lysis 
buffer containing 50mM Tris-HCl, 120mM NaCl, 5mM KCl and 2μg/ml 
pepstatin A and subjected to protein quantification. The lysates were diluted to 
the same concentration, mixed with 2 x Laemmli sample buffer (Bio-Rad) 
containing 5% β-ME and boiled for 10 minutes before storage at -80oC. 25μl 
of brain lysate was loaded per lane for sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE). 
2.6.2 Protein isolation 
Following aspiration of culture media, cells were washed with ice-cold PBS. 
After the first wash, cells were scraped in ice-cold PBS and centrifuged at 300 
x g for three minutes at 4oC. The supernatant were discarded and cell pellets 
were lysed at 4°C for 20 minutes with constant agitation in Radio Immuno 
Precipitation Assay (RIPA) buffer made up of 50mM Tris-HCl pH 7.4 (1st 
BASE), 1% Igepal CA-630, 0.5% Sodium deoxycholate, 0.1% SDS, 150mM 
NaCl, 2mM EDTA, 50mM NaF, 0.2mM Sodium orthovanadate (Sigma-
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Aldrich) and Complete Protease Inhibitor (Roche). The latter was added prior 
to use. After centrifugation at 14 000 x g for 15 minutes at 4oC, the 
supernatant containing the proteins were collected. 
2.6.3 Separation of cytoplasmic and nuclear extracts 
Cytoplasmic and nuclear extracts from 4 x 106 control SH-SY5Y cells, SH-
SY5Y cells transiently transfected with pcDNA-APP695 and SH-SY5YAPP695 
cells were collected using the NE-PER Nuclear and Cytoplasmic Extraction 
Kit (Thermo Scientific). Following aspiration of culture media, cells were 
washed with ice-cold PBS. After the first wash, cells were scraped in ice-cold 
PBS and centrifuged at 500 x g for three minutes at 4oC. CER I buffer 
containing Halt Protease Inhibitor (Thermo Scientific) was added to the cell 
pellets and lysis took place on ice for 10 minutes. After addition of CER II 
buffer, lysates were centrifuged at 16 000 x g for 10 minutes at 4oC. 
Cytoplasmic extracts in the supernatant were collected and the remaining 
pellets were washed twice with ice-cold PBS before NER buffer containing 
protease inhibitor was added. To facilitate nuclear lysis, samples were 
vortexed for 15 seconds after every 10-minute interval while incubation on ice 
took place for a total of 40 minutes. Nuclear extracts were collected after 
centrifugation at 16 000 x g for 10 minutes at 4oC. All extracts were stored at -
80°C before use. 
2.6.4 Protein quantification 
Protein concentration was determined using the Bicinchoninic acid (BCA) 
Protein Assay Kit (Thermo Scientific). 10μl of bovine serum albumin (BSA) 
 61 
dilutions ranging from 0-1500μg/ml or 10μl of unknown protein 
concentrations that were pre-diluted 10 times in lysis buffer were added in 
duplicate into a 96-well plate. As per the manufacturer’s instructions, Reagent 
A was first mixed with Reagent B in a ratio of 1:50 before adding 200μl of 
reagent to the protein samples using a multi-channel pipette and incubation at 
37oC for 30 minutes. Interaction of proteins with the reagent resulted in the 
formation of a complex that exhibited an absorbance at 562nm. The 
colorimetric property, which varied linearly with increasing protein 
concentrations, was detected using the Tecan Infinite M1000 microplate 
reader. A standard curve was plotted using the series of BSA dilutions. By 
assaying proteins of interest alongside the BSA dilutions, the concentration of 
each unknown was determined from the standard curve and equal amounts of 
protein (150μg for AICD detection, 80μg for cytoplasmic extracts, 40μg for 
nuclear extracts or 50μg otherwise) were loaded for SDS-PAGE.  
2.6.5 SDS-PAGE and Western blot 
Protein samples were boiled at 95oC for 10 minutes with 4x Sample Buffer 
consisting of 10% SDS, 50% Glycerol, 0.4M dithiothreitol (Sigma-Aldrich), 
0.05% bromophenol blue (Bio-Rad), and 0.313M Tris-HCl, pH 7 (1st BASE). 
For AICD detection, samples were loaded on a 16% Tricine-SDS acrylamide 
gel containing 6M Urea (Sigma-Aldrich) for better resolution of small 
molecular weight proteins (Schagger, 2006). Cytoplasmic and nuclear extracts 
were resolved using the 10-20% Mini-Protean Tris-Tricine Precast Gel (Bio-
Rad). For all other samples, 10% Tris-Glycine acrylamide gels were used. Run 
conditions were 100V for 1.5 hours and 2.5 hours for the Glycine-SDS and 
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Tricine-SDS gels respectively. For the former, protein transfer to 0.45μm 
nitrocellulose membrane (Bio-Rad) was carried out at 200mA for 100 minutes 
while protein transfer to Immun-Blot PVDF membrane (Bio-Rad) lasted for 
one hour in the case of the latter. Depending on the antibody that was to be 
added in the subsequent step, the membrane was either blocked with 5% low-
fat milk (Sunlac) or 5% BSA (Sigma-Aldrich) in Tris-buffered saline (1st 
BASE) containing 0.1% Tween-20 (Sinopharm) (TBST) at room temperature 
for one hour. Primary antibody was added directly into the blocking solution 
based on the concentration recommended by the manufacturer (if available) 
and incubation took place overnight at 4oC with constant agitation. After 
washing three times for 10 minutes per wash in TBST, the membrane was 
incubated with the appropriate horseradish peroxidise (HRP)-conjugated 
secondary antibody for one hour at room temperature. Following another 
round of washing in TBST, chemiluminescence detection was performed 
using Luminata Forte Western HRP substrate (Millipore) or SuperSignal West 
Femto Maximum Sensitivity Substrate (Thermo Scientific) and protein bands 
were visualised using the ImageQuant LAS 4000 (GE). Images were directly 
exported to the ImageJ software (NIH) for densitometry analysis. Membranes 
were stripped with Restore PLUS Western Blot Stripping Buffer (Thermo 
Scientific) for 30 minutes at 37oC with agitation, washed, blocked, and 
reprobed with anti-GAPDH; which was used to verify the initial protein 





Primary antibodies used for Western blot are listed in the following sequence: 
Name (C/N-terminus, if applicable), dilution factor (catalogue number, 
company: epitope, if available) 
Rabbit anti-APP (C-terminus), 1:4000 (A8717, Sigma-Aldrich: 
KMQQNGYENPTYKFFEQMQN corresponding to amino acids 676-695 of 
APP 695) 
Mouse anti-APP (N-terminus), 1:100 (MAB348, Millipore: 
KEGILQYCQEVYPELQ corresponding to amino acids 66-81 of APP 695) 
Mouse anti-GAPDH (C-terminus), 1: 5000 (MAB374, Millipore: 
EKPAKYDDIKKVVKQASEGP corresponding to amino acids 250-269 of 
GAPDH) 
Goat anti-CACNA2D1, 1: 5000 (NB100-60951, Novus Biologicals: 
QEIFNKYNKDKKVR corresponding to amino acids 370-383 of 
CACNA2D1) 
Mouse anti-CD10 (external domain), 1:100 (NCL-L-CD10-270, Leica: 
sequence unavailable) 
Rabbit anti-EGFR (C-terminus), 1:100 (sc-03, Santa Cruz: sequence 
unavailable) 
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Mouse anti-PDE7A1/2, 1:100 (sc-28374, Santa Cruz: 
FSNTRLSQTMLGHVGLNKASWKGLQREQSSSEDTDAAFELNSQLLPQ
ENRLS corresponding to amino acids 431-482 of PDE7A1) 
Goat anti-Tip60 (N-terminus), 1:100 (sc-5725, Santa Cruz: sequence 
unavailable) 
Mouse anti-GSK3B (C-terminus), 1:1000 (9832, Cell Signalling: sequence 
unavailable) 
Rabbit anti-MCM4, 1:1000 (3228, Cell Signalling: residues surrounding 
Glycine 431 of MCM4) 
Rabbit anti-SP1, 1:1000 (5931, Cell Signalling: residues surrounding Proline 
593 of SP1)  
Rabbit anti-SPOPL, 1: 500 (AP54029PU-N, Acris: 
FEHEMEESKKNRVEINDLDPEVFKEMMRFIYTGRAPNLDKMADNLLA
AADKYALERLKVMCEEALCSNLSVENVADTLVLADLHSAEQLKAQAI
DFINRCSVLRQLGCKDGKNWNSNQATDIMETSGWK corresponding to 
amino acids 228-357 of SPOPL) 
Goat anti-mouse, goat anti-rabbit and mouse anti-goat HRP-conjugated 
secondary antibodies (Thermo Scientific) were used at a dilution of 1:5000. 
2.7 Protein identification 
2.7.1 Coomassie staining of SDS-PAGE gels 
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Coomasie stain was prepared by dissolving 0.1% Coomassie Brilliant Blue 
R250 in 10% acetic acid (Millipore) and 40% methanol (Fisher). After 
filtering to remove particulates, Coomassie stain was boiled using a 
microwave and added to SDS-PAGE gels. Gels were rocked on the Stuart see-
saw rocker for at least 30 minutes or until adequate staining was achieved. 
Gels were destained in buffer consisting of 20% methanol and 10% acetic acid 
for three hours at room temperature with replacement of destaining solution 
every 45 minutes. Bands of interest were excised from the gel and stored in a 
microcentrifuge tube containing deionized water before submission to the 
NUS Protein and Proteomics Centre (PPC) for mass spectrometry. 
2.7.2 Mass spectrometry 
In-gel reduction, alkylation, digestion, desalting, clean-up and concentration of 
protein samples from the Coomassie-stained gels were conducted by Ms Wang 
Xianhui (PPC). Samples were run using the Eksigent NanoLC Triple 
TOF5600 system and the protein identification report was prepared by Mr. 
Lim Teck Kwang (PPC). Results were viewed using the ProteinPilot software 
(AB Sciex). 
2.8 Statistical analysis 
Statistical analysis was performed using SPSS 13.0 for Windows (IBM). Two-
tailed Student's t test was used to compare differences in gene or protein 
expression between APP overexpression and control samples, APP 
knockdown and control samples, leupeptin-treated and control samples, and 
between AD brain lysates and non-AD controls. One-way analysis of variance 
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(ANOVA) was conducted to determine significant differences in APP/AICD 
target protein expression following GSI treatment as well as in CuBD and 
AICD transfection experiments. Where multiple comparisons were made, 
Bonferonni correction was applied to the probability values to control for error 
rates. Results are presented as the mean ± SEM (standard error of mean) from 






























3.1 Shortlisting APP/AICD candidates from ChIP-Seq and microarray 
datasets 
In previous work, the hypothesis that AICD is linked to AD pathogenesis by 
transcriptional regulation of target genes was tested. The AICD chromatin 
binding profile, which represents gene regions bound by the AICD 
transcription complex, was investigated from a genome-wide perspective 
using ChIP-Seq. ChIP is ideally carried out using a cell line that endogenously 
expresses AICD in order to reflect physiological conditions. SH-SY5Y cells 
are a widely used model for studies of AD-related biology (Belyaev et al., 
2009). However, AICD ChIP in SH-SY5Y cells was unsuccessful and this was 
attributed to low levels of AICD as a consequence of its rapid degradation. To 
counter the challenge of detecting and immunoprecipitating AICD, SH-
SY5YAPP695 cells were used and AICD levels were further stabilized upon 
addition of ammonium chloride into the medium 24 hours prior to ChIP 
(Wong, 2012). Upregulation of full-length APP in these cells was 
accompanied by increased proteolytic processing as evidenced by the elevated 
levels of several APP metabolites including AICD (Figure 28). The stable 
transfection model also countered the technical challenge of having to 
transfect large numbers of cells for each biological repeat and requiring large 
amounts of transfection reagent to be used in order to produce the required 
starting amount of DNA for ChIP-Seq. While ChIP-Seq revealed more than 30 
000 AICD binding sites, physical interaction between AICD and its target 
genes may not be sufficient for the regulation of gene expression. To 
complement the ChIP-Seq results, microarray analysis was carried out in both 
APP overexpression (SH-SY5YAPP695 cells) and APP knockdown models 
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(transfection of APP siRNA in SH-SY5Y cells) in order to identify genes that 
were differentially expressed following indirect manipulation of AICD levels. 
The large data sets generated by ChIP-Seq and microarray studies are prone to 
false positive errors (Blalock et al., 2005; Blalock et al., 2004; Boulesteix and 
Strimmer, 2005; Ge et al., 2003; Miller et al., 2001; Pawitan et al., 2005) and 
may mislead investigators to make inaccurate conclusions upon which further 
work may be based. False positives generated by multiple comparisons while 
testing thousands of genes for significant change at the p < 0.05 level imply 
that up to 5% of the genes tested will be found positive by chance alone. 
Furthermore, the long lists of genes produced pose a challenge to the 
evaluation of functional usefulness of the data (Blalock et al., 2005; Blalock et 
al., 2004). Relying primarily on fold change differences generated from 
microarray data also yields false positives when small groups are involved (as 
in this case) because sample variances are neglected (Blalock et al., 2005; 
Miller et al., 2001). In the event that two hypothetical datasets with the same 
coefficient of variance were analyzed, fewer false positives would be found in 
the one derived from a larger sample size or more biological replicates. The 
fact that variation in performance between laboratories, protocols, and 
algorithms within the same array platform is actually greater than the variation 
between array platforms (Johnson et al., 2008) generates further concern over 
the interpretation of data from any single proteomic or genomic approach.  
One way to overcome the high false discovery rates that are determined by the 
proportion and distribution of differentially expressed genes, measurement 
variability and sample size (Pawitan et al., 2005) is the proposal of a two-stage 
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design in which significance testing of -omics data is used to guide a second 
round of hypothesis testing using distinct experimental samples (Miller et al., 
2001). In order to validate the ChIP-Seq and microarray data, we employed an 
integrative analysis strategy for shortlisting APP/AICD candidate genes before 
using independent methods and new sets of samples to address reliability and 
relevance of the data to AD.  
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Figure 4. Schematic of strategies used to search for APP/AICD candidate genes from ChIP-Seq and microarray datasets. Three methods were employed in choosing candidate genes for target validation and are ordered in terms of stringency, with Strategy 1 being the least stringent. CHS012_hg9 and CHS013_hg9 are lists of genes derived from two ChIP-Seq biological repeats. 
ChIP-Seq was carried out in SH-SY5YAPP695 cells using the BR188 antibody 
(donated by Dr. M. Goedert) that was raised against the last 20 amino acids of 
APP (Caputo et al., 1992) and makes up part of AICD . After the final elution 
step, short reads of 36 base pairs were sequenced and mapped to the hg19 
Human Genome Assembly (GRCh37, February 2009). Mapped reads were 
converted to an integer count of ‘tags’ at respective positions in the genome. 
After comparing experimental and background tag distributions, regions of tag 
enrichment were assigned as ‘peaks’. The Model-based analysis for ChIP-Seq 
(MACS) software uses preset local Poisson distribution p-value as a threshold 
to determine which peaks might be considered significant and peaks are 
assigned scores based on the p-values (Pepke et al., 2009).  
CHS012_hg9 is the MACS output file from one of two ChIP-Seq biological 
repeats and consists of 21569 potential AICD binding sites while 
CHS013_hg9 is a list of 17917 binding sites (Figure 4). Since a higher peak 
score indicates a greater likelihood that an identified genomic region is truly 
bound by the transcriptional complex of interest, AICD binding sites that are 
represented by peaks were sorted according to peak score. In addition, 
information pertaining to the location of the binding site; such as the 
chromosome number, position on the + or – strand and whether binding takes 
place at the transcriptional start site (TSS), exon, intron, untranslated or 
intergenic regions are accessible from the output files. In Strategy 1, the search 
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for candidate AICD targets was limited to genes bound by AICD at the TSS. 
This was followed by manual matching of 4215 genes from CHS012_hg9 to 
3895 genes from CHS013_hg9 and those that appeared in both MACS output 
files were selected for further analysis. 
In Strategy 2, we were interested in searching for genes with altered mRNA 
levels as a consequence of AICD binding to the TSS. We took the existence of 
physical interaction between the transcription factor and TSS to be represented 
by either 4215 genes from CHS012_hg9 or 3895 genes from CHS013_hg9 
(from Strategy 1) and they were compared with 789 genes that changed in 
expression following APP knockdown as determined using microarray. The 
latter was carried out on an Illumina platform and the significant gene list 
criteria was limited to genes displaying absolute fold change of at least 1.5, 
with p-value < 0.05, after Benjamini-Hochberg multiple testing correction. 
Corresponding analysis of microarray results from an APP overexpression 
system was not possible due to inaccessibility to the output file. 
The last and most stringent strategy involved searching for AICD target genes 
that would be significantly altered in both scenarios whereby AICD promoter 
binding was increased or decreased indirectly as a result of manipulating APP 
levels. We first identified genes that displayed absolute fold change of at least 
1.5, with p-value < 0.05, after Benjamini-Hochberg multiple testing correction 
from the overlapped microarray lists of APP knockdown samples and APP 
overexpression samples. We then searched for the presence of any of the 204 
genes in either ChIP-Seq MACS output file while fulfilling the condition that 
AICD peaks appeared at the TSS region. 
 73 
Using a combination of search methods, 57 APP candidate genes were 
shortlisted for qPCR validation of mRNA expression. However, only 35 genes 
appear in the final analysis due to exclusion of gene amplification products 
that did not fulfill certain criteria despite repeated attempts at designing 
suitable primers. For instance, analysis of melt-curve profiles revealed 
presence of nonspecific targets in addition to the appropriate target sequence; 
PCR contamination was detected in the non-template control wells due to 
unintended amplification products like primer dimers; or the amplicon could 
not be detected or did not appear at the expected size when run on DNA 
agarose gels that were stained with ethidium bromide following qPCR.  
3.1.1 qPCR quantification of APP/AICD target mRNA expression 
following APP overexpression or knockdown 
For accurate comparison of mRNA concentrations of target genes relative to 
the reference gene during qPCR analysis, all gene products should be 
amplified with comparable efficiencies (Bustin et al., 2009). A standard curve 
was plotted with logarithm of the initial template concentration on the x-axis 
and threshold cycle number (CT) on the y-axis. After determining PCR 
efficiency from the slope of the standard curve for each gene using the 
formula: PCR efficiency = 10-1/slope-1 (Bustin et al., 2009), only genes with 
reaction efficiencies of between 90 and 100% were included in our analysis 
(data not shown). 
The fold differences in expression of APP/AICD target genes between two 
samples were calculated using the Livak method (Livak and Schmittgen, 
2001). CT values of target genes in both sample types were normalized against 
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the CT value for the reference gene, RPLP0. In other words, ΔCT was obtained 
by subtracting the CT of RPLP0 from the CT of each target gene in respective 
samples. ΔΔCT was then calculated by subtracting ΔCT of genes from SH-
SY5Y samples from ΔCT of genes from the APP overexpression or APP 
knockdown samples. Finally, fold differences in expression were calculated 
using the equation 2- ΔΔCT and are displayed on the y-axis.  
Following siRNA-targeted APP knockdown, nine out of 35 candidate 
APP/AICD target genes were found to be differentially expressed (four were 
upregulated and five were downregulated). mRNA levels of three genes 
(MCM4, PDE7A and PDE8B) from Strategy 1 and six genes (MCM4, LHPP, 
PAG1, ARL5B, SPOPL and PACRGL) from Strategy 3 were significantly 
altered as a result of the reduction in APP expression (Figure 5). Since none 
of the genes from Strategy 2 demonstrated significant changes following APP 
knockdown, only genes from Strategy 1 and 3 were included for subsequent 
qPCR validation of candidate APP/AICD target genes in SH-SY5YAPP695 cells. 
This was justified on two accounts: 1) we were eventually interested in 
shortlisting targets that displayed significant changes in mRNA levels 
following both APP overexpression and APP knockdown and 2) in order to 









Figure 6. qPCR validation of APP/AICD target mRNA expression following APP overexpression. Six candidate APP/AICD target genes were differentially expressed in SH-SY5YAPP695 cells compared with SH-SY5Y cells (unpaired t test with p value adjusted using Bonferonni correction). APP mRNA overexpression in SH-SY5YAPP695 cells exceeded 12.5-fold and is not indicated in the figure so as to allow visualisation of changes in expression that occur on a smaller scale. The horizontal line marks the relative expression of respective genes in control cells. Data are expressed as mean ± SEM; n = 3; *p < 0.05, **p < 0.01. 
Expression of CACNA2D1 and SP3 increased while PDE7A, PDE8B, MCM4 
and SPOPL levels decreased in SH-SY5YAPP695 cells compared with SH-
SY5Y cells (Figure 6). With the exception of SP3, the other five genes were 
also altered following endogenous APP knockdown in SH-SY5Y cells 
(Figure 5). To simplify matters, we assumed that APP/AICD possessed a 
direct relationship with target gene transcriptional regulation. We surmised 
that target gene expression would change in one direction when APP/AICD 
levels were increased but would shift in the opposite direction when 
APP/AICD levels were decreased. Based on the analysis of significant mRNA 
alterations and taking into consideration the direction of changes induced by 
manipulation of APP levels (summarized in Table 3); CACNA2D1, PDE7A, 
MCM4 and SPOPL were chosen for further validation as APP/AICD targets. 
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Table 3. Direction of change in APP/AICD target gene expression following APP knockdown or overexpression  Gene Direction of change  APP KD APP OE CACNA2D1 Down Up PDE7A Up Down PDE8B Down Down MCM4 Up Down SPOPL Up Down  
3.1.2 Western blot analysis of APP/AICD target protein expression 
following APP overexpression or knockdown  
Detecting the presence of mRNA provides no information on whether it will 
subsequently be translated into a protein product (Bustin et al., 2009). Parallel 
metabolic pulse labelling for more than 5000 genes in mammalian cells 
revealed that mRNAs are less stable than proteins, with a median half-life of 9 
hours as opposed to 46 hours for the latter and there is no correlation between 
the two half-lives (Schwanhausser et al., 2011). In mammalian cells, mRNAs 
are produced at a much lower rate than proteins. For every two copies of a 
given mRNA produced per hour, dozens of copies of the corresponding 
protein are generated (Vogel and Marcotte, 2012). Hence, using mRNA 
concentrations as proxies for concentrations of corresponding proteins is 
inaccurate because steady-state transcript abundances only partially predict 
protein abundances. Squared Pearson correlation coefficient estimates lies 
around 0.4, meaning that only about 40% of the variance in protein expression 
can be explained by changes at the transcript level but a greater part of the 
variance is actually determined by other factors (de Sousa Abreu et al., 2009) 
that will be discussed in Section 4.2. Since protein molecules are ultimately 
 78 
the functional units in the cell, it was imperative to corroborate the qPCR 
results using Western blot. 
In addition, Western blot analysis was crucial to overcome the limitations in 
our qPCR experimental design. Since qPCR data are not absolute, but relative, 
the reference gene used for standardization is of utmost importance. In 
previous work, a single reference gene, GAPDH, was chosen for qPCR 
validation of genes that displayed positive or negative microarray expression 
fold changes (Wong, 2012). In the present work, RPLP0 was chosen to test 
whether the data could be reproduced using a different reference gene that was 
similarly expressed in all (SH-SY5Y and SH-SY5YAPP695) samples, was 
resistant to experimental conditions (i.e. siRNA knockdown) and was 
amplified with similar efficiency to the target genes; all of which are criteria 
that should be met by any particular reference gene (VanGuilder et al., 2008). 
However, there is increasing support for the use of a “basket” approach of 
normalization instead (Coulson et al., 2008; Nolan et al., 2006; Vandesompele 
et al., 2002; VanGuilder et al., 2008). Normalization against three or more 
validated reference genes is recommended as the most appropriate method 
(Derveaux et al., 2010). Although more labor-intensive and costly, this method 
takes the geometric mean of several reference genes into consideration, thus 
minimizing the impact of different experimental conditions on the endogenous 
control set and increases the stringency of resultant data (Vandesompele et al., 
2002). In view of the inadequacy in our experimental design, Western blot 
results were necessary to back up the qPCR data. 
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Samples used for Western blot validation of APP/AICD targets were the same 
as those used in qPCR quantification of gene expression. Transfection of SH-
SY5Y cells with siRNA to knockdown APP levels was successful as 
determined by qPCR (Figure 5) and Western blot (Figure 7A). APP mRNA 
expression was reduced 5-fold (p = 0.0043) and densitometry analysis 
revealed a 3.8-fold reduction in APP protein expression (p = 0.00041) in cells 
incubated with APP siRNA compared with cells treated with non-target 
siRNA. As a result of APP knockdown, CACNA2D1, MCM4 and SPOPL 
protein levels were significantly altered but PDE7A expression remained 
stable (Figure 7). CACNA2D1, MCM4 and SPOPL proteins demonstrated the 
same direction of change as their respective mRNA transcripts, with the 
former decreasing by about 2.9-fold (Figure 7B, p = 0.048) following APP 
knockdown and the latter two increasing in expression by 1.3- (Figure 7C, p = 
0.012) and 2.3-fold (Figure 7E, p = 0.045) respectively.  
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Figure 7. Representative Western blots of newly identified APP/AICD target protein expression following siRNA-mediated APP knockdown in SH-SY5Y cells for 48 hours and relative fold change quantification by densitometry analysis. APP knockdown induced a significant decrease in (B) CACNA2D1 protein expression and resulted in significant increases in (C) MCM4 and (E) SPOPL protein expression. No significant difference was found for (D) PDE7A protein expression (paired t test). Lane 1 represents non-target siRNA transfection (Control) and Lane 2 represents APP siRNA transfection (APP KD). Data are expressed as mean ± SEM; n = 3; *p < 0.05, ***p < 0.001. The antibody used to detect APP is the rabbit anti-APP that binds to the epitope KMQQNGYENPTYKFFEQMQN corresponding to amino acids 676-695 of APP695 (A8717, Sigma-Aldrich). 
In a second round experiments, changes in protein levels of several previously 
reported APP/AICD targets were assessed following APP knockdown. EGFR, 
GSK3B, Tip60 and CD10 were chosen because antibodies that bind to these 
four proteins were available in the laboratory. To demonstrate that any effect 
resulting from APP knockdown is specific to APP/AICD targets, GAD65 was 
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used as a negative control because the expression of this protein is not known 
to be associated with AD or APP. This time, the 1.7-fold (Figure 8A, p = 
0.042) reduction in APP protein expression that was achieved following 
siRNA transfection was less pronounced compared to the previous data. 
Regardless, the significant change in APP expression was associated with a 4-
fold (Figure 8B, p = 0.0043) decrease in EGFR protein levels. However, the 
expression of GSK3B, Tip60 and CD10 were not significantly altered, just as 
GAD65 expression remained unchanged following APP knockdown (Figure 
8). 





1           2       (kDa)
A
C

























Figure 8. Representative Western blots of previously reported APP/AICD target protein and negative control protein expression following siRNA-mediated APP knockdown in SH-SY5Y cells for 48 hours and relative fold change quantification by densitometry analysis. APP knockdown induced a significant decrease in (B) EGFR protein expression. No significant difference was found for (C) GSK3B, (D) Tip60, (E) CD10 or (F) GAD65 protein expression (paired t test). Lane 1 represents non-target siRNA transfection (Control) and Lane 2 represents APP siRNA transfection (APP KD). Data are expressed as mean ± SEM; n = 3; *p < 0.05, **p < 0.01. The antibody used to detect APP is the rabbit anti-APP that binds to the epitope KMQQNGYENPTYKFFEQMQN corresponding to amino acids 676-695 of APP695 (A8717, Sigma-Aldrich). 
Although APP mRNA concentration increased by more than 12.5 fold (p value 
<0.001) in SH-SY5YAPP695 cells compared with control cells, the 
corresponding protein expression was upregulated by only about 2.2-fold (p = 
0.035) (Figure 9A). This was associated with decreases in protein levels of 
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MCM4, PDE7A and SPOPL by 3.5- (Figure 9C, p = 0.00014), 1.7- (Figure 
9D, p = 0.019) and 2.9-fold (Figure 9E, p = 0.00025) respectively. Although 
CACNA2D1 was not significantly altered in the APP-overexpressing cells, the 
protein band was found to shift higher in the gel in four out of six cases when 
SH-SY5YAPP695 cell lysates were run on SDS-PAGE. The stable transfection 
of APP probably resulted in post-translational modifications of the 
CACNA2D1 protein and further investigation is required to determine the 
nature of these changes. 



























Figure 9. Representative Western blots of newly identified APP/AICD target protein expression in SH-SY5YAPP695 cells and relative fold change quantification by densitometry analysis. APP overexpression induced significant decreases in (C) MCM4 (D) PDE7A and (E) SPOPL protein expression. No significant difference was found for (B) CACNA2D1 protein expression (unpaired t test). Lane 1 represents SH-SY5Y lysates (Control) and Lane 2 represents SH-SY5YAPP695 lysates (APP OE). Data are expressed as mean ± SEM; n = 3; *p < 0.05, ***p < 0.001. The antibody used to detect APP is the rabbit anti-APP that binds to the epitope KMQQNGYENPTYKFFEQMQN corresponding to amino acids 676-695 of APP695 (A8717, Sigma-Aldrich). 
While APP knockdown altered only one of the previously reported APP/AICD 
targets, APP overexpression was associated with significant changes in EGFR 
and CD10 protein levels. When APP expression increased by 1.7-fold (Figure 
10A, p = 0.046), there was a corresponding increase in EGFR levels by 2.5-
fold (Figure 10B, p = 0.026). As AICD was previously reported to increase 
CD10 levels (Grimm et al., 2015; Pardossi-Piquard et al., 2005), the 3.7-fold 
(Figure 10E, p = 0.0052) decrease in CD10 expression following APP 
overexpression was unexpected and indicated that APP and AICD regulation 
of target expression might not be parallel.  
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Figure 10. Representative Western blots of previously reported APP/AICD target protein and negative control protein expression in SH-SY5YAPP695 cells and relative fold change quantification by densitometry analysis. APP overexpression induced a significant increase in (B) EGFR protein expression but a significant decrease in (E) CD10 protein expression. No significant differences were found for (C) GSK3B, (D) Tip60 protein or (F) GAD65 expression (unpaired t test). Lane 1 represents SH-SY5Y lysates (Control) and Lane 2 represents SH-SY5YAPP695 lysates (APP OE). Data are expressed as mean ± SEM; n = 3; *p < 0.05, **p < 0.01. The antibody used to detect APP is the rabbit anti-APP that binds to the epitope KMQQNGYENPTYKFFEQMQN corresponding to amino acids 676-695 of APP695 (A8717, Sigma-Aldrich). 
Where changes in protein expression were found to be statistically significant, 
the directions of change corresponded to the mRNA alterations detected from 
qPCR experiments. Despite the agreement in direction of changes displayed 
by APP/AICD target mRNAs and proteins, the magnitudes of fold change that 
were measured following qPCR and Western blot analysis were different in 
several cases. Fold change magnitudes that differed by more than 1 unit are 
highlighted in Table 4. Discordances from mRNA results were also observed 
as PDE7A protein expression did not change significantly following APP 
knockdown and CACNA2D1 levels remained steady after APP 
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overexpression. This substantiates the notion that quantification of mRNA 
transcripts alone cannot be fully relied upon as an estimation of the expression 
levels of their translated products. 
Table 4. Estimated fold change of APP/AICD target mRNA and protein expression following APP knockdown or overexpression. APP Knockdown APP Overexpression  mRNA  Protein mRNA Protein APP -5 -3.8 >+12.5 +2.2 CACNA2D1 -2.9 -2.9 +6.5 -- MCM4 +1.2 +1.3 -2.3 -3.5 PDE7A +1.5 -- -1.2 -1.7 SPOPL +2.2 +2.3 -1.9 -2.9 
3.2 Analysis of CACNA2D1, MCM4, PDE7A and SPOPL expression in 
AD 
Two of four APP/AICD targets identified thus far show consistent alterations 
in protein expression as a result of changes in APP levels in neuroblastoma 
cells. Since it was beyond the scope of this dissertation to correlate changes in 
protein levels with their functional outcomes, the question of whether 
alterations in CACNA2D1, MCM4, PDE7A and SPOPL expression are 
directly associated with molecular mechanisms that are linked to disease 
remains unanswered. Nevertheless, we strove to demonstrate the relevance of 
our findings to AD by comparing the expression of CACNA2D1, MCM4, 
PDE7A and SPOPL between AD patients and non-AD controls.  
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Lateral view of Brodmann areas Medial view of Brodmann areas
 Figure 11. Lateral and medial views of Brodmann areas. BA9 region is circled in red. Brain illustrations were reproduced based on lithograph plates from the 20th U.S. edition of Gray's Anatomy of the Human Body, originally published in 1918 and downloaded from wikipedia.org. Images are available in the public domain. http://en.wikipedia.org/wiki/Brodmann_area File: Gray726-Brodman.png and File: Gray727-Brodman.png 
BA9 region (Figure 11) of brains from 16 AD patients (mean age: 88 + 8 
years), who were diagnosed based on clinical neuropathology, and 20 non-AD 
controls (mean age: 80 + 8 years) were dissected free of white matter and 
meninges before homogenization in lysis buffer in preparation for Western 
blot. The BA9 region, which contributes to the dorsolateral and medial 
prefrontal association cortex, is known to be an AD-sensitive brain region. 
Ultrastructural studies of biopsied tissue from the right frontal lobe of patients 
with mild to moderate AD revealed that the number of synapses in lamina III 
of BA9 are significantly decreased when compared with age-matched controls. 
As synapse density decreases, there is significant enlargement of the mean 
apposition length of the remaining synapses. More importantly, there is a 
significant correlation between synapse counts and MMSE scores. Specifically, 
lower mental status scores are associated with greater loss of synapses in the 
BA9 region. In addition, choline acetyltransferase activity is significantly 
decreased in the BA9 region of AD brains (DeKosky and Scheff, 1990). In 
another example, a quantitative meta-analysis of task-related functional brain 
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imaging techniques that examined episodic memory function confirms 
previously reported deficits in medial temporal lobe activity among AD 
patients (Golby et al., 2005; Rémy et al., 2005; Sperling et al., 2003). By 
contrast, AD patients demonstrate large areas of prefrontal activation, 
including the BA9 region during episodic memory encoding and retrieval 
(Schwindt and Black, 2009). In a recent study, the MS4A6A locus was found 
to be associated with increased risk of developing AD. Out of three transcript 
variants (V1, V2 and V4), the minor V4 allele appears to be protective. 
Although total MS4A6A expression is significantly higher in AD compared 
with controls, the more copies of V4 allele an individual possessed, the lower 
the expression of MS4A6A in the blood. Unlike other variants, MS4A6A V4 
does not appear to be expressed in human primary neuronal cells but is 
detectable in whole brain homogenates from AD and control individuals. 
Expression quantitative trait loci analysis of brain samples revealed that a 
significant association between genotype and expression is found for V4 only 
in the BA9 region. As with blood, expression of the protective allele is 
associated with lower MS4A6A expression (Proitsi et al., 2014). Further 
evidence linking altered protein expression in the BA9 region to disease 
comes from the observation that vesicular glutamate transporters VGLUT1 
and VGLUT2 levels are decreased in the abovementioned brain region of AD 
patients compared with controls as assessed by Western blot and 
immunoautoradiography. Glutamate is a major excitatory neurotransmitter of 
the brain that is involved in higher mental functions such as cognition, 
learning and memory. Consequently, the decline in VGLUT1 and VGLUT2 
protein levels in the BA9 region correlate with the progression of cognitive 
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impairment in AD as assessed using the CDR, albeit to different degrees 
(Kashani et al., 2008). Evidently, changes in the BA9 region have been 
analyzed in many studies that aimed to elucidate the pathologic alterations 
associated with AD. 
In the present work, we examined the protein levels of CACNA2D1, MCM4, 
PDE7A and SPOPL in the BA9 region since changes in protein expression 
and/or activity in this part of the brain have been found to alter the risk of 
developing AD or influence cognitive functioning of AD individuals. Thus, 
any differences in APP/AICD target expression that we observed in this region 
would likely be relevant to disease as well. Our results revealed that 
expression of all four APP/AICD targets decreased significantly in AD 
compared with controls. In AD patients, CACNA2D1 protein levels were 
reduced by more than 3-fold (Figure 12A, p = 0.0014), PDE7A expression 
decreased by more than 1.6-fold (Figure 12C, p = 0.037) and SPOPL 
expression dropped nearly 2.5-fold (Figure 12D, p = 0.00069). Although 
MCM4 levels were reduced by about 1.6-fold in AD, this difference barely 
reached the threshold for significance (Figure 12B, p = 0.049). This was 
probably due to the lower quality of bands that appeared like smears in the 
Western blots, which led to increased background signals during the 
densitometry quantification process. 
Although further studies are required to determine whether alterations in 
expression of the four newly identified APP/AICD targets are responsible for 
causing AD or arise as a consequence of AD; the fact that CACNA2D1, 
MCM4, PDE7A and SPOPL levels are significantly altered in the brains of 
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diseased individuals warrants attention to their potential either as biomarkers 
for disease or as targets for therapeutic invention of AD. 
CACNA2D1



















Figure 12. Representative Western blots of newly identified APP/AICD target expression in five AD and five control subjects (abbreviated as C) and relative fold change quantification by densitometry analysis. Protein expression of (A) CACNA2D1, (B) MCM4, (C) PDE7A and (D) SPOPL decreased significantly in the AD samples compared with controls (unpaired t test). Data are expressed as mean ± SEM; AD: n = 16, C: n =20; *p < 0.05, **p < 0.01, ***p < 0.001. 
In addition, we examined the expression levels of some of the previously 
reported APP/AICD targets in the BA9 region. Consistent with a previous 
report that examined CD10 expression in homogenates of the frontal cortex, 
we found that CD10 protein levels were reduced (Figure 13C) in AD but not 
significantly (Miners et al., 2006). However, EGFR levels were significant 
reduced by nearly 4-fold (Figure 13A, p = 0.018) in AD. On the other hand, 
GSK3B levels were not significantly altered (Figure 13B). We were unable to 
detect Tip60 or GAD65 (negative control) expression in the human brain 
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Figure 13. Representative Western blots of previously reported APP/AICD target expression in five AD and five control subjects (abbreviated as C) and relative fold change quantification by densitometry analysis. Protein expression of (A) EGFR decreased significantly in the AD samples compared with controls (unpaired t test). No significant changes were observed for (B) GSK3B and (C) CD10. Data are expressed as mean ± SEM; AD: n = 16, C: n =20; *p < 0.05. 
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3.3 Role of APP metabolites as regulators of CACNA2D1, MCM4, 
PDE7A and SPOPL expression  
Knowing that APP acts as a substrate for several enzymes and undergoes 
proteolysis to release multiple fragments either extracellularly or into the cell, 
we were interested to see if we could identify one of the APP metabolites as 
being responsible for the regulation of CACNA2D1, MCM4, PDE7A or 
SPOPL expression. Naturally, the prime candidate of our investigation was 
AICD because it is the only APP metabolite known to be capable of either 
translocation into the nucleus and gaining access to the promoters of target 
genes; or mediating transactivation of target genes through interactions with 
adaptor proteins, without directly entering the nucleus. More importantly, all 
four APP/AICD targets appeared in the ChIP-Seq output lists that were 
generated following IP using the BR188 antibody that binds to part of the 
AICD sequence. 
In order to investigate the effect of increased AICD expression on 
CACNA2D1, MCM4, PDE7A or SPOPL expression, we transiently 
transfected SH-SY5Y cells with the empty pCDF vector or the pCDF-AICD 
vector. However, the transient nature of AICD and its low expression posed a 
challenge to the detection of AICD and hampered the process of determining 
the success of our experimental manipulations. To date, three methods have 
been reported by which AICD levels can be sustained. AICD is known to be 
stabilized following binding of the neuron-specific adaptor protein, Fe65, 
before entering the nucleus (Cao and Südhof, 2004; Chang et al., 2006; 
Grimm et al., 2011; Kimberly et al., 2001; Liu et al., 2007; Ma et al., 2008; 
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Sumioka et al., 2005; Taylor Kimberly et al., 2005; von Rotz et al., 2004; 
Weggen et al., 2003). Alternatively, the addition of alkalizing agents such as 
ammonium chloride (Vingtdeux et al., 2007); or treatment with phenanthroline 
monohydrate, which is a metal chelator that inhibits metalloproteases 
(Huysseune et al., 2007), are known to promote AICD accumulation. In order 
to maximize AICD accumulation and detection, SH-SY5Y cells were co-
transfected with the pCDF-Fe65 plasmid and ammonium chloride was added 
to the medium 24 hours prior to protein collection. To determine whether 
involvement of the adaptor protein was important for the regulation of 
APP/AICD target expression, an AICD* mutant that is incapable of binding to 
Fe65 was overexpressed in a third set of SH-SY5Y cells.  
Our results revealed that transient pCDF-AICD transfection of SH-SY5Y cells 
followed by addition of ammonium chloride significantly increased AICD 
expression by nearly 6-fold compared with cells transfected with the empty 
vector. The effect of ammonium chloride on AICD accumulation seems to be 
dependent on the ability of AICD to bind to Fe65 because no significant 
difference in AICD expression was found between AICD*-transfected cells 
and cells transfected with the empty vector (Figure 14). The change in AICD 
expression among the three groups was statistically significant as determined 
by ANOVA [F (2, 6) = 16.26, p = 0.0038] and our results are consistent with 
previous findings that binding of Fe65 to AICD is important for the 
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Figure 14. Representative Western blot of AICD expression following transient transfection of SH-SY5Y cells and densitometry analysis. Cells were transfected with respective plasmids for 48 hours. After discarding the culture medium and washing the cells with PBS, lysis buffer was added directly to the wells and all the lysate was loaded onto SDS-PAGE gels without protein quantification. AICD densitometry was normalized to GAPDH densitometry to account for differences in protein loading. A significant AICD increase was observed in pCDF-AICD transfected cells compared with control or pCDF-AICD* transfected cells (ANOVA). Data are expressed as mean ± SEM; n = 3; **p < 0.01. The antibody used to detect AICD is the rabbit anti-APP that binds to the epitope KMQQNGYENPTYKFFEQMQN corresponding to amino acids 676-695 of APP695 (A8717, Sigma-Aldrich). 
Should an increase in AICD levels alter CACNA2D1, MCM4, PDE7A or 
SPOPL expression, it was equally important to determine whether inhibition 
of AICD production would have a converse effect on APP/AICD target 
protein levels. To this end, we treated SH-SY5YAPP695 cells with two different 
GSIs: L-685,458 or BMS 299897. Following γ-secretase cleavage of C99, Aβ 
and AICD are released in the amyloidogenic pathway. Both L-685,458 and 
BMS 299897 exhibit similar potency in the inhibition of Aβ40 and Aβ42 
production, with IC50 values within the nanomolar range. While L-685,458 
also inhibits Notch signaling in vitro, BMS 299897 reportedly exhibits no 
Notch toxicity (information from manufacturer datasheet). The APP stable cell 
line was chosen over SH-SY5Y cells because AICD expression was extremely 
difficult to detect in the latter. Thus, we anticipated a more observable AICD 
inhibition with GSI treatment of SH-SY5YAPP695 cells.  
 97 
To ensure maximal inhibition of AICD production, SH-SY5YAPP695 cells were 
treated with drug concentrations that were 1000-fold higher than the 
IC50 values of both GSIs (1μM, 5μM or 10μM) for 48 hours. Since AICD 
could not be detected in our Western blots, we quantified the expression of the 
APP C-terminal fragment (CTF); which is the substrate for GSIs, as an 
estimate of the amount of AICD that was not released following treatment of 
SH-SY5YAPP695 cells with L-685,458 or BMS 299897. When SH-SY5YAPP695 
cells were treated with varying amounts of L-685,458, the differences in CTF 
accumulation between groups was statistically significant [F (3, 8) = 11.73, p 
= 0.0027]. Post hoc comparisons indicated that expression of the 12 kDa CTF 
was at least 6.3-fold higher in cells treated with 1μM, 5μM, or 10μM of drug 
(Figure 15A) compared with DMSO-treated cells. Although there was no 
significant difference in CTF expression among the drug-treated groups, there 
appeared to be a trend pointing towards a dose-dependent effect of L-685,458 
concentration on CTF accumulation. This trend was not evident in BMS 
299897-treated SH-SY5YAPP695 cells and there was no significant difference in 
CTF expression among the drug-treated groups. Nonetheless, significant 
differences in the accumulation of CTF were observed between groups [F (3, 
8) = 16.41, p = 0.00089]. CTF levels were increased by at least 2.4-fold in 
cells treated with 1μM, 5μM or 10μM of BMS 299897 (Figure 15B) 
compared with cells incubated with absolute ethanol.  
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Figure 15. Representative Western blots of APP CTF expression following treatment of SH-SY5YAPP695 cells with GSIs and densitometry analysis. Cells were incubated with 1μM, 5μM or 10μM of (A) L-685,458 or (B) BMS 299897 for 48 hours. After discarding the culture medium and washing the cells with PBS, lysis buffer was added directly to the wells and all lysate was loaded onto SDS-PAGE gels without protein quantification. CTF densitometry was normalized to GAPDH densitometry to account for differences in protein loading. Control samples were loaded between drug-treated samples in order to prevent “spill-over of signal” that would have impeded the process of distinguishing the thick CTF bands in respective lanes during densitometry analysis. Significant CTF accumulation was observed in drug-treated cells compared with control (ANOVA). Data are expressed as mean ± SEM; n = 3; *p < 0.05, **p < 0.01. The antibody used to detect APP CTF is the rabbit anti-APP that binds to the epitope KMQQNGYENPTYKFFEQMQN corresponding to amino acids 676-695 of APP695 (A8717, Sigma-Aldrich). 
3.3.1 Screening previously reported AICD targets for use as positive 
control in SH-SY5Y cells 
Although several AICD targets have been reported in the literature (Table 2), 
the identity of these targets remains controversial because some of the results 
could not be replicated independently. It appears that the extent of their 
modulation by AICD is heavily influenced by cell type and density, passage 
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number, type of APP isoform expressed and the difficulty in detecting cellular 
AICD because of its short-lived nature (Bauer et al., 2011; Belyaev et al., 
2010). Among the reported AICD targets, we chose to analyze the expression 
of APP, EGFR, GSK3B, Tip60 and CD10 in our transiently transfected SH-
SY5Y cells or GSI-treated SH-SY5YAPP695 cells because antibodies that bind 
to the five proteins were available in the laboratory. Inclusion of a known 
AICD target protein as a positive control in our experiments was important to 
demonstrate that any changes in protein expression observed was due to 
alterations in AICD levels in SH-SY5Y cells. In the event that no change in 
protein expression was detected, monitoring the expression of the positive 
control would allow us to verify whether or not the lack of results was due to 

























pCDF AICD      AICD*   (kDa)
D
E
 Figure 16. Representative Western blots of previously reported AICD targets following transfection of SH-SY5Y cells with a control plasmid, AICD or an AICD* mutant that does not bind to Fe65 and densitometry analysis. Comparison of (A) APP, (B) EGFR, (C) GSK3B, (D) Tip60, and (E) CD10 protein expression among the three groups was not statistically significant (ANOVA). Data are expressed as mean ± SEM; n = 3. The antibody used to detect APP is the rabbit anti-APP that binds to the epitope KMQQNGYENPTYKFFEQMQN corresponding to amino acids 676-695 of APP695 (A8717, Sigma-Aldrich). 
Although AICD levels were increased by about 6-fold following transient 
transfection of SH-SY5Y cells and the addition of ammonium chloride, the 
protein levels of previously reported AICD targets appeared to be unaltered 
(Figure 16). Among the AICD targets analyzed, CD10 levels showed the 
biggest difference in fold change compared to control cells. Even though 
CD10 was upregulated by about 1.5-fold in AICD-transfected cells and 1.25-
fold in AICD*-transfected cells compared with control cells, the differences in 
expression missed the threshold for statistical significance by a slight margin, 
as determined from ANOVA (Figure 16E, p = 0.055). However, paired t test 
analysis of CD10 expression in pCDF-transfected cells and AICD-transfected 
cells revealed that the 1.5-fold increase in CD10 protein levels was significant 
(p = 0.022). With this, we have confirmed that a previously reported AICD 
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target, CD10, is suitable for use as a positive control in AICD-related studies 
conducted in the SH-SY5Y cell line.  
On the other hand, accumulation of APP CTF was observed following 
treatment of SH-SY5YAPP695 cells with 1μM, 5μM or 10μM of GSI and this 
was assumed to reflect the lack of AICD that was released from the CTF. 
However, none of the previously reported AICD targets appeared to be 
significantly altered by various concentrations of L-685,458 (Figure 17) or 
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Figure 18. Representative Western blots of previously reported AICD targets before and after treatment of SH-SY5YAPP695 cells with the BMS 299897 GSI and densitometry analysis. (A) APP, (B) EGFR, (C) GSK3B, (D) Tip60 and (E) CD10 protein expression were not significantly altered before and after treatment of SH-SY5YAPP695 cells with 1μM, 5μM or 10μM of drug (ANOVA). Data are expressed as mean ± SEM; n = 3. The antibody used to detect APP is the rabbit anti-APP that binds to the epitope KMQQNGYENPTYKFFEQMQN corresponding to amino acids 676-695 of APP695 (A8717, Sigma-Aldrich). 
3.3.2 Effect of transient AICD overexpression or inhibition of AICD 
release on CACNA2D1, MCM4, PDE7A and SPOPL expression 
No significant differences in the expression of CACNA2D1, MCM4, PDE7A 
and SPOPL proteins were observed after transfection of SH-SY5Y cells with a 
control plasmid, AICD or AICD* (Figure 19). Nevertheless, MCM4, PDE7A 
and SPOPL protein levels displayed a trend of being downregulated when 
AICD was overexpressed and this is consistent with the direction of change 
that was observed in APP-overexpressing cells. Furthermore, the slight 
influence that AICD had on MCM4, PDE7A and SPOPL protein expression 
seemed to be dependent on its ability to bind to Fe65 because MCM4 (Figure 
19B), PDE7A (Figure 19C) and SPOPL (Figure 19D) levels in AICD*-
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transfected cells seemed to be more similar to control cells. The results 
suggest that on its own, AICD seemed to have a very weak effect on MCM4, 
PDE7A and SPOPL protein expression. Although CACNA2D1 mRNA was 
upregulated following APP overexpression, CACNA2D1 protein levels did 
not appear to be significantly altered by APP or AICD overexpression (Figure 






















Figure 19. Representative Western blots of CACNA2D1, MCM4, PDE7A and SPOPL proteins following transfection of SH-SY5Y cells with a control plasmid, AICD or an AICD* mutant that does not bind to Fe65 and densitometry analysis. Comparison of (A) CACNA2D1, (B) MCM4, (C) 
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PDE7A and (D) SPOPL protein expression among the three groups was not statistically significant (ANOVA). Data are expressed as mean ± SEM; n = 3. 
As in the case of previously reported AICD targets, no significant changes 
were found in CACNA2D1, MCM4, PDE7A and SPOPL protein levels after 
treatment of SH-SY5YAPP695 cells with increasing concentrations of either L-
685,458 (Figure 20) or BMS 299897 (Figure 21). It is highly likely that in the 
absence of a physiological modifier, basal AICD expression in the SH-
SY5YAPP695 cells is low. Thus, although accumulation of APP CTF was 
detected following GSI treatment of SH-SY5YAPP695 cells, the actual amount 
of AICD that was not released might not be very different from cells that were 
not treated with GSIs and this might explain why we could not detect 
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Figure 21. Representative Western blots of CACNA2D1, MCM4, PDE7A and SPOPL before and after treatment of SH-SY5YAPP695 cells with the BMS 299897 GSI and densitometry analysis. (A) CACNA2D1, (B) MCM4, (C) PDE7A and (D) SPOPL protein expression were not significantly altered before and after treatment of SH-SY5YAPP695 cells with 1μM, 5μM or 10μM of drug (ANOVA). Data are expressed as mean ± SEM; n = 3. 
3.3.3 Effect of APP CuBD mutation on CACNA2D1, MCM4, PDE7A and 
SPOPL expression 
There have been several accounts of target gene regulation by APP that do not 
involve AICD generation or function. In one example, Transthyretin (TTR) 
and Klotho transcripts are downregulated in neuronal-specific 
APP/APLP2 double-conditional knockout mice but upregulated in APP 
transgenic mouse brains. Since co-transfection of an APP CTF expression 
vector with or without Fe65 and a luciferase reporter construct driven by the 
TTR promoter did not result in significant induction of luciferase activity, an 
extracellular APP fragment was postulated to be involved in 
modulating TTR and Klotho expression. One of these fragments is the soluble 
ectodomain fragment which is secreted following amyloidogenic processing of 
APP by β-secretase (sAPPβ). A sAPPβ knock-in (ki) was introduced in order 
to generate mice with the sAPPβ ki/−/APLP2−/− genotype. Early postnatal 
lethality of the sAPPβ ki/−/APLP2−/− mice limited the analysis of TTR and 
Klotho expression to the newborn stage. Since TTR and Klotho levels in the 
brain are low, expression of these targets were examined in the P0 liver 
instead. Absence of APLP1 in the liver means that the only APP-related 
protein expressed in the sAPPβ ki/−/APLP2−/− mouse liver is sAPPβ. Since 
decreased TTR and Klotho expression are observed in the P0 
APP/APLP2 double-conditional knockout mice but not in sAPPβ ki/−/APLP2−/− 
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mice, sAPPβ was identified as the APP metabolite responsible for regulating 
TTR and Klotho expression (Li et al., 2010). However, other studies seem to 
suggest that rather than being regulated by sAPPβ, TTR expression is 
regulated by AICD. ChIP was used to demonstrate that AICD binds directly to 
the TTR promoter. Furthermore, treatment of cells with the tyrosine kinase 
inhibitor, Gleevec, or ammonium chloride to stabilize AICD levels results in 
an upregulation of TTR mRNA levels. Accordingly, treatment of cells with the 
L-685,458 GSI reduces TTR mRNA expression (Kerridge et al., 2014). Since 
further evidence is needed to support the role of sAPPβ in target gene 
regulation, we did not test whether this particular fragment could be 
responsible for CACNA2D1, MCM4, PDE7A or SPOPL expression. 
In another example, AChE mRNA and protein expression as well as catalytic 
activity are repressed in SN56 or SH-SY5Y cells that were stably transfected 
with APP695. On the other hand, siRNA knockdown of APP resulted in a 
significant increase in transcription of AChE. Treatment of cells with α- or β-
secretase inhibitors to prevent the formation and release of soluble APP 
ectodomains; or with the DAPT GSI to prevent AICD production had no 
effect on total AChE mRNA expression or catalytic activity. When three key 
residues in the APP copper-binding domain (ΔCuBD) were mutated (to affect 
APP dimerization and protein-protein interactions) and overexpressed in SN56 
cells, AChE expression and activity in these cells were not repressed despite 
the overall increase in APP expression. Thus, transcriptional repression of 
AChE was determined to be mediated by the APP CuBD (Hicks et al., 2013).  
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We requested the APP CuBD plasmid from Hicks and colleagues in order to 
test whether this domain could also be important for regulating CACNA2D1, 
MCM4, PDE7A or SPOPL expression. Control SH-SY5Y cells were 
transfected with the empty pcDNA vector while the expression of 
CACNA2D1, MCM4, PDE7A or SPOPL was compared between cells that 
were transiently transfected with wild type APP or APP ΔCuBD. 
Unexpectedly, our results revealed a startling finding. It appears that transient 
APP695 overexpression did not induce the same changes in CACNA2D1, 
MCM4, PDE7A or SPOPL protein levels as observed following stable 
APP695 overexpression in SH-SY5Y cells. As a matter of fact, no significant 
differences in CACNA2D1 (Figure 22B), MCM4 (Figure 22C), PDE7A 
(Figure 22D) or SPOPL (Figure 22E) expression were found among the 
control cells, APP- or ΔCuBD-transfected cells; even though APP levels were 
similarly upregulated by at least 4-fold in APP- and ΔCuBD-transfected cells 
(Figure 22A, [F (2, 6) = 26.95, p = 0.001]). Thus, we are unable to comment 
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Figure 22. Representative Western blots of CACNA2D1, MCM4, PDE7A 
and SPOPL proteins following transfection of SH-SY5Y cells with a 
control plasmid, wild type APP or an APP ΔCuBD mutant that does not 
bind to copper ions and densitometry analysis. Unlike in SH-SY5YAPP695 
cells, (B) CACNA2D1, (C) MCM4, (D) PDE7A and (E) SPOPL protein levels 
were unaltered in SH-SY5Y cells that were transiently transfected with APP. 
Comparison of CACNA2D1, MCM4, PDE7A and SPOPL protein expression 
among the three groups was not statistically significant (ANOVA). Data are 
expressed as mean ± SEM; n = 3. The antibody used to detect APP is the 
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rabbit anti-APP that binds to the epitope KMQQNGYENPTYKFFEQMQN 
corresponding to amino acids 676-695 of APP695 (A8717, Sigma-Aldrich). 
Besides sAPPβ and APP CuBD, Aβ and sAPPα are known to be capable of 
modulating mRNA or protein expression of target genes (refer to Sections 
1.4.2-1.4.3). However, we did not have enough time to investigate Aβ or 
sAPPα as potential regulators of CACNA2D1, MCM4, PDE7A or SPOPL 
expression within the duration of this project as we were focused on another 
APP metabolite (refer to following sections).  
3.3.4 Comparison of APP/AICD target expression in cells that were 
transiently transfected with AICD or APP and cells that were stably 
transfected with APP 
To put things into perspective, we conducted a side-by-side comparison of 
newly identified and previously reported APP/AICD target expression in cells 
that were transiently transfected with AICD or APP and cells that were stably 
transfected with APP. In the transiently and stably transfected cells, APP 
levels were significantly upregulated by 2.5- (Figure 23A, p = 0.023) and 3.1-
fold (Figure 23A, p = 0.003) respectively compared with control cells that 
were transfected with an empty vector. However, cells that were transiently 
transfected with AICD did not display any significant change in full length 
APP expression compared with controls. As a result, the expression of 
APP/AICD targets in cells that were transiently transfected with AICD were 
not significantly different from their corresponding levels in the control cells.  
 112 
The expression of GAD65 did not differ across all conditions (Figure 23F), 
which was expected, given that it is being used as a negative control. However, 
GSK3B (Figure 23C), Tip60 (Figure 23D), CACNA2D1 (Figure 23G) and 
MCM4 (Figure 23H)  levels were also similar in all four groups. Despite the 
similar increase in full-length APP expression, EGFR was significantly 
upregulated by 5-fold (Figure 23B, p = 0.001) in SH-SY5YAPP695 cells 
compared with SH-SY5Y cells that were transiently transfected with APP. 
Conversely, CD10 levels were downregulated by 3.7-fold (Figure 23E, p = 
0.022) in stably transfected cells compared with transiently transfected cells. 
PDE7A and SPOPL expression were also reduced by about 5-fold (Figure 23I, 
p = 0.006) and 3.7-fold (Figure 23J, p = 0.036) respectively in SH-
SY5YAPP695 cells compared with transiently transfected SH-SY5Y cells. On 
the whole, the results indicate that target expression is differentially modulated 
by AICD and APP. APP regulation of target expression may also be 
significantly different, depending on whether manipulations to APP levels are 


































































































































































































































Figure 23. Representative Western blots of newly identified and previously reported APP/AICD targets in cells that were transiently transfected with AICD or APP and cells that were stably transfected with APP and densitometry analysis. (A) APP was similarly upregulated in transiently and stably transfected cells but not in AICD-transfected cells. In stably transfected cells, (B) EGFR expression increased while (E) CD10, (I) PDE7A and (J) SPOPL expression decreased compared with cells that were transiently transfected with APP. Comparison of (C) GSK3B, (D) Tip60, (F) GAD65, (G) CACNA2D1 and (H) MCM4 protein expression among the four 
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groups was not statistically significant (ANOVA). Data are expressed as mean ± SEM; n = 3; *p < 0.05, **p < 0.01, ***p < 0.001. The antibody used to detect APP is the rabbit anti-APP that binds to the epitope KMQQNGYENPTYKFFEQMQN corresponding to amino acids 676-695 of APP695 (A8717, Sigma-Aldrich). 
3.4 Identification of APP fragment that may be responsible for 
modulating CACNA2D1, MCM4, PDE7A and SPOPL expression 
We did not expect to find that transient transfection of full-length APP in SH-
SY5Y cells did not alter the expression of CACNA2D1, MCM4, PDE7A and 
SPOPL; as seen in SH-SY5YAPP695 cells. Nevertheless, we surmised that one 
or more APP metabolites produced in the SH-SY5YAPP695 cells but not in 
transiently transfected or control cells must be responsible for causing the 
changes in CACNA2D1, MCM4, PDE7A and SPOPL levels. Similarly, 
analysis of the differentially-expressed APP fragments in AD samples 
compared with control human samples might provide clues to the identity of 
the APP fragment that is responsible for modulating CACNA2D1, MCM4, 
PDE7A and SPOPL expression. 
First, we compared the expression of APP fragments in SH-SY5YAPP695 cells 
and in the human AD samples because these were the only two sample types 
in which significant differences in CACNA2D1, MCM4, PDE7A and SPOPL 
expression were detected. The dual bands that migrated together with the 100 
kDa protein ladder marker represent the mature and immature forms of full-
length APP. Mature APP, which is represented by the top band, consists of N- 
and O-glycosylated forms of APP and is subject to amyloidogenic or non-
amyloidogenic processing in the late protein secretory pathway and/or at 
plasma membrane. The lower band represents immature APP (N-glycosylated 
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APP or unglycosylated), which is localized to organelles of the early secretory 
pathway such as the endoplasmic reticulum or cis-Golgi and is not subject to 
proteolytic processing (Saito et al., 2011). While the proportions of mature and 
immature APP was roughly equal in SH-SY5YAPP695 cells (Figure 24B), 
immature APP appeared to be the predominant form of full-length APP in 
non-AD subjects (Figure 24A). However, it is also possible that the top band 
observed in the human lysates might be the longer 751-770 APP isoforms that 
are present in non-neuronal cells of the brain. Reduced detection of the 100 
kDa band in the AD BA9 lysates could probably be attributed to preferential 
processing or partial degradation of full-length APP, which consequently 
accumulated as a thick 50 kDa fragment. This 50 kDa fragment was also 
detected in control samples, albeit at a significantly lower level of expression. 
However, two other fragments appeared to be upregulated in control subjects 
and were either present at very low levels or were almost undetectable in AD 
subjects. These fragments had molecular weights of approximately 70 kDa 

















Figure 24. Representative Western blots of APP metabolites produced in 
AD brain lysates and SHSY5YAPP695 lysates and densitometry analysis. 
(A) Full length APP expression was not significantly altered between AD 
patients and controls but 40 kDa, 50 kDa and 70 kDa APP fragments were 
expressed at different levels in the two samples. (B) Significant upregulation 
of full-length APP was detected in SH-SY5YAPP695 cells compared with SH-
SY5Y cells and differential expression of two other APP fragments were also 
observed between the two samples. A 50 kDa APP fragment was significantly 
upregulated in AD samples and SH-SY5YAPP695 samples compared with 
controls (unpaired t test). Data are expressed as mean ± SEM; AD: n = 16, C: 
n =20, SH-SY5Y: n = 3, SH-SY5YAPP695: n = 3; *p < 0.05, **p < 0.01. The 
antibody used to detect APP is the rabbit anti-APP that binds to the epitope 
KMQQNGYENPTYKFFEQMQN corresponding to amino acids 676-695 of 
APP695 (A8717, Sigma-Aldrich). 
Since overexpression of APP in the form of APP gene duplications is 
sufficient to cause AD in humans (Kasuga et al., 2009; Sleegers et al., 2006; 
Thonberg et al., 2011), the increased expression of APP in SH-SY5YAPP695 
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cells was used here as a model of AD pathology. Other than the 4.5-fold 
overexpression of the 100 kDa APP band (p = 0.028), expression of the 70 
kDa and 40 kDa bands were also increased in SH-SY5YAPP695 cells compared 
with control SH-SY5Y cells (Figure 24B). This was unexpected because the 
APP bands produced in SH-SY5YAPP695 cells seemed to reflect the pattern of 
APP expression in control human subjects rather than AD subjects. On closer 
inspection, we observed that the “40 kDa band” in SH-SY5YAPP695 cells 
actually appeared mid-way between the 50 kDa and 37 kDa protein ladder 
markers in this particular Western blot experiment. Depending on conditions 
such as the percentage or composition of the gel that was used for SDS-PAGE, 
the equivalent band in SH-SY5YAPP695 lysates could actually be detected 
nearer to the 50 kDa protein ladder marker instead (Figure 28). On the other 
hand, the “40 kDa band” in human control lysates always appeared closer to 
the 37 kDa protein ladder marker. As a matter of fact, a band that appeared 
closer to the 37 kDa protein ladder marker could be detected in SH-
SY5YAPP695 cells following longer exposure of the Western blot membrane 
after HRP incubation (Figure 28). We were not able to demonstrate the 
appearance of the true “40 kDa band” in Figure 24B because membrane 
exposure conditions were not optimized for the detection of fragments smaller 
than 100 kDa. At this point, we would like to remind the reader that the 
differential expression of APP fragments was discovered serendipitously as 
the original objective of probing for APP was to check for full-length APP 
overexpression in our samples. Based on our retrospective observations, it was 
reasonable to suggest that the “40 kDa band” in Figure 24B could be the 
equivalent form of the 50 kDa band that appeared in AD samples and we 
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attributed the difference in molecular weight to several factors such as the 
different buffers that the proteins were diluted in; different Western blot run 
conditions; possible presence of albumin from the cell culture medium that 
persisted due to incomplete aspiration of PBS during preparation of cell 
lysates; and differences in post-translational modifications between the 
cortical samples and neuroblastoma lysates. For example, deglycosylation of 
amyloid plaque core purifications by trifluoromethane sulfonic acid followed 
by size-exclusion high performance liquid chromatography (HPLC) showed 
that some fractions change in molecular weight by as little as 3 kDa or as 
much as 80 kDa although HPLC was conducted under the same conditions 
used for native plaque purifications (Roher et al., 1993). In view of the fact 
that control human brain lysates demonstrated a higher proportion of immature 
full-length APP whereas the two forms of full-length APP were present in a 
roughly equal ratio in SH-SY5YAPP695 cells, it is likely that differences in 
glycosylation could underlie the alterations in molecular weight of the same 
APP fragment in different samples.  
The differential accumulation of APP fragments observed in the human 
samples probably arose as a result of altered processing of endogenous APP in 
association with disease, whereas full length APP and shorter APP 
cleavage/degradation products were upregulated in the SH-SY5YAPP695 cells 
due to increased processing of the constitutively and stably overexpressed 
APP. Given that a 50 kDa APP fragment was upregulated by 15-fold (p = 
0.0024, Figure 24A) and 4.3-fold (p = 0.024, Figure 24B) respectively in AD 
and SH-SY5YAPP695 cell lysates compared with control samples, we postulated 
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that this fragment could be involved in the regulation of CACNA2D1, MCM4, 
PDE7A and SPOPL expression.  
3.4.1 Neither a frameshifted APP mutation nor a 50 kDa APP fragment 
induced by leupeptin treatment altered CACNA2D1, MCM4, PDE7A and 
SPOPL expression 
To test our hypothesis, identification of the 50 kDa APP fragment was 
essential in order to overexpress the fragment in the SH-SY5Y cell line or 
target it for siRNA knockdown before checking for changes in CACNA2D1, 
MCM4, PDE7A and SPOPL levels. A search of the literature for previous 
reports documenting a 50 kDa APP fragment yielded several results. In a bid 
to disrupt amyloidogenic APP processing, human monocyte and T lymphocyte 
cells were treated with leupeptin, which is a potent inhibitor of lysosome 
proteases. As a result, several protein bands became prominent while others 
were diminished or undetectable. Among these, production of a 50 kDa 
fragment in the compartment closely related to the endosomal/lysosomal 
system became prominent. Based on detection using antibodies targeting 
different regions of APP, this 50 kDa band contains the complete Aβ sequence 
and part of the cytoplasmic domain of APP (Tsuzuki et al., 1994). We 
analyzed the sequences of the C-terminal antibodies used to detect the 50 kDa 
band with reference to the AICD sequence. Apparently, the 50 kDa fragment 
that was induced by leupeptin could be detected using an antibody that bound 
to part of the first half of AICD but not by an antibody against the last 20 
amino acids of AICD. Hence, this 50 kDa fragment is not likely to be the one 
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that we detected in our Western blot using the A8717 antibody that binds to 
the last 20 amino acids of AICD.   
With respect to AD, increased proteolytic processing in vulnerable brain 
regions is thought to be responsible for the upregulation of a 50 kDa fragment 
in the AD hippocampus and neocortex compared with controls. An additional 
45 kDa protein, which is considered a sub-fragment of the 50 kDa protein, is 
observed in some cases. Both fragments cannot be detected using an antibody 
specific for Aβ but are detected by an antibody that binds to residues 16-30 in 
the N-terminal domain of APP as well as an antibody that is specific for 
APP695. The latter was designed to bind to amino acids 281-296 of APP695 
as this epitope spans the splice junction where the KPI domain would have 
been inserted in other APP isoforms. The authors made no mention of the use 
of C-terminal APP antibodies such as the one used in our experiments (Loffler, 
1993). In another study, a dinucleotide deletion within the GAGAG motifs 
clustered in exon 9 of APP resulted in the formation of a frameshifted and 
truncated APP mutant consisting of 348 amino acids (APP+1). The same group 
reported this mutant as having a molecular weight of 38 kDa in 1998 (van 
Leeuwen et al., 1998) but showed in subsequent Western blots published in 
2003 (Hol et al., 2003) and 2004 (van Dijk et al., 2004) that APP+1 is detected 
as a double band at 50-60 kDa, with the higher band representing the mature 
form of the mutant and the lower band representing the immature form of the 
mutant. APP+1 that was isolated from the cell culture medium appears as a 
single band and does not run at exactly the same height as either of the two 
APP+1 doublets that were detected from cell lysates. Regardless, expression of 
APP+1 is reported to be prominent in FAD and LOAD and is even more 
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prominent in Down syndrome patients compared with controls who had been 
thoroughly matched for age, sex, postmortem delay and duration of fixation. 
In cortical homogenates of AD patients, a 3.4-fold increase in intracellular 
APP+1 expression is detected compared with the non-demented control group. 
On the other hand, APP+1 levels in the cerebrospinal fluid (CSF) of non-
demented controls are much higher than in the CSF of AD patients, leading to 
the conclusion that APP+1 is normally secreted by neurons in order to prevent 
intra-neuronal accumulation of APP+1 in the brains of non-demented 
individuals (Hol et al., 2003). As a result of translation of APP transcripts 
containing a dinucleotide deletion in exon 9, the APP+1 fragment has a C-
terminus consisting of 19 amino acids that are distinct from the C-terminus of 
wild type APP. Theoretically, APP+1 cannot be detected using an antibody 
against the last nine amino acids of the APP wild type C-terminus. However, 
when this antibody was used for IP, a band at the height of APP+1 is detected 
even though the authors claimed that APP+1 should not have been present in 
control cell lysates (van Dijk et al., 2004). We propose that this particular 
species could be the 50 kDa fragment which we detected using the A8717 C-
terminal antibody in human AD BA9 homogenates and SH-SY5YAPP695 cells.  
Our suspicions were confirmed by another study that described the detection 
of a 50-55 kDa APP degradation product following IP of Tg2576 AD 
transgenic mouse fibroblasts with the A8717 antibody. This APP fragment 
remains stable despite being subjected to the harsh denaturing conditions of 
SDS-PAGE and can also be detected using an antibody for Aβ or an antibody 
that recognizes anhydromannose (anMan)-containing oligosaccharides (Cheng 
et al., 2011). Thus, Cheng and colleagues proposed that the 50 kDa band 
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consists of anMan-containing heparan sulfate degradation products that are 
associated with C99. Treatment with proteinase K resulted in partial 
degradation of the protein component of this complex to generate a 30-35 kDa 
anMan- and Aβ-positive component whereas treatments with heparan sulfate 
and heparan lyases did not significantly change the size of the putative 
complex. This led the authors to hypothesize that the anMan-containing 
oligosaccharides associated with C99 are small. Because APP C-terminal 
fragments are only about 10-12 kDa in size, the authors speculated that the 50 
kDa fragment is actually a tetrameric C99 that is conjugated to anMan heparan 
sulfate adducts that are approximately 2.5–3.8 kDa in size. Because anMan 
immunoreactivity is also demonstrated in amyloid plaques from human AD 
brains (Cheng et al., 2011), the 50 kDa APP degradation product that we 
detected in the BA9 region of AD brains and SH-SY5YAPP695 cells are 
probably one and the same. 
Nevertheless, we could not ignore the possibility that the 50 kDa species 
which appeared in our Western blot could be a consequence of non-specific 
binding of the A8717 antibody (refer to Section 4.6), so we sought to replicate 
the leupeptin study in the SH-SY5Y cells. Evidently, the use of an N-terminal 
APP antibody revealed the upregulation of a 50 kDa band by nearly 2-fold (p 
= 0.043) in leupeptin-treated cells compared with controls but the C-terminal 
A8717 antibody did not detect any significant difference in the expression of 
APP fragments between drug-treated and control cells (Figure 25). 
Accordingly, leupeptin treatment of SH-SY5Y cells did not alter the 
expression of CACNA2D1, MCM4, PDE7A or SPOPL (Figure 26). As a side 
note, we would like to point out that the N-terminal APP antibody that we 
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used did not recognize the same epitope as any of the N-terminal APP 
antibodies used by Tsuzuki and colleagues. Nevertheless, we could safely 
conclude that the A8717 antibody recognized a 50 kDa APP fragment that was 
specifically altered in cells that have been modified to model AD pathology or 
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Figure 26. Representative Western blots of CACNA2D1, MCM4, PDE7A and SPOPL proteins following incubation of SH-SY5Y cells with or without 20μM of leupeptin for 24 hours and relative fold change quantification by densitometry analysis. Leupeptin treatment did not significantly alter CACNA2D1, MCM4, PDE7A or SPOPL protein expression (paired t test). Data are expressed as mean ± SEM; n = 3. 
3.4.2 Determining the identity of the 50 kDa fragment by mass 
spectroscopy 
We sought to characterize the upregulated 50 kDa APP metabolite that we 
detected in our Western blots using mass spectroscopy. We loaded SH-
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SY5YAPP695 lysates onto a 10% glycine gel and conducted SDS-PAGE under 
the same conditions used to generate the blot in Figure 24. These parameters 
were chosen because the band of interest could be clearly distinguished from 
other bands that would have appeared in close proximity had other parameters 
been used. The gel was stained with Coomassie blue after the run was 
completed. After destaining, the band that appeared halfway between the 50 
kDa and 37 kDa protein marker ladders (corresponding to the same position as 
the “50 kDa” band in Figure 24) was cut out and another band that appeared 
closer to the 50 kDa protein marker ladder was also sent for analysis for safe 
measure. Mass spectroscopy results revealed that two peptides with a 
combined sequence of “THPHFVIPYRCLVGEFVSDALLVPDK”, which 
corresponds to amino acid residues 107-132 of the APP N-terminal domain, 
were detected in the band that appeared halfway between the 50 kDa and 37 
kDa protein marker ladders but no APP peptides were associated with the 
other band (Figure 27).  
 
 
Figure 27. Screen capture of the ProteinPilot software (AB Sciex) that was used to analyze mass spectroscopy results of the upregulated 50 kDa 
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fragment in SH-SY5YAPP695 cells. Mass spectroscopy revealed the partial amino acid sequence of the APP metabolite that constitutes the 50 kDa fragment.  
Since the A8717 antibody binds to the last 20 amino acids of APP, we used 
two protein molecular weight predictor software that are available online 
(web.expasy.org/compute_pi/ and bioinformatics.org/sms/prot_mw.html) to 
predict the molecular weight of an APP fragment consisting of residues 107 to 
695. Both software predicted the molecular weight of full-length APP695 to be 
78.7 kDa and the molecular weight of an APP fragment consisting of residues 
107 to 695 to be 66.9 kDa. There are various reasons why the band that is 
observed in Western blots may differ in size from the predicted molecular 
weight. In this case, post-translational modifications like phosphorylation and 
glycosylation; composition of charged versus non-charged amino acids; and 
possible formation of dimers may alter the size of the protein detected (Abcam). 
Although the latter is usually prevented in reducing conditions such as SDS-
PAGE, strong interactions can result in the appearance of bands that appear 
bigger than the predicted molecular weight as demonstrated by Cheng and 
colleagues. Because both software tended to underestimate the molecular 
weight of proteins as compared to the sizes detected from Western blots, we 
suspected that an APP fragment made up of all residues between 107 and 695 
would actually appear bigger than 66.9 kDa in Western blot membranes probed 
with A8717. Hence, our 50 kDa fragment might not consist of all the APP 
amino acid residues between 107 and 695 but would probably be processed in a 
way that removes many of the residues in between. Although this fragment 
may be associated with anMan heparan sulfate adducts that are bound to the 
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Aβ portions of the fragment, it remains unclear whether it could be oligomeric 
as hypothesized by Cheng and colleagues. 
To date, several alternatively spliced APP mRNAs coding for proteins that 
range from 487 to 770 amino acids have been reported. The 487 amino acid 
APP isoform was identified from a clone isolated following screening of 
cDNA libraries constructed from the cerebral cortex or the cerebellum of a 54-
year-old individual with AD using a 1.4kb cDNA fragment. Compared to the 
sequence of APP695, APP487 lacks 208 amino acids at the C-terminus which 
are replaced by 20 amino acids derived from nucleotide sequences with 
homology to the Alu repeat family (de Sauvage and Octave, 1989). We put 
forward the notion that the 50 kDa APP fragment described in our study could 
be one of many uncommon APP products that is only generated under certain 
conditions, such as chronic APP overexpression accompanied by increased 
APP processing as well as in ageing and AD.  
3.4.3 Comparison of APP metabolite expression following cellular 
fractionation of control SH-SY5Y cells and cells that were transiently or 
stably transfected with APP 
Because our previous APP Western blots from human lysates and SH-
SY5YAPP695 cells (Figure 24) were derived from SDS-PAGE conditions that 
were not optimized for the detection of small molecular weight proteins, it is 
reasonable to suggest that APP metabolites other than the 50 kDa fragment 
could be responsible for modulating the expression of CACNA2D1, MCM4, 
PDE7A and SPOPL. We made a side-by-side comparison of APP metabolites 
that were expressed in control SH-SY5Y cells and cells that were transiently 
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or stably transfected with APP to identify other differentially expressed APP 
fragments. In addition, the lysates were subjected to cellular fractionation 
before SDS-PAGE in order to determine whether APP metabolites were also 
localized to different cellular fractions among the three samples. Proper 
segregation of lysates into cytoplasmic and nuclear fractions was verified by 
examining the expressions of the cytoplasmic protein, GAPDH, and the 
predominantly nuclear protein, SP1. 
Besides the 50 kDa and 70 kDa fragments identified earlier, SH-SY5YAPP695 
cells expressed higher levels of a 30 kDa fragment, an 18 kDa fragment and 
the CTF in the cytoplasm. Upregulation of a 37 kDa fragment was also 
observed in the nuclear and cytoplasmic fractions of SH-SY5YAPP695 cells 
compared with cells that were transiently transfected with APP. Furthermore, 
AICD expression, which was higher in the SH-SY5YAPP695 cells, appeared to 
be mainly localized to the cytoplasm. Although there appeared to be an 
accumulation of CTF in the nuclear fraction of transiently transfected cells, we 
were not able to conclude whether nuclear AICD expression was lower in 
these cells compared with SH-SY5YAPP695 cells for several reasons. First, 
technical limitations prevented us from loading high concentrations of nuclear 
protein in order to directly detect the low AICD expression in neuroblastoma 
cells. Second, the lack of CTF accumulation in the nuclear fraction of SH-
SY5YAPP695 cells could either mean that more AICD was released or that all 
the CTF was localized to the cytoplasm. In addition to a higher CTF 
accumulation in the nuclear fraction, transiently transfected cells expressed 
higher levels of a 60 kDa fragment, a 32 kDa fragment and a 27 kDa fragment 
in the nucleus. The molecular weights indicated are merely rough estimations 
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(Figure 28). Clearly, the samples would have to be run on two separate gels – 
one that is optimized for the detection of large proteins and the other for small 
proteins to allow better discrimination of the closely-spaced bands. Before we 
can conclude that any of the differentially expressed bands could potentially 
modulate CACNA2D1, MCM4, PDE7A or SPOPL expression, we would 
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4.1 Evaluation of strategies used to search for APP/AICD targets  
The greatest merit of using microarray and ChIP-Seq techniques is the ability 
to monitor the relative abundance of large numbers of gene transcripts 
simultaneously under the experimental condition of interest. Compared with 
traditional methods that study the functions of one or a few genes at a time, 
genome-wide studies accelerate the process of searching for APP/AICD target 
genes and co-regulators. Since the majority of gene products interact with 
other macromolecules that influence their function, biological processes 
should be considered as networks of interconnected pathways. This is made 
possible through the use of bioinformatics and computational analysis to aid 
inference from microarray and ChIP-Seq data.  
Nevertheless, the sheer amount of data generated from high throughput studies 
may also be a disadvantage. Being costly to conduct (Blalock et al., 2005) 
means that the number of replicates reported in microarray and ChIP-Seq 
studies might not be very large in most cases. Coupled to the fact that multiple 
comparisons are made while testing thousands of genes for significant change, 
data from genome-wide studies are susceptible to false positive errors. In view 
of this, we applied stringent criteria in selecting putative APP/AICD target 
genes for follow-up studies despite inevitably subjecting ourselves to the risk 
of committing false negative errors because of the inverse relationship 
between Type I and Type II errors. In our case, eliminating genes with less 
than 1.5-fold expression changes might have caused us to miss out on 
biologically important genes that have a small but statistically significant fold 
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change that could actually be measured with high precision in many biological 
replicates (Wolfinger et al., 2001).  
In addition, we felt that it was important to choose APP/AICD targets that 
demonstrated significant changes in expression in both SH-SY5YAPP695 cells 
and in SH-SY5Y cells treated with APP siRNA for a couple of reasons. Since 
SH-SY5YAPP695 cells were used as a model for AD, which can be caused by 
the increase in APP levels associated with APP gene duplication (Kasuga et al., 
2009); APP/AICD targets that were altered in these cells could be indicative of 
proteins that are associated with disease. In the event that APP or any of the 
proteins regulated by APP were to be targeted as a means to restore the 
original levels/functions of proteins that were changed in disease, APP/AICD 
targets would have to display significant but opposite changes in direction 
when APP was knocked down in SH-SY5Y cells to provide some indication 
that intervention might be effective. 
4.2 AICD target mRNA and protein expression within the same sample 
and across samples 
All of the APP/AICD targets identified in this study demonstrated significant 
changes in mRNA expression following either stable APP transfection or APP 
knockdown. However, there were two instances where alterations in target 
mRNA levels did not translate to significant differences in protein expression. 
CACNA2D1 and PDE7A protein expression remained stable in SH-
SY5YAPP695 cells and in SH-SY5Y cells treated with APP siRNA respectively, 
although both were expected to increase based on their mRNA expression 
profile. The lack of concordance between mRNA and protein expression is not 
 134 
unique to our case but has been frequently reported elsewhere (Bustin et al., 
2009; reviewed in Greenbaum et al., 2003). The poor correlations reported in 
the literature between mRNA and protein levels have been attributed to the 
numerous complicated and varied post-transcriptional mechanisms involved in 
converting mRNAs into proteins; the substantially different half-lives between 
some mRNAs and their translated products; and the technical limitation 
presented by the amount of error and noise in both protein and mRNA 
experiments (Greenbaum et al., 2003). Following simultaneous measurement 
of absolute mRNA and protein abundances and turnover for more than 5000 
genes in mammalian cells, Schwanhausser and colleagues classified the 
mRNA-protein sets into four groups: genes with stable mRNAs and stable 
proteins, genes with unstable mRNAs and proteins, genes with stable proteins 
but unstable mRNAs and genes with stable mRNAs but unstable proteins. 
Factors influencing mRNA stability include the length of the 3’ untranslated 
region (UTR) and the presence of certain binding motifs. mRNAs with long 3′ 
UTRs are less stable than those with shorter 3′ UTRs and the density of AU-
rich elements and binding motifs may be negatively correlated with mRNA 
stability. For proteins, highly structured ones are found to be more stable than 
unstructured ones and unstable proteins tend to exhibit an over-representation 
of certain amino acids. Genes with stable mRNAs and stable proteins are 
usually involved in constitutive cellular processes like translation, respiration 
and central metabolism. Hence, housekeeping genes have stable mRNAs and 
proteins. The subset of genes with unstable mRNAs and proteins includes 
transcription factors, signaling genes, chromatin modifying enzymes and 
genes with cell cycle-specific functions. These act as information carriers, so 
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their degradation has to be timed properly in order to regulate the persistence 
of genetic information. Genes with stable proteins but unstable mRNAs are 
related to the processing of mRNAs, tRNAs and non-coding RNAs while 
extracellular proteins make up the majority of genes with stable mRNAs and 
unstable proteins (Schwanhausser et al., 2011).  
Evidently, mRNA expression changes do not necessarily reflect similar 
changes in corresponding protein levels even within the same sample. Thus, it 
is not surprising that CACNA2D1 levels were found to be significantly 
decreased in AD brain lysates although results from the SH-SY5YAPP695 cells 
indicated that the direction should have been reversed (mRNA) or no change 
should have been observed (protein). Although SH-SY5YAPP695 cells were 
used in our study to model AD, this is still a relatively simple system that does 
not encompass all the pathogenic changes that manifest in humans. 
Furthermore, AD is known to be presented with other commonly occurring co-
morbidities such as vascular changes, metabolic changes and diseases 
associated with old age, like hypertension or diabetes; all of which are likely 
to influence AD pathology in one way or another but have not been modeled 
by the SH-SY5YAPP695 cells. 
In any case, all of the APP/AICD targets chosen proved to be associated with 
AD because protein levels of CACNA2D1, MCM4, PDE7A and SPOPL are 
altered in actual brain lysates from AD patients. Reproducibility of our 
findings using different samples adds confidence to the identity of 
CACNA2D1, MCM4, PDE7A and SPOPL as APP/AICD targets and their 
altered expression in AD indicates that they might be useful as biomarkers for 
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AD or that targeting these proteins for intervention may be potentially useful 
for alleviating AD.  
4.3. Possible roles of CACNA2D1, MCM4, PDE7A and SPOPL in AD  
In our study, we have shown that manipulating the expression of APP alone 
results in changes to numerous target genes and this could consequently affect 
other players in the pathways that they are involved in as well. Therefore, 
designing new drugs against downstream players in AD might be more 
beneficial because their specificity of action might reduce the risk of side 
effects. Whether CACNA2D1, MCM4, PDE7A and SPOPL could provide the 
answer to slowing down disease progression or in the best case scenario, to 
cure AD, calls for further investigation. In the following sections, we discuss 
how CACNA2D1, MCM4, PDE7A and SPOPL might be involved in AD 
based on previously reported evidence or as an extension of their known 
functions in physiology.  
4.3.1 CACNA2D1 
CACNA2D1 immunostaining in the rat central nervous system revealed high 
expression in areas like the spinal dorsal horn, anterior olfactory nucleus, 
anterior amygdala, basolateral and cortical amygdala, and the piriform, 
perirhinal, insular and entorhinal cortices. In the hippocampus, staining is 
heterogeneous with greater density in areas of glutamate terminals such as the 
mossy fiber endings on CA3 pyramidal cells and perforant path endings on 
granule cells and CA1 stratum radiatum. In addition, moderate staining is 
observed in the lateral posterior nucleus of the thalamus, superficial layers of 
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neocortex, periaqueductal gray, substantia nigra, stria terminalis, nuclieus 
accumbens and tegmental nucleus (Taylor and Garrido, 2008).  
The α2δ proteins are accessory subunits of voltage-gated calcium channels 
that play a role in enhancing the forward trafficking of the pore-forming 
calcium channel α1 subunits and decreasing their turnover at the plasma 
membrane. In this way, α2δ proteins increase the expression of many 
permutations of high voltage-activated calcium channel subunit combinations, 
and have similar effects on current amplitude. α2δ subunits also affect other 
calcium current parameters, such as inactivation of calcium channels. 
CACNA2D1, or α2δ1 as it is commonly referred to, is one out of four α2δ 
subunits that have been cloned to date (reviewed in Bauer et al., 2010; Davies 
et al., 2007). Independent of its effects on calcium channels, α2δ1 is also 
involved in synaptogenesis. α2δ1 binds to the extracellular matrix proteins of 
the thrombospondin family that are secreted by glia and is required for 
thrombospondin- and astrocyte-induced excitatory synapse formation (Eroglu 
et al., 2009). 
α2δ1 is an extracellular protein that is glycosylphosphatidylinositol-anchored 
to the membrane and displays marked localization in lipid rafts (Davies et al., 
2006). It contains a von Willebrand factor type A domain in its extracellular 
sequence which consists of a Rossmann fold with a metal ion-dependent 
adhesion site (MIDAS) motif that mediates divalent cation-dependent 
interactions with ligands. It is thought that the MIDAS motif enables α2δ1 to 
undergo divalent cation-dependent structural rearrangement between a closed 
and open conformation and an intact MIDAS motif is essential for the 
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trafficking function of α2δ (Canti et al., 2005). In addition, α2δ1 contains 
Cache domains which may be important for drug-binding (Anantharaman and 
Aravind, 2000). Specifically, gabapentinoid drugs bind to α2δ1 to result in 
impaired trafficking and α2δ1-dependent excitatory synapse formation (Eroglu 
et al., 2009).  
In terms of relevance to disease, α2δ1 is closely linked to neuropathic pain. 
Upregulation of α2δ1 mRNA and protein levels is observed in the dorsal root 
ganglion and spinal cord on the same side as an experimental nerve crush 
injury and this correlates with the onset of allodynia, which is characterized by 
pain-related behavior in response to non-noxious stimuli (Luo et al., 2001). 
The elevated α2δ1 expression is mainly intracellular with localization within 
the endoplasmic reticulum in association with tubulo-vesicular structures 
involved in protein trafficking. On the other hand, increased α2δ1expression at 
the plasma membrane is only observed on excitatory nerve terminals. Mice 
overexpressing α2δ1 may display allodynia in the absence of nerve injury (Li 
et al., 2006). Conversely, downregulation of α2δ1 following intrathecal 
administration of antisense oligonucleotides directed against α2δ1 reduces 
pain-related behavior (Li et al., 2004). Thus, it is apt that α2δ1 is the site 
where gabapentinoid drugs exert their anti-nociceptive effects.  
The reduced α2δ1 expression in AD could be a compensatory mechanism to 
counter neuronal death as a result of excitotoxicity (refer to Section 1.1.2). By 
reducing the trafficking of voltage-gated calcium channel subunits and 
allowing their turnover, calcium current amplitudes can be lowered. 
Furthermore, excitatory synapse formation may be impaired due to the lack of 
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α2δ1. However, reduced α2δ1 expression could be related to the alterations to 
pain threshold and tolerance that have been reported in AD. In one study, AD 
patients and elderly patients without dementia were matched for the existence 
of painful conditions. Both groups were given questionnaires pertaining to 
pain and a comparison was made regarding their use of analgesics. It was 
found that AD patients experience less intense pain and less pain affect 
compared to controls even though the number of AD patients using analgesics 
did not differ from controls (Scherder et al., 1999). When electrical 
stimulation or arm ischemia was used to induce pain in AD patients and age-
matched control subjects, no difference is observed in terms of stimulus 
detection and pain thresholds. However, the more severe the cognitive 
impairment in AD patients, the higher is their tolerance to pain. In addition to 
having lower MMSE scores, EEG analysis revealed that patients with low 
alpha and high delta peaks demonstrate increased tolerance to both electrical 
stimulation and ischemia (Benedetti et al., 1999). Similar results were 
obtained in another study in which MRI was used to observe activity in both 
medial and lateral pain pathways. Moderate pain that was evoked in AD and 
control subjects is associated with the same network of pain-related activity 
incorporating the cingulate, insula and somatosensory cortices in both groups. 
As a matter of fact, AD patients actually show greater amplitude and duration 
of pain-related activity in sensory, affective and cognitive processing regions 
compared to controls (Cole et al., 2006). It would seem that pain perception 
and processing are not altered in AD, so the higher pain tolerance could be 
attributed to cognitive and affective factors. Since overexpression of α2δ1 is 
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associated with allodynia in the absence of painful stimuli, reduction of α2δ1 
levels in AD might possibly lead to increased tolerance to noxious stimuli. 
4.3.2 MCM4  
MCM4 encodes a subunit of the MCM2-7 complex, which is made up of a 
group of structurally related proteins that form a heterohexamer. MCM2-7 is 
recruited to replication origins as part of the pre-replication complex that 
assembles from late mitosis to early G1 phase of the cell cycle. Genome 
replication is restricted to once per cell cycle through the coordinated action of 
the origin recognition complex (ORC) Cdc6 and Cdt1 proteins that clamp 
MCM2-7 around the DNA (Woodward et al., 2006). The MCM2-7 complex 
plays the role of a DNA-unwinding enzyme or helicase during the initiation of 
DNA replication (Bochman and Schwacha, 2009; Byun et al., 2005; McGeoch 
et al., 2005; Tye and Sawyer, 2000). While the ATP binding activity of the 
MCM6 protein is critical for DNA helicase activity, it appears that MCM4 
may have an important role in single-stranded DNA binding activity of the 
complex (You et al., 1999). Activity of the MCM2-7 complex may be 
regulated by phosphorylation of MCM4. Cdc2 or CDK2 phosphorylation 
inactivates the MCM2-7 complex from late S phase through mitosis in order to 
prevent unwarranted DNA replication (Hendrickson et al., 1996; Ishimi and 
Komamura-Kohno, 2001); whereas phosphorylation by Cdc7 facilitates 
interaction with Cdc45, which is a key protein required for initiation of DNA 
replication (Masai et al., 2006). 
Under normal circumstances, MCM2-7 complexes are loaded onto DNA in a 
20-fold excess over the number of DNA-bound ORC molecules and 
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replication origins. Since a single initiation of DNA synthesis takes place from 
MCM-bound replication origins in S phase, the additional sites that are bound 
by MCM2-7 remain “dormant”. However, the situation changes under 
conditions of replication stress, in which slowing or stalling of replication fork 
progression and/or DNA synthesis occurs. Generation of aberrant replication 
fork structures containing single-stranded DNA activates the replication stress 
response, which is primarily mediated by the ATR kinase (Zeman and 
Cimprich, 2014). Along with the MCM2-7 complex, ATR stabilizes and helps 
to restart stalled replication forks in order to avoid DNA damage and genome 
instability. Hence, the excess MCM2-7 complexes play an important role in 
licensing “dormant” replication origins, which are effectively suppressed 
during unperturbed DNA replication but can support initiation when 
replication forks are stalled in response to replication stress (Woodward et al., 
2006). 
In general, reduced dosage of MCM proteins permits replication initiation but 
is thought to be insufficient for completion of S phase and cell cycle 
progression (Liang et al., 1999). Although neurons are thought to be 
terminally differentiated cells, AD brains are characterized by the presence of 
a higher number of hyperploid neurons that are prone to cell death (refer to 
Section 1.1.2). The signal that drives re-entry of these neurons into the cell 
cycle remains unclear but excitotoxicity, hypoxia, proinflammatory processes 
and elevations in growth factor release have been suggested as possible 
candidates (Woods et al., 2007). In particular, increased levels of nerve growth 
factor, transforming growth factor-1 and basic fibroblast growth factor are 
found in AD (reviewed in Raina et al., 1999). In this case, the loss of MCM4 
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expression in AD may represent a means to prevent the genomic instability 
that would arise following unscheduled cell cycle re-entry that eventually 
results in neurodegeneration.  
MCM4 mutations that result in partial MCM4 deficiency are associated with a 
genetic syndrome of growth retardation with adrenal failure and natural killer 
(NK) cell deficiency in humans (Gineau et al., 2012; Hughes et al., 2012). 
With the exception of one study (Araga et al., 1991), AD has been consistently 
associated with the overproduction of cytokines from NK cells and enhanced 
NK cell toxicity to physiological modifiers (Masera et al., 2002; Solerte et al., 
2000; Solerte et al., 1998; Solerte et al., 1996). In view of the significant 
negative correlations found between the spontaneous release of IFN-γ and 
TNF-α from NK cells and the MMSE scores of AD patients, it is thought that 
NK cell-derived cytokine release could be involved in neuroinflammatory 
mechanisms related to neurodegeneration in AD (Solerte et al., 2000). Thus, 
the decrease in MCM4 levels observed in AD could be a compensatory 
response to reduce the number of NK cells in order to overcome NK cell 
hyperactivity in AD. 
4.3.3 PDE7A (Phosphodiesterase 7A) 
The family of cyclic nucleotide PDEs catalyze hydrolysis of the 3’ cyclic 
phosphate bonds of adenosine (cAMP) and/or guanosine 3’, 5’ cyclic 
monophosphate (cGMP). There are three main reasons why PDEs make good 
therapeutic targets. First, regulating degradation of the second messenger in a 
signaling pathway can make a more rapid and larger change in availability of 
the molecule as opposed to regulating its rate of synthesis. Second, because 
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levels of cAMP and cGMP in most cells are typically within the micromolar 
range; inhibitors that are designed against PDEs do not need to have very high 
affinity for their respective targets or compete with very high levels of 
endogenous substrate to be effective. Finally, because the presence of 
alternative transcriptional start sites and alternative splicing result in the 
generation of more than 100 different mRNA products from the 11 PDE 
family members, it is possible to develop isoform-selective inhibitors to target 
specific functions and pathological conditions without causing side effects 
(reviewed in Bender and Beavo, 2006). As proof of concept, the use of PDE 
inhibitors for AD intervention has been studied in Phase 2, 3 and 4 clinical 
trials. The safety and tolerability of PF-04447943, which is a PDE9A 
inhibitor; and its effects on the cognitive, behavioral and overall symptoms of 
AD were studied in a Phase 2 trial. The PDE4 inhibitors EHT 0202 and 
MK0952 were administered in two different Phase 2 clinical trials and tested 
for the ability to improve cognitive impairment in mild-to-moderate AD. 
Although the abovementioned trials have been completed, no results were 
posted. On the other hand, the PDE3 inhibitor, cilostazol, has progressed to 
Phase 3 and 4 of clinical trials (https://clinicaltrials.gov/). While the former 
has yet to start recruiting participants, the latter has been completed. 46 
subjects who were diagnosed with probable AD and scored between 10 and 26 
in the MMSE were enrolled into the Phase 4 clinical trial. Subjects received 
10mg of donepezil and 200mg of cilostazol in the study group or 10mg of 
donepezil and 200mg of placebo in the control group for two years. However, 
no significant changes were observed in all of the outcome measures 
(ClinicalTrials.gov Identifier: NCT01409564).   
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The PDE7 family is highly selective for cAMP as a substrate and consists of 
two genes, PDE7A and PDE7B. Although a previous study has reported the 
association between reduction of PDE7A mRNA expression and AD (Perez-
Torres et al., 2003), we are the first to demonstrate that this phenomenon is 
sustained at the protein level and arises due to changes in APP signaling. In 
their study, Perez-Torres and colleagues demonstrated that PDE7A is 
heterogeneously expressed in the physiological human brain and is present in 
both gray and white matter. Using in situ hybridization, highest PDE7A 
mRNA expression is found in the cerebral cortex and hippocampal formation. 
In AD, PDE7A mRNA expression is decreased in the dentate gyrus of Braak 
III–VI compared with Braak I–II brains. A decrease in PDE7A mRNA levels 
in myelinated fiber tracts is also observed in the capsula interna, anterior 
commissure and both lamina medularis medialis and lateralis in AD brains 
compared with control brains. A trend towards a decline is observed in the 
white matter of the EC but no difference is detected in the white matter from 
frontal and temporal cortices. Hence, the reduction in PDE7A levels that we 
described in the BA9 region probably resulted from decreased expression of 
PDE7A in the gray matter. 
Inhibition of endogenous PDE7 expression is known to promote 
oligodendrocyte precursor survival and differentiation into myelin-forming 
oligodendrocytes, without affecting the rate of oligodendrocyte precursor 
proliferation (Medina-Rodriguez et al., 2013). Thus, reduction in PDE7A 
levels could represent a mechanism to cope with the loss of oligodendrocytes 
that are associated with the white matter lesion in AD (discussed in Section 
1.1.2). Since drug inhibition of PDE7A has also been shown to suppress 
 145 
proliferation of NK cells as well their ability to produce proinflammatory 
cytokines (Goto et al., 2009), reduced PDE7A levels in AD might possibly 
contribute to the increased apoptosis of NK cells that have been described in 
AD (Schindowski et al., 2006). This could be an attempt to deal with the 
overproduction of IFN-γ and TNF-α cytokines from NK cells that are 
associated with the cognitive deterioration in AD (Solerte et al., 2000). The 
compensatory mechanisms associated with reduced PDE7A expression in AD 
appear to be limited in their effectiveness and further reduction of PDE7A 
levels through the use of inhibitors would probably improve the cognition of 
AD patients by promoting the survival of “beneficial cell types” and apoptosis 
of “pathogenic cell types”. APP/PS1 AD transgenic mice that were treated 
daily with the PDE7 inhibitor, S14, demonstrated restored visual short-term 
memory; decreased Aβ deposition; enhanced Aβ degradation; and decreased 
tau phosphorylation at the end of four weeks (Perez-Gonzalez et al., 2013). 
Therefore, the use of PDE7A or PDE7 inhibitors in general might be a viable 
therapeutic option to explore for AD. 
4.3.4 SPOPL (Speckle-type POZ protein-like) 
Segmental duplication and retrotranposition events that took place during 
evolution are thought to give rise to SPOPL, which belongs to the family of 
bipartite TD/POZ proteins that are composed of TD (TRAF domain)/MATH 
(meprin and TRAF homology) and POZ (poxvirus and zinc finger)/BTB 
(Broad complex,Tramtrack, Bric à brac) domains. SPOPL orthologs exist in 
human, rat and mouse genomes and the translated proteins share 96.2–98.5% 
sequence identity, suggesting that they are under strong negative selection and 
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may have important functions that are conserved among the three species 
(Choo et al., 2010).  
SPOPL shares 85% sequence identity with its paralog SPOP, which functions 
as an E3 ubiquitin ligase adaptor protein that forms complexes with the Cullin 
3 (Cul3) scaffold protein of the E3 ligase. SPOP has been shown to directly 
target proteins such the apoptosis factor Daxx, the inositol kinase PIPKIIb, 
Hedgehog signaling transcription factors Gli2 and Gli3 and at least six other 
substrates for ubiquitylation and subsequent proteolysis by the 26S 
proteasome via its MATH domain. However, interaction of SPOPL with 
SPOP through BTB-BTB heterodimerization prevents SPOP self-assembly 
into oligomers and results in inhibition of E3 ubiquitin ligase activity. Thus, 
the combined action of SPOPL and SPOP is one method by which effects of 
the SPOP/Cul3 E3 ligase towards multiple protein substrates can be regulated 
(Errington et al., 2012). At the molecular level, reduced SPOPL expression in 
AD could lead to excessive ubiquitylation and proteolysis of proteins, which 
may be associated with a host of effects such as a reduction or loss of signal 
transduction and protein function and/or increased cell death. Since non-
degradative APP polyubiquitylation by ubiquilin-1 results in the sequestration 
of APP in the Golgi apparatus and delays its access to the cell surface (El 
Ayadi et al., 2012), SPOPL could similarly play a role as a sorting signal to 
influence APP amyloidogenic processing by virtue of its ability to modulate 
the ubiquitylation process. Like SPOPL, ubiquilin-1 levels are also reduced in 
AD brains (Stieren et al., 2011). 
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Array-comparative genomic hybridization analysis revealed that a 6Mb 
deletion in the long arm of chromosome 2 (from 2q22.1 to 2q22.3) is 
associated with severe mental retardation, autism spectrum disorder, 
congenital malformations comprising hypospadia and omphalocele and 
episodes of high blood pressure. Within this region, the eight genes that are 
deleted include: HNMT, SPOPL, NXPH2, LOC64702, LRP1B, KYNU, 
ARHGAP15 and GTDC1. It appears that the locus in which SPOPL is located 
might be important for cognition because a loss of function leads to 
intellectual disability or mental retardation and the associated behavioral 
disorders such as occasional tantrums, stereotyped movements of the trunk 
and repetitive whistling (Mulatinho et al., 2012). Since SPOPL is 
downregulated in AD patients, the cognitive impairment and behavioral and 
psychological symptoms presented in AD might be contributed in part by the 
reduction in SPOPL expression. It would be interesting to determine whether 
expression of the other seven genes found in the same locus are also affected 
in AD, in order to assess whether SPOPL’s role in AD is a combined effect 
with genes that are located in close proximity. 
4.4 Lack of evidence for AICD regulation of APP, EGFR, GSK3B, Tip60 
or CD10 expression in SH-SY5Y cells?  
APP, EGFR, GSK3B, Tip60 and CD10 are previously reported AICD targets 
that we tested in the SH-SY5Y cell line for use as positive controls in our 
AICD overexpression or AICD inhibition experiments. With the exception of 
CD10, all other proteins did not show significant changes in response to 
alterations in AICD levels. This is not surprising given the fact that there is a 
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general lack of consensus in the field regarding the identity of AICD targets 
because various factors can influence reproducibility of the findings, as 
highlighted in Sections 1.4.5, 1.5 and 3.3.1. We took a closer look at the 
original studies and found that out of the five, evidence for direct regulation by 
AICD was only available for CD10 (Kerridge et al., 2014) and EGFR (Zhang 
et al., 2007); based on the fact that binding of AICD to the promoters of CD10 
(Belyaev et al., 2009; Kerridge et al., 2014) and EGFR had been established 
using ChIP. While EGFR regulation by AICD was demonstrated using 
samples derived from mice, CD10 regulation by AICD has been replicated in 
a number of samples including fibroblasts (Bauer et al., 2011) and four 
different neuroblastoma cell lines. The latter include the SK-N-SH, SK-N-SS, 
NB7 (Xu et al., 2011) and SH-SH5Y as well as SH-SY5YAPP695 cell lines 
(Belyaev et al., 2009; Kerridge et al., 2014); albeit ones that were derived 
from different sources compared with the cells used in our study. Because 
AICD regulation of a particular target transcript seems to be cell type-specific, 
this could explain why we could only detect a significant upregulation of 
CD10 (but not APP, EGFR, GSK3B or Tip60) expression in our cells 
following transient AICD transfection as compared with control cells.  
It was previously shown that AICD occupancy of the CD10 promoter could be 
detected in SH-SY5YAPP695 cells but not in SH-SY5Y cells which 
endogenously express low levels of CD10 (Belyaev et al., 2009; Kerridge et al., 
2014). Since we were capable of detecting an increase in CD10 protein 
expression following AICD overexpression in our SH-SY5Y cells, we were 
concerned as to why the corresponding decrease in CD10 protein levels was 
not apparent following inhibition of AICD production through GSI treatment 
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of SH-SY5YAPP695 cells. Apparently, AICD levels were not altered in L-
685,458-treated SH-SY5Y cells, so quantification of CD10 using qPCR or 
conventional PCR in previous studies did not detect any significant changes in 
CD10 mRNA expression (Belyaev et al., 2009). In our study, we examined the 
levels of APP CTF expression as a measure of the amount of AICD that was 
not released following GSI treatment. Since we could not directly demonstrate 
that AICD levels were reduced in GSI-treated cells, the lack of observable 
changes in CD10 levels could probably be due to the insignificant reduction of 
AICD expression. 
4.5 Are CACNA2D1, MCM4, PDE7A and SPOPL AICD target genes? 
The results from at least two independent studies indicate that endogenous 
AICD, which is generated following γ-secretase cleavage of full-length 
transmembrane APP; and exogenous AICD, which is usually introduced 
following transfection, have different capacities for stabilization by Fe65 and 
thus, have different requirements for the presence of Fe65 in mediating 
transactivation of target genes (Huysseune et al., 2007; Yang et al., 2006). 
Overexpression of Fe65 does not alter endogenous AICD levels in the 
membrane or cytosolic fractions; or increase endogenous AICD nuclear 
translocation (Yang et al., 2006). On the other hand, co-transfection of AICD 
and Fe65 results in the stabilization of exogenous AICD and enhances the 
levels of exogenous AICD-driven luciferase reporter expression. Microarray 
analysis of transcriptome changes during AICD-dependent gene regulation in 
neuroblastoma SHEP-SF cells overexpressing AICD, Fe65, or the 
combination of both in an inducible manner revealed different regulation 
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patterns of exogenous AICD-dependent target genes. One group of genes is 
induced solely by AICD transfection and displays similar expression levels 
even when AICD and Fe65 were co-expressed. The second group of genes is 
differentially expressed after AICD induction and these changes are enhanced 
upon co-expression of Fe65. The last group of genes do not change in 
expression when only AICD was transfected but are significantly altered when 
both AICD and Fe65 were co-expressed. What is more important is the fact 
that the microarray did not detect significant changes in the expression of 
previously described AICD targets, including KAI1, GSK3B, APP, and CD10 
(Müller et al., 2007). Out of the four, AICD occupancy of KAI1 and CD10 
promoters have been shown in ChIP experiments, so they are more likely to be 
directly regulated by AICD. KAI1 was identified as an AICD target following 
overexpression of APP, Fe65 and Tip60 in human embryonic kidney 293 cells 
and was further validated in vivo using brain samples from APP-
overproducing transgenic mice (Baek et al., 2002). At this point, we would 
like to point out that as in the case of CD10; KAI1 was identified as an AICD 
target using an APP overexpression system which is associated with increased 
AICD production from its precursor, and not from AICD that is expressed 
exogenously. The heterogeneity of target gene modulation by AICD suggests 
that there may be a need to distinguish which experimental model best reflects 
physiological AICD regulation of target gene expression. 
The AICD targets validated in our study were derived from ChIP-Seq 
experiments conducted in SH-SY5YAPP695 cells, which revealed that AICD 
occupied the TSS of CACNA2D1, MCM4, PDE7A and SPOPL. The increased 
AICD levels in these cells originated via physiological means, specifically 
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through γ-secretase cleavage of full-length APP and AICD stabilization was 
further augmented by the addition of ammonium chloride. In view of our 
discussion on the differences between endogenous and exogenous AICD and 
the way they regulate target gene expression, it is understandable why 
exogenous AICD overexpression did not induce significant changes in 
CACNA2D1, MCM4, PDE7A and SPOPL protein expression. Furthermore, 
AICD is mainly localized to the cytoplasm when HEK293 cells were 
transfected with AICD or Fe65 alone but co-expression of Fe65 and Tip60 
caused the appearance of nuclear spots and AICD is localized within these 
nuclear spots when all three plasmid were transfected together (Müller et al., 
2013). Since AICD binds to the promoter regions of CACNA2D1, MCM4, 
PDE7A and SPOPL; AICD nuclear translocation is a requirement for the 
regulation of these targets. Seeing that we only co-transfected AICD and Fe65 
into the SH-SY5Y cells, the overexpressed AICD could similarly remain in 
the cytoplasm; so we cannot rule out a role for AICD in the regulation of 
CACNA2D1, MCM4, PDE7A and SPOPL. As we could not directly quantify 
whether GSI treatment inhibited AICD production in SH-SY5YAPP695 cells, we 
can only speculate that CACNA2D1, MCM4, PDE7A and SPOPL protein 
expression remained unaltered because AICD levels that were low to start 
with, were not significantly reduced by GSI treatment. However, the question 
of why transient transfection of full length APP was not able to alter 
CACNA2D1, MCM4, PDE7A and SPOPL levels remains unanswered. It 
would be of interest to determine whether Fe65 and Tip60 levels were 
inherently upregulated in SH-SY5YAPP695 cells as compared with SH-SY5Y 
cells that were transiently transfected with APP as this might explain the lack 
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of changes in CACNA2D1, MCM4, PDE7A and SPOPL expression in the 
latter cell type. However, confocal microscopy imaging revealed that 
overexpression of either wild type APP or APP expressing the Swedish FAD 
mutation in HEK293 cells does not result in nuclear localization of AICD 
(Müller et al., 2013). In our cellular fractionation experiments, we could only 
detect AICD expression in the SH-SY5YAPP695 cells and AICD was mainly 
localized to the cytoplasmic fraction, which is consistent with previous 
findings. It should be highlighted that the SH-SY5YAPP695 cells that were used 
in the cellular fractionation experiments were not subjected to a two step-
crosslinking protocol or ammonium chloride treatment like the cells used in 
the original ChIP experiments. This could explain why we could not detect 
nuclear localization of AICD as demonstrated by Wong (Wong, 2012). In 
another study, localization of biotinyl-tagged AICD in SH-SY5Y cells that 
was observed using confocal microscopy revealed that AICD is located both 
in the nucleus and cytoplasm, with a predominant expression in the nucleus 
(Yang et al., 2012). Thus, we cannot exclude the possibility that CACNA2D1, 
MCM4, PDE7A and SPOPL are AICD targets and we attempt to explain how 
they may be regulated by AICD in Section 4.9. 
4.6 Detection of the upregulated 50 kDa fragment in SH-SY5YAPP695 cells 
is a result of non-specific binding of the A8717 antibody? 
Of all the samples tested in our study; the only two in which CACNA2D1, 
MCM4, PDE7A and SPOPL levels were significantly altered compared to 
controls were the SH-SY5YAPP695 cells and the AD brain lysates. A 
comparison of APP Western blots from the two samples revealed the presence 
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of a commonly upregulated 50 kDa fragment. From our cellular fractionation 
experiments, we found that this 50 kDa fragment was upregulated in the 
cytoplasmic and nuclear fractions of SH-SY5YAPP695 cells compared with cells 
that were transiently transfected with APP.  
At some point, we questioned whether the A8717 antibody might be detecting 
a non-specific 50 kDa band that happened to be upregulated in the process of 
subjecting SH-SY5Y cells to the stable transfection protocol, regardless of 
what was actually being transfected. This was a valid cause for concern 
because an antibody directed against the extracellular portion of APP was 
previously reported to also recognize an intermediate filament-associated 
protein in AD and control fibroblasts. Incubation of Western blot membranes 
with the MAB22C11 antibody revealed a 57 kDa band in addition to the 
predicted molecular weights for full-length APP. However, the appearance of 
this 57 kDa band was not evident in human brain samples (Dooley et al., 
1992). In the discussion section of their follow-up paper published two years 
later, Dooley and colleagues named a few APP antibodies other than 
MAB22C11 that reportedly label cytoskeletal structures in cultured astrocytes 
and in sections of the human brain (Durham et al., 1994). These accounts of 
non-specific binding were related to immunohistological studies but not 
Western blot. A majority of the non-specific antibodies were directed to 
epitopes at the extracellular region of APP. Coincidentally, the only C-
terminal antibody that labeled neurofilaments in control brains and glial 
filaments in astrocytic processes surrounding senile plaques in AD brains has 
a similar epitope to A8717. The former was raised against amino acids 666-
 154 
695 of APP695 (Yamaguchi et al., 1992) while A8717 was raised against 
residues 676-695.  
If the A8717 antibody was in fact exhibiting non-specific antigen recognition, 
then it should not have detected the differentially expressed 50 kDa APP 
fragments in human brain lysates that were not subjected to stable transfection 
procedures. Furthermore, the 50 kDa APP fragment was not significantly 
upregulated in SH-SY5Y cells that were transiently transfected with APP 
because any cellular changes arising from the modification were not sustained 
since transiently transfected genetic materials can be lost by environmental 
factors and cell division (Kim and Eberwine, 2010). The only common factor 
linking the human brain samples and SH-SY5YAPP695 samples is the fact that 
there is a prolonged and progressive increase in amyloidogenic processing of 
APP in the former that is associated with ageing and AD respectively while 
both amyloidogenic and non-amyloidogenic APP processing were probably 
chronically increased in SH-SY5YAPP695 cells and sustained as a result of the 
overall excess in APP that was introduced following stable transfection. Mass 
spectroscopy identification of APP as one of the proteins in the 50 kDa band 
that was upregulated in SH-SY5YAPP695 lysates provides support for the 
specificity of the A8717 antibody. It is surprising that the peptide sequence 
detected matched the N-terminal region of APP when the epitope recognized 
by A8717 lies at the C-terminal region. During mass spectroscopy sample 
preparation, the C-terminal region could be inaccessible to trypsin digestion, 
which makes random cuts after arginine or lysine residues, because of anMan 
adducts that were bound to the Aβ portion of the fragment. On a side note, we 
would like to point out that if the previously reported 50 kDa fragment that 
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accumulates in AD (Hol et al., 2003; van Dijk et al., 2004; van Leeuwen et al., 
1998) purely consists of the frameshifted APP+1 mutant, it should not have 
been detected by A8717 because it has a truncated C-terminus with a different 
amino acid sequence. This will be further discussed in Section 4.9. 
4.7 Stable versus transient APP/AICD transfection models in relation to 
AD 
Cells that express wild-type APP or co-express wild-type APP and wild-type 
PS 1/2 produced more AICD fragments that are 50 amino acids in length 
compared to AICD fragments that are 51 amino acids length. The proportions 
of AICD fragments are reversed in cells expressing mutant APP or in cells that 
co-express wild-type APP and mutant PS1/2 (Kakuda et al., 2006). This raises 
the possibility that the ratio of short and long AICD fragments could also be 
different in cells that are stably- or transiently-transfected with APP. As the 
stoichiometry of AICD species released differs in a cellular model of AD, 
AICD fragments that vary in length may have different functional capabilities 
when it comes to the regulation of target expression in relation to AD. 
Elevated AICD levels are associated with increased apoptotic gene 
transcription and upregulation of proteins that promote cell death (Ha et al., 
2011; Kögel et al., 2012; Nakayama et al., 2008; Ozaki et al., 2006; Vázquez 
et al., 2009; Wang et al., 2014). SH-SY5Y cells overexpressing biotinyl-
tagged AICD grow slower than control cells and measurement of cell 
proliferation using the BrdU assay revealed that AICD is responsible for the 
deficits in cell proliferation. However, the cells do not undergo cell death as a 
result of the elevation in AICD levels. On the other hand, treatment with 
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retinoic acid to promote neurogenesis in SH-SY5Y cells resulted in a 
significant increase in the number of dead cells that overexpressed AICD 
(Yang et al., 2012). This is consistent with the previous finding that AICD 
induces neuron-specific cell death because a significant increase in apoptosis 
is observed only in embryonic carcinoma P19 cell lines that have been 
differentiated into neurons but not in control cells or P19 cells that were 
differentiated into muscle cells (Nakayama et al., 2008).  Clearly, AICD can 
modulate cell proliferation and apoptosis differently, depending on changes 
induced at the genomic level within the same cell line.  
Besides retinoic acid-induced differentiation of cells, changes at the genomic 
level can be introduced experimentally when cells are stably transfected with 
plasmids. In SH-SY5YAPP695 cells, the introduced APP transgene becomes part 
of the genome. Following cell proliferation, descendants of stably transfected 
cells continue to express increased APP/AICD levels. On the other hand, SH-
SY5Y cells that are transiently transfected with APP express the introduced 
gene but do not integrate it into their genome. Thus, APP levels are increased 
for a finite period of time (usually several days) after which the transgene is 
lost through cell division or other factors. The transient APP transfection 
experiments conducted in this study were always compared with cells that 
were transiently transfected with the empty pcDNA vector. An additional 
control would be to use cells that were treated with the transfection reagent 
alone. 
Perhaps, one of the reasons why AICD has such a short half-life is to allow 
essential (non-apoptotic related) signaling/transcriptional events to take place 
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while making way for “rescue mechanisms” to kick in so as to prevent 
unnecessary cell death. In cases where there is a prolonged increase in AICD 
levels that preserves the functions of AICD beyond its usual half-life (e.g. in 
AD or in cells or mice that stably overexpress APP/AICD), “rescue 
mechanisms” would probably also have to be programmed at the genomic 
level so that they can be sustained over an extended period to balance the 
effects of long-term AICD increase. These adaptive changes could include 
altered APP processing and the subsequent accumulation of APP 
proteolytic/degradation products that induce the upregulation of a particular 
subset of AICD-binding proteins distinct from those that interact with AICD 
when there is only a transient increase in AICD expression.  
Evidently, AD is a progressive disease that takes time to manifest. FAD 
individuals are not diagnosed with AD as soon as they are born and sporadic 
AD affects individuals over the age of 65. Thus, the accumulation of long-
term changes in the functions of molecular players could be fundamental to 
the development of a pathologic state. In retrospect, it seems that a stable APP 
transfection system would be a better cell culture model for AD as opposed to 
cells that are transiently transfected with APP. SH-SY5YAPP695 cells reflect the 
mechanisms of long-term genetic regulation more accurately because we have 
observed the upregulation of a 50 kDa APP fragment in these cells and in AD 
but not in transiently transfected cells or controls. Furthermore, the expression 
levels of APP/AICD targets that have been identified from the SH-SY5YAPP695 
cells are also altered in AD. On the whole, we strongly advocate a stringent 
evaluation of the type of transfection system that will be used in future studies 
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to model progressive diseases such as AD, Parkinson’s disease or Type 2 
diabetes.  
4.8 Indirect role of APP metabolites in regulating the expression of 
APP/AICD targets 
As total APP levels were manipulated in most of the experiments described in 
this study, we cannot rule out the possibility that changes in expression of the 
different APP metabolites might have indirect effects on CACNA2D1, MCM4, 
PDE7A and SPOPL expression by triggering other cellular cascades. For 
instance, equimolar production of Aβ and AICD following amyloidogenic 
processing means that more Aβ is expected to be released when the total dose 
of APP is increased, as in the case of the SH-SY5YAPP695 cells. Aβ may form 
oligomers in various intracellular compartments such as the endosomes and 
mitochondria, thereby triggering responses such as the production of reactive 
oxygen species, DNA-damage response and pro-apoptotic signalling. The 
toxic effects brought about by the cellular cascades themselves might then be 
responsible for causing the changes to CACNA2D1, MCM4, PDE7A and 
SPOPL expression as opposed to a direct consequence of changes in the 
activity of any of the APP metabolites. If this were indeed the case, we would 
expect to see similar changes in CACNA2D1, MCM4, PDE7A and SPOPL 
expression in the cells that were transiently transfected with APP. However, it 
is possible that proportion of APP that undergoes amyloidogenic processing 
might be different in the stably- and transiently-transfected cells, thus 
accounting for the differences in the regulation of CACNA2D1, MCM4, 
PDE7A and SPOPL expression in the two cell types.  
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4.9 Possible role of a 50 kDa fragment or other APP metabolites in 
regulating the expression of APP/AICD targets 
Although APP is thought to undergo proteolytic processing via the 
amyloidogenic or non-amyloidogenic pathway, examination of APP CTF 
expression in the human brain cortex reveals that in addition to C83 and C99, 
a 22 kDa species that results from cleavage upstream of the β-secretase site is 
also present (Evin et al., 2003). It is difficult to speculate how this 22 kDa 
fragment may be generated from what we currently know about α-, β- or γ-
secretase activity and their respective cleavage sites on APP. A 17-28 kDa 
APP N-terminal fragment (NTF) has also been detected in human and mouse 
brains and is generated independently of α-secretase or β-secretase activity. 
Rather, a novel APP processing pathway that is regulated by protein kinase C 
appears to be responsible for the production of this NTF. Expression of the 
NTF is developmentally regulated because very low levels are detected in the 
embryonic to P0 stages but expression increases following birth and continues 
through to adulthood (Vella and Cappai, 2012). Evidence for alternative APP 
processing pathways have also been presented in AD and some examples are 
highlighted in Sections 3.4.1-3.4.2.  
The thick 50 kDa band detected in AD brain lysates is another example of a 
metabolite that can be produced from altered APP processing and probably 
consists of different APP species that differ very slightly in size. These species 
include APP+1, which does not express the normal AICD sequence, as well as 
the 50 kDa species that can be detected using a commercial polyclonal 
antibody that recognizes the last 20 amino acids of AICD. Based on antibody-
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binding to various portions of the 50 kDa species, APP+1 and the 50 kDa 
species detected in our study may be produced from two different alternative 
APP processing pathways that are probably suppressed in the normal 
physiological state but become enhanced in ageing and even more so in AD. 
In vitro, the 50 kDa fragment that contains the last 20 amino acids of AICD 
could have been induced by prolonged cellular changes brought about by 
nuclear integration of an additional APP gene because it was upregulated 
following stable but not transient APP transfection. The equivalent 50 kDa 
fragment could be produced in human samples as a result of long-term 
changes associated with the process of ageing and is further upregulated in AD. 
Some of the factors contributing to the accumulation of the 50 kDa fragment 
in vivo might include the accumulation of reactive oxygen species, 
deregulation of metal ion homeostasis in the cell and stimuli that result in 
altered APP processing and/or defective clearance of the pathogenic fragment. 
From the ChIP-Seq study, we know that an APP fragment that includes the 
last 20 amino acids of AICD has to be responsible for binding to the promoter 
regions of target genes to regulate their expression because the BR188 
antibody that was used for the pull-down recognizes the same epitope as the 
commercial antibody that we have been using throughout this study. Although 
AICD seems to be the only APP fragment capable of translocation into the 
nucleus and participating in gene transcriptional regulation, our transient 
AICD transfection model failed to produce significant changes in 
CACNA2D1, MCM4, PDE7A and SPOPL expression. One explanation could 
be that AICD modulation of the four targets is very weak compared to other 
molecular players that could affect the expression of CACNA2D1, MCM4, 
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PDE7A and SPOPL. However, we also detected increased nuclear localization 
of the 50 kDa fragment and another 37 kDa fragment, which contains the last 
20 amino acids of AICD, in SH-SY5YAPP695 cells compared with transiently 
transfected cells. It is possible that these fragments could have been 
immunoprecipitated by the BR188 antibody that was used in the original ChIP 
study and were responsible for modulating CACNA2D1, MCM4, PDE7A and 
SPOPL expression either in place of AICD or in concert with AICD.  
Both BACE (Holsinger et al., 2002) and C99 (Evin et al., 2003) levels are 
significantly upregulated by at least 2-fold in AD. Consistent with the fact that 
AICD generated from C99 is thought to be the transcriptionally active species, 
AICD expression has been found to be enriched in the nuclear fractions of 
human cortical homogenates (Evin et al., 2003). Although AICD-transfected 
cells express higher levels of CD10 in vitro, the majority of studies show that 
CD10 levels and activity are decreased in AD (reviewed in Grimm et al., 
2013). In view of this discrepancy and in line with our discussion on the 
differences between stable and transient transfection cell culture systems, we 
propose two models of AICD transcriptional regulation of target expression. 
In both cases, we are referring to AICD that is generated from cleavage of 
full-length APP as this would be reflective of AICD production in vivo. The 
first model (Figure 29) represents the predominant AICD transactivation 
mechanism in non-aged and healthy individuals. AICD is produced from 
conventional amyloidogenic or non-amyloidogenic processing and has a short 
half-life. AICD that is stabilized through binding of certain adaptor proteins 
escapes degradation and gets translocated to the nucleus where other 
molecular players may be recruited to form a transcriptionally active complex 
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that binds to the promoters of target genes like CD10 and regulate their 
expression. The proteins that interact with AICD in this first model are 
referred to as co-factors Set A and are distinct from those that interact with 
APP in the second model. Although the AICD target modulation described in 
Model 1 still occurs in ageing and AD, changes in the environment or cellular 
state could increase the proportion of APP that undergoes non-conventional 
processing to result in the accumulation of APP metabolites that are rarely 
detected in the non-aged and healthy state (Figure 30). At least one of the 
APP metabolites generated in Model 2 will be pathogenic and could be 
involved in recruiting a different set of co-factors for interaction with AICD. 
Binding of co-factors Set B also stabilizes AICD but promotes the expression 
and/or assembly of different transcriptionally active complexes that regulate a 
different set of target genes. Alternatively, one or more of the pathogenic APP 
metabolites could also translocate into the nucleus directly and regulate target 
expression. Specifically, expression of targets like CACNA2D1, MCM4, 
PDE7A and SPOPL would probably be explained by Model 2. To account for 
the decreased CD10 levels and activity in AD, we surmise that in general, the 
environmental or cellular changes that bring about AICD target modulation in 
Model 2 override AICD target modulation that is described in Model 1. For 
instance, the reported downregulation of somatostatin and Vitamin D in aged 
individuals and AD patients (reviewed in Grimm et al., 2013) as well as 
oxidative stress may be responsible for reducing CD10 mRNA and protein 
expression and function (Fisk et al., 2007; Shinall et al., 2005).  
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5.1 Conclusions  
In conclusion, we have verified that CACNA2D1, MCM4, PDE7A and 
SPOPL are novel APP/AICD targets that are significantly altered in SH-SY5Y 
cells that have been modified to model AD pathology as well as in a region of 
the human brain that is closely associated with AD. Protein levels of all four 
APP/AICD targets are significantly lower in AD subjects compared with non-
demented controls. Whether these changes are associated with altered function 
of the APP/AICD targets in the disease state remain to be investigated. Future 
studies are also needed to evaluate their potential for use as AD biomarkers or 
as potential targets for AD intervention.  
Through the observation that CACNA2D1, MCM4, PDE7A and SPOPL 
expression were only altered in cells that were stably transfected with APP but 
not following transient APP or AICD transfection, we recapitulated the 
inherent differences between stable and transient transfection model systems 
and proposed that stable transfection models might be better suited for the 
study of progressive diseases. Specifically, observations from our stable 
transfection model brought attention to the fact that APP can undergo 
processing via routes that are distinct from the conventional amyloidogenic or 
non-amyloidogenic pathways. Accordingly, APP metabolites that are not 
usually detected or are expressed at very low levels become prominent as a 
result of altered APP processing that is associated with increasing age and is 
enhanced in AD. Detection and further characterization of differentially 
expressed APP fragments will advance the understanding of proteolytic 
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mechanisms involved in the physiology of APP and perhaps lead to the 
identification of processes leading to AD. 
5.2 CACNA2D1, MCM4, PDE7A or SPOPL as biomarkers for AD? 
In order to investigate the potential value of the identified APP/AICD targets 
for use as biomarkers for AD, we propose measuring their respective mRNA 
and/or protein levels in samples (CSF, iPS, etc.) from individuals harboring 
FAD mutations, regardless of whether they have been diagnosed with the 
disease or not; in order to corroborate the data that we have from sporadic AD 
patients. Following comparison with age-matched controls, changes in 
expression of any target would warrant further analysis. Alternatively, 
expression of CACNA2D1, MCM4, PDE7A or SPOPL in the same individual 
harboring the FAD mutation can be monitored over time and changes in 
expression can be correlated with alterations in cognition that are measured 
from CDR or MMSE. We recommend that the four APP/AICD targets should 
be assessed in unison as a potential biomarker signature for AD because 
changes in just one protein might not be specific to AD but may be indicative 
of some other disorder. 
5.3 CACNA2D1, MCM4, PDE7A or SPOPL as potential therapeutic 
intervention targets for AD? 
While the evaluation of CACNA2D1, MCM4, PDE7A or SPOPL as potential 
biomarkers for AD can be conducted directly in human subjects, their 
suitability for therapeutic intervention has to be firstly determined from cell 
culture or animal model studies. The increase or decrease in function that 
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arises as a consequence of changes in APP/AICD target expression would 
have to be verified in a cellular or animal model by the use of 
immunohistochemical methods and functional assays. In cases where changes 
are observed, further experiments can be planned in order to increase 
(transfection, agonist treatment, etc.) or decrease (knockdown, antagonist 
treatment, etc.) the expression/function of a particular APP/AICD target, 
followed by an evaluation of the efficacy of the manipulation in preventing or 
alleviating AD. After determining preliminary usefulness of the intervention; 
safety (e.g. tolerated dose or side effects) and effectiveness of the intervention 
can be assessed in AD transgenic mouse models before progressing to clinical 
trials. 
5.4 Targeting upstream of CACNA2D1, MCM4, PDE7A or SPOPL? 
Since AD is a complex disease that involves multiple cellular players as well 
as various environmental factors, interventions targeting one molecule may 
not be successful in curing the disease. In view of this, it might be better to 
target the molecule that is responsible for changing the expression of 
CACNA2D1, MCM4, PDE7A and SPOPL, rather than targeting each of these 
proteins individually. Thus, there is a need to identify the APP metabolite or 
the AICD interacting partner(s) involved in mediating the transcriptional 
regulation of CACNA2D1, MCM4, PDE7A and SPOPL. We propose 
conducting IP experiments on SH-SY5Y and SH-SY5YAPP695 samples using 
the A8717 APP C-terminal antibody to pull down APP fragments and 
interacting partners. The resulting APP fragments and interacting proteins can 
be visualized via Coomassie staining following SDS-PAGE. Bands that appear 
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in the SH-SY5YAPP695 sample but not the SH-SY5Y sample can be cut out and 
sent for mass spectroscopy for protein identification. Conversely, bands that 
do not appear in the SH-SY5YAPP695 sample but appear in the SH-SY5Y 
sample may also be of value. To alleviate the concern that bands may arise 
due to non-specific antibody binding, IP results can be corroborated using the 
MAB343 antibody from Millipore that recognizes the last 52 amino acids of 
APP695. Results may also be verified in samples from aged AD transgenic 
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